

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Hyperopic Population

Protocol CR-6392

Version: 3.0

Date: 02 October 2020

Investigational Products: JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3 material

Control: Dailies Total 1® Multifocal Contact Lenses manufactured in delefilcon A material

Key Words: Multifocal, Senofilcon A C3, Delefilcon A, Presbyopia, Daily Wear, Daily Disposable, Dispensing, Randomized

**Statement of Compliance to protocol, GCP and applicable regulatory guidelines:**

This trial will be conducted in compliance with the protocol, ISO 14155,<sup>1</sup> the International Conference on Harmonization Good Clinical Practice E6 (ICH-GCP),<sup>2</sup> the Declaration of Helsinki,<sup>3</sup> and all applicable regulatory requirements.

**Confidentiality Statement:**

This document contains confidential information, which should not be copied, referred to, released or published without written approval from Johnson & Johnson Vision Care, Inc. The information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee approval and informed consent, or as required by International, Federal and State Laws, as applicable. Persons to whom this information is disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of Johnson & Johnson Vision Care, Inc. Any supplemental information that may be added to this document is also confidential and proprietary to Johnson & Johnson Vision Care, Inc. and must be kept in confidence in the same manner as the contents of this document.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**TABLE OF CONTENTS**

PROTOCOL TITLE, NUMBER, VERSION .....	6
SPONSOR NAME AND ADDRESS .....	6
MEDICAL MONITOR.....	6
AUTHORIZED SIGNATURES.....	7
CHANGE HISTORY .....	9
SYNOPSIS.....	10
COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS .....	15
1. INTRODUCTION AND BACKGROUND .....	17
1.1. Name and Descriptions of Investigational Products .....	17
1.2. Intended Use of Investigational Products.....	17
1.3. Summary of Findings from Nonclinical Studies.....	17
1.4. Summary of Known Risks and Benefits to Human Subjects.....	17
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical Study .....	17
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES .....	18
2.1. Objectives.....	18
2.2. Endpoints.....	18
2.3. Hypotheses .....	19
3. TARGETED STUDY POPULATION .....	20
3.1. General Characteristics .....	20
3.2. Inclusion Criteria.....	20
3.3. Exclusion Criteria.....	20
3.4. Enrollment Strategy.....	21
4. STUDY DESIGN AND RATIONALE .....	21
4.1. Description of Study Design .....	21
4.2. Study Design Rationale.....	22
4.3. Enrollment Target and Study Duration .....	22
5. TEST ARTICLE ALLOCATION AND MASKING .....	22
5.1. Test Article Allocation .....	22
5.2. Masking.....	23
5.3. Procedures for Maintaining and Breaking the Masking.....	23
6. STUDY INTERVENTION.....	24
6.1. Identity of Test Articles.....	24

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

6.2. Ancillary Supplies/Products .....	25
6.3. Administration of Test Articles.....	25
6.4. Packaging and Labeling .....	25
6.5. Storage Conditions .....	26
6.6. Collection and Storage of Samples .....	26
6.7. Accountability of Test Articles .....	26
7. STUDY EVALUATIONS .....	27
7.1. Time and Event Schedule.....	27
7.2. Detailed Study Procedures .....	31
VISIT 1 .....	31
VISIT 2 .....	36
VISIT 3 .....	40
VISIT 4 .....	47
VISIT 5 .....	51
VISIT 6 .....	57
FINAL EVALUATION.....	59
7.3. Unscheduled Visits.....	60
7.4. Laboratory Procedures .....	62
8. SUBJECTS COMPLETION/WITHDRAWAL.....	62
8.1. Completion Criteria.....	62
8.2. Withdrawal/Discontinuation from the Study .....	62
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION .....	63
9.1. Systemic Medications .....	63
10. DEVIATIONS FROM THE PROTOCOL .....	64
11. STUDY TERMINATION .....	64
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS.....	65
13. ADVERSE EVENTS.....	66
13.1. Definitions and Classifications .....	66
13.2. Assessing Adverse Events .....	68
13.2.1. Causality Assessment.....	68
13.2.2. Severity Assessment.....	69
13.3. Documentation and Follow-Up of Adverse Events.....	69
13.4. Reporting Adverse Events .....	70
13.4.1. Reporting Adverse Events to Sponsor .....	71

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities .....	71
13.4.3. Event of Special Interest .....	72
13.5. Reporting of Pregnancy .....	72
14. STATISTICAL METHODS .....	72
14.1. General Considerations .....	72
14.2. Sample Size Justification .....	72
14.3. Analysis Populations .....	74
14.4. Level of Statistical Significance .....	74
14.5. Primary Analysis .....	74
14.6. Secondary Analysis .....	75
14.7. Other Exploratory Analyses .....	76
14.8. Interim Analysis .....	76
14.9. Procedure for Handling Missing Data and Drop-Outs .....	76
14.10. Procedure for Reporting Deviations from Statistical Plan .....	77
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING .....	77
15.1. Electronic Case Report Form/Data Collection .....	77
15.2. Subject Record .....	77
15.3. ClinicalTrials.gov .....	78
16. DATA MANAGEMENT .....	78
16.1. Access to Source Data/Document .....	78
16.2. Confidentiality of Information .....	78
16.3. Data Quality Assurance .....	78
17. CLINICAL MONITORING .....	79
18. ETHICAL AND REGULATORY ASPECTS .....	79
18.1. Study-Specific Design Considerations .....	79
18.2. Investigator Responsibility .....	80
18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB) .....	80
18.4. Informed Consent .....	81
18.5. Privacy of Personal Data .....	81
19. STUDY RECORD RETENTION .....	82
20. FINANCIAL CONSIDERATIONS .....	83
21. PUBLICATION .....	83
22. REFERENCES .....	84

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) .....	85
APPENDIX B: PATIENT INSTRUCTION GUIDE (To be provided seperately) .....	112
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) .....	113
APPENDIX D: BINOCULAR OVER REFRACTION .....	116
APPENDIX E: PRESBYOPIA SYMPTOMS QUESTIONNAIRE .....	117
APPENDIX F: OCULAR DOMINANCE .....	118
APPENDIX G: LENS FITTING GUIDE .....	119
APPENDIX H: Control Lens fitting guide .....	121
APPENDIX I: C-QUANT STRAYLIGHT MEASUREMENT .....	154
APPENDIX J: VISIONIX CORNEAL TOPOGRAPHY AND WAVEFRONT .....	161
APPENDIX K: [REDACTED] .....	170
[REDACTED], Limbal & Conjunctival (Bulbar) Redness .....	171
[REDACTED], Expanded Sodium Fluorescein Corneal Staining .....	178
[REDACTED], Determination of Near Addition .....	185
[REDACTED], Near LogMAR Visual Acuity Measurement Procedure .....	191
[REDACTED], Lens Fitting Characteristics .....	194
[REDACTED], Subject Reported Ocular Symptoms/Problems .....	200
[REDACTED], Determination of Distance Spherocylindrical Refractions .....	202
[REDACTED], Biomicroscopy Scale .....	209
[REDACTED], Keratometry Procedure .....	215
[REDACTED], Distance and Near Visual Acuity Evaluation .....	217
[REDACTED] Distance LogMAR Visual Acuity Measurement Procedure .....	222
[REDACTED], Patient Reported Outcomes .....	226
[REDACTED], Visual Acuity Chart Luminance and Room Illumination Testing .....	228
APPENDIX L: Guidelines for COVID-19 Risk Mitigation .....	234
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE .....	244

**TABLE OF CONTENTS**

Figure 1: Study Flowchart .....	14
---------------------------------	----

**TABLE OF CONTENTS**

Table 1: Test Articles .....	24
Table 2: Ancillary Supplies .....	25
Table 3: Time and Events .....	27
Table 4: Disallowed systemic medications (less than 6 months of continual use) .....	63

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**PROTOCOL TITLE, NUMBER, VERSION**

Title: Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Hyperopic Population

Protocol Number: CR-6392

Version: 3.0

Date: 02 October 2020

**SPONSOR NAME AND ADDRESS**

Johnson & Johnson Vision Care (JJVC)  
7500 Centurion Parkway  
Jacksonville, FL 32256

**MEDICAL MONITOR**



The Medical Monitor must be notified by the clinical institution/site by e-mail, fax, or telephone within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may be contacted during business hours for adverse event questions. General study related questions should be directed towards your assigned clinical research associate.

The Medical Monitoring Plan is maintained as a separate document and included in the Trial Master File.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**AUTHORIZED SIGNATURES**

The signatures below constitutes the approval of this protocol and the attachments and provide the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable U.S. federal regulations,<sup>4</sup> ICH guidelines,<sup>2</sup> ISO 14155,<sup>1</sup> and the Declaration of Helsinki.<sup>3</sup>

Author	<i>See Electronic Signature Report</i> [REDACTED]	DATE
	Sr. Principal Research Optometrist, Clinical Sciences	
Clinical Operations Manager	<i>See Electronic Signature Report</i> [REDACTED]	DATE
	Clinical Operations Manager, Clinical Operations	
Biostatistician	<i>See Electronic Signature Report</i> [REDACTED]	DATE
	Biostatistician III, Clinical Science	
Data Management	<i>See Electronic Signature Report</i> [REDACTED]	DATE
	Clinical Project Manager-Data and Systems, Clinical Operations	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Medical Safety  
Officer

*See Electronic Signature Report*

\_\_\_\_\_ [REDACTED]  
Medical Safety Officer, Global Medical  
Affairs

DATE

Reviewer

*See Electronic Signature Report*

\_\_\_\_\_ [REDACTED]  
Clinical Research Fellow, Clinical  
Sciences

DATE

Reviewer

*See Electronic Signature Report*

\_\_\_\_\_ [REDACTED]  
Presbyopia Platform Sr. Manager,  
Clinical Operations

DATE

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**CHANGE HISTORY**

Version	Originator	Description of Change(s) and Section Number(s) Affected	Date
1.0	[REDACTED]	Original Protocol	22 Jul 2020
2.0	[REDACTED]	Section 22: Corrected typo Appendix A: Updated PRO specification Throughout Document: Updated version and date	21 Aug 2020
3.0	[REDACTED]	Synopsis and Section 3.3-removed term “dry eye”  Section 6.1-added +4.25D distance power to Control lens.  Section 7.2-visits 1 and 3 added additional wording to lens fitting step to be consistent with rest of document.  Throughout protocol-updated version and date.	02 Oct 2020

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**SYNOPSIS**

Protocol Title	Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Hyperopic Population
Sponsor	JJVC, 7500 Centurion Parkway, Jacksonville, FL 32256
Clinical Phase	Development phase, Phase 2b
Trial Registration	This study will be registered on ClinicalTrials.gov.
Test Article(s)	Investigational Product: JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3 material Control Product: Dailies Total 1® Multifocal Contact Lenses manufactured in delefilcon A material
Wear and Replacement Schedules	Wear Schedule: The test and control lenses will be used on a daily disposable basis. Replacement Schedule: The lenses will be replaced after a day of wear.
Objectives	The purpose of this study is to evaluate visual performance (logMAR) and subjective response of the JJVC Investigational Multifocal Contact Lens compares to the marketed Dailies Total 1® Multifocal Contact Lens.
Study Endpoints	Primary endpoint <ul style="list-style-type: none"> <li>• Visual Performance (logMAR)</li> </ul> Secondary endpoint <ul style="list-style-type: none"> <li>• CLUE vision scores</li> </ul>
Study Design	<p>This is a single-masked, 2×3 crossover, randomized-controlled, dispensing clinical trial. Approximately 70 hyperopic eligible subjects will be targeted to complete the study. Eligible subjects will be randomized and fit at Visit 1 in a study lens based on the randomization scheme. Subjects will be dispensed lenses at Visit 1 for <math>3\pm1</math> day, then undergo optimization (Visit 2). Subjects will wear the optimized pair for approximately 1 week (<math>7\pm1</math> day). After approximately 1-week of wear, (Visit 3) the study endpoints will be measured and subjects will be fit in the 2<sup>nd</sup> study lens. The visits will be repeated wearing the 2<sup>nd</sup> study lens (Visit 3 Fit/Visit 4 Optimization/Visit 5 Follow up). At Visit 5 the subjects will be fit in the 3<sup>rd</sup> study lens that match the same power they were dispensed at Visit 4 and wore to Visit 5 and wear the lenses for 1 week (<math>7\pm1</math> day). After approximately 1-week of wear, (Visit 6) the study endpoints will be measured and the subject will be exited from the study.</p> <p>See the flow chart at the end of the synopsis table for the schematic of the study visits and procedures of main observations (Figure 1).</p>
Sample Size	Approximately 80 eligible subjects will be enrolled with the target of approximately 70 subjects to complete.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Study Duration	The study will last approximately 2 to 4 months.
Anticipated Study Population	<p>Healthy male and female volunteers with presbyopia will be screened as per criteria outlined below. All volunteers will have baseline measurements taken to ensure eligibility. The baseline procedures will occur after informed consent has been obtained. Subjects will have medical and contact lens history recorded, baseline questionnaires completed, and refractive and anterior segment status determined. For a detailed flowchart of procedures see below.</p>
Eligibility Criteria	<p>Potential subjects must satisfy all of the following criteria to be enrolled in the study</p> <p><b>Inclusion Criteria after Screening:</b></p> <ol style="list-style-type: none"> <li>1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.</li> <li>2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.</li> <li>3. The subject must be at least 40 years of age and not greater than 70 years of age at the time of consent.</li> <li>4. Subjects must own a wearable pair of spectacles if required for their distance vision.</li> <li>5. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 1 month or more duration).</li> <li>6. The subject must either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".</li> </ol> <p><b>Inclusion Criteria after Baseline:</b></p> <ol style="list-style-type: none"> <li>7. The subject's distance spherical equivalent refraction must be in the range of +1.25 D to +3.75 D in each eye.</li> <li>8. The subject's refractive cylinder must be <math>\leq 0.75</math> D in each eye.</li> <li>9. The subject's ADD power must be in the range of +0.75 D to +2.50 D.</li> </ol>

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

	<p>10. The subject must have distance best corrected visual acuity of 20/20<sup>-3</sup> or better in each eye.</p> <p>Potential subjects who meet any of the following criteria will be excluded from participating in the study:</p> <p>Exclusion Criteria after Screening:</p> <ol style="list-style-type: none"><li>1. Currently pregnant or lactating.</li><li>2. Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.</li><li>3. Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).</li><li>4. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.).</li><li>5. A history of amblyopia, strabismus or binocular vision abnormality.</li><li>6. Use of any of the following medications within 2 weeks prior to enrollment: oral retinoids, oral tetracyclines, anticholinergics, systemic/topical steroids, oral phenothiazines. See section 9.1 for additional details regarding excluded systemic medications.</li><li>7. Use of any ocular medication, with the exception of rewetting drops.</li><li>8. History of herpetic keratitis.</li><li>9. History of irregular cornea.</li><li>10. History of pathological dry eye.</li><li>11. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.</li><li>12. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).</li><li>13. Any known hypersensitivity or allergic reaction to non-preserved rewetting drop solutions or sodium fluorescein.</li></ol> <p>Exclusion Criteria after Baseline:</p>
--	---


**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

	<p>14. Clinically significant (Grade 2 or greater) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.</p> <p>15. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions.</p> <p>16. Any current ocular infection or inflammation.</p> <p>17. Any current ocular abnormality that may interfere with contact lens wear.</p>
Disallowed Medications/Interventions	Use of any prescription or over-the-counter (OTC) medications that may affect contact lens wear. See section 9.1 for details regarding disallowed systemic medications.
Measurements and Procedures	logMAR Visual performance and subjective responses for vision using the CLUE™ questionnaire.
Microbiology or Other Laboratory Testing	None
Study Termination	The occurrence of one or more Unanticipated Adverse Device Effect (UADE), or any serious adverse event (SAE) where relationship to study agent cannot be ruled out, will result in stopping further dispensing investigational product. In the event of a UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of subject(s) and may discuss this with the Principal Investigator before any further subjects are enrolled.
Ancillary Supplies/ Study-Specific Materials	Non-Preserved Rewetting drops, lens cases, glass vials, saline, ETDRS light cabinet, 4M logMAR charts, and Near logMAR charts.
Principal Investigator(s) and Study Institution(s)/Site(s)	A full list of Principal Investigators, clinical sites, and institutions is kept separately from the Study Protocol and is included in the study Trial Master File.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

Figure 1: Study Flowchart



**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS**

ADD	Plus Power Required For Near Use
ADE	Adverse Device Effect
AE	Adverse Event/Adverse Experience
BCVA	Best Corrected Visual Acuity
BSCVA	Best Spectacle Corrected Visual Acuity
CFR	Code of Federal Regulations
CLUE	Contact Lens User Experience
COAS	Complete Ophthalmic Analysis System
COM	Clinical Operations Manager
CRA	Clinical Research Associate
CRF	Case Report Form
CRO	Contract Research Organization
CT	Center Thickness
■■■■■	■■■■■
D	Diopter
DMC	Data Monitoring Committee
eCRF	Electronic Case Report Form
EDC	Electronic Data Capture
ETDRS	Early Treatment Diabetic Retinopathy Study
FDA	Food and Drug Administration
GCP	Good Clinical Practice
HIPAA	Health Insurance Portability and Accountability Act
IB	Investigator's Brochure
ICF	Informed Consent Form
ICH	International Conference on Harmonization
IDE	Investigational Device Exemption
IEC	Independent Ethics Committee
IRB	Institutional Review Board
ISO	International Organization for Standardization
ITT	Intent-to-Treat
JJVC	Johnson & Johnson Vision Care, Inc.
LC	Limbus Center
LogMAR	Logarithm of Minimal Angle of Resolution
MedDRA <sup>®</sup>	Medical Dictionary for Regulatory Activities
MOP	Manual of Procedures
NIH	National Institutes of Health
OD	Right Eye
OHRP	Office for Human Research Protections
OHSR	Office for Human Subjects Research
OS	Left Eye
OU	Both Eyes
PD	Protocol Deviation
PHI	Protected Health Information
PI	Principal Investigator

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

PIG	Patient Instruction Guide
PQC	Product Quality Complaint
PRO	Patient Reported Outcome
QA	Quality Assurance
QC	Quality Control
SAE	Serious Adverse Event/Serious Adverse Experience
SAP	Statistical Analysis Plan
SAS	Statistical Analysis System
SD	Standard Deviation
SOP	Standard Operating Procedure
UADE	Unanticipated Adverse Device Effect
USADE	Unanticipated Serious Adverse Device Effect
VA	Visual Acuity

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

### **1. INTRODUCTION AND BACKGROUND**

The purpose of this study is to evaluate the visual performance and subjective response of the JJVC Investigational Multifocal Contact Lens and compare to the marketed Dailies Total 1® Multifocal Contact Lenses manufactured in delefilcon A material.

#### **1.1. Name and Descriptions of Investigational Products**

Investigational Product: JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3 material

Control: Dailies Total 1® Multifocal Contact Lenses manufactured in delefilcon A material

#### **1.2. Intended Use of Investigational Products**

All lenses are intended to correct spherical refractive error and presbyopia. For this study both of the lenses will be worn as a daily disposable lens, with the lenses being discarded after a day of wear. The Lenses will be fit in a randomized fashion. After fitting, each subject will return for an optimization visit and then a follow-up. The sequence will then be repeated with the other study lens type and then the lens type worn at visit 5 will be re-worn for an additional 6-8 days. Each study lens type will be worn for a total of approximately 14-20 days.

#### **1.3. Summary of Findings from Nonclinical Studies**

Not Applicable

#### **1.4. Summary of Known Risks and Benefits to Human Subjects**

Anticipated risks and adverse reactions with this lens are similar to those with other soft daily wear contact lenses used to correct presbyopia. A listing of examples of adverse reactions is found in the Section 13 of this protocol. The investigator should follow normal clinical guidelines regarding examination and care of subjects who participate in this trial. Refer to study lens package insert for additional details for the control lens and the Investigational Brochure (IB) for the Investigational lens. Both the study multifocal contact lenses are designed for the correction of refractive spherical refractive error and presbyopia. The investigational study contact lens is manufactured in senofilcon A C3 and the control lens is manufactured in delefilcon A. Both of the lenses will be worn in a daily disposable wear modality. These lenses are not intended for extended wear in this study.

#### **1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical Study**

The Test lenses have been previously tested in clinical studies [REDACTED], [REDACTED] and [REDACTED], however at the time of writing of this protocol [REDACTED] was still in progress.

In [REDACTED], 30 subjects completed the study per the protocol. The lenses displayed good clinical vision performance with binocular, high luminance, high contrast logMAR visual acuity of -0.057 and 0.091 at distance and near respectively.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

There was one adverse event reported during the study. The subject experienced mild upper respiratory virus and did not receive any treatment for this event. The event resolved and the subject completed the study. The investigator considered the event to be not related to study article/procedure.

In [REDACTED], 41 subjects completed the study per the protocol. The lenses displayed good clinical vision performance with binocular, high luminance, high contrast logMAR visual acuity of -0.104 and 0.058 at distance and near respectively.

There were no adverse events reported during the study.

For information about the control product refer to study lens package insert for additional details (APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) and the Investigational Brochure (IB) for the Investigational product.

## **2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES**

### **2.1. Objectives**

The objective of this study is to evaluate the visual performance (logMAR) and subjective vision responses of the Investigational Multifocal Contact Lenses manufactured in senofilcon A C3 material (Test) compared to the Dailies Total 1® Multifocal Contact Lenses (Control) manufactured in deleficon A material.

### **2.2. Endpoints**

Primary Endpoint:

#### Visual Performance (logMAR)

Multiple assessments of binocular and monocular visual acuity will be made during the study, but the binocular measurements made at the 1-week follow-up evaluation using high contrast letters in bright illuminance conditions will be the primary endpoint. At distance (4 meters), VA is assessed using ETDRS Charts; while near (40 cm) and intermediate (64 cm) assessments will be made using reduced Guillon-Poling charts. Visual acuity will be measured using high and low contrast charts in bright illuminance conditions. Visual acuity will also be measured using high contrast charts in dim illuminance conditions created by the use of goggles. See [REDACTED], [REDACTED] and [REDACTED] in Appendix I for details regarding the collection of visual acuity (logMAR).

Secondary Endpoint:

#### Subjective Vision

Subjective vision will be assessed using the Contact Lens User Experience (CLUE™) questionnaire at the 1-Week follow-up evaluation. CLUE™ is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE™ scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. A 5-point increase in an average CLUE™ score translates into 10% shift in the distribution of scores for population of soft contact lens wearers.<sup>6</sup>

Other Endpoints:

- CLUE™ Comfort
- CLUE™ Handling
- Lens Optimization Summary
- Mechanical Lens Fit
- Slit Lamp Findings

### **2.3. Hypotheses**

All primary and secondary hypotheses must be met in order to satisfy the objective of this study.

#### Primary Hypotheses

1. After approximately 1-week of wear in the optimized test lens, the mean distance visual acuity score of the Test lens will be statistically lower than 0.00 on logMAR scale.
2. After approximately 1-week of wear in the optimized test lens, the mean intermediate visual acuity score of the Test lens will be statistically lower than 0.17 on logMAR scale.
3. After approximately 1-week of wear in the optimized test lens, the mean near visual acuity score of the Test lens will be statistically lower than 0.17 on logMAR scale.

#### Secondary Hypotheses

1. After approximately 1-week of wear in the optimized test lens, the mean overall quality of vision score of the Test lens will be statistically better than 32 points on CLUE scale.
2. After approximately 1-week of wear in the optimized lenses, the Test lens will be non-inferior to the Control lens with respect to the overall quality of vision score. A non-inferiority margin of 5 points will be used.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### **3. TARGETED STUDY POPULATION**

#### **3.1. General Characteristics**

Healthy male and female subjects who are habitual soft contact lens wearers will be recruited. Subjects will be at least 40 years of age and not older than 70 years of age. They will be hyperopic and have presbyopia.

#### **3.2. Inclusion Criteria**

Potential subjects must satisfy all the following criteria to be enrolled in the study:

Inclusion Criteria after Screening:

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. The subject must be at least 40 years of age and not greater than 70 years of age at the time of consent.
4. Subjects must own a wearable pair of spectacles if required for their distance vision.
5. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 1 month or more duration).
6. The subject must either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or, if not respond positively to at least one symptom on the “Presbyopic Symptoms Questionnaire” (Appendix E).

Inclusion Criteria after Baseline:

7. The subject's distance spherical equivalent refraction must be in the range of +1.25 D to +3.75 D in each eye.
8. The subject's refractive cylinder must be  $\leq 0.75$  D in each eye.
9. The subject's ADD power must be in the range of +0.75 D to +2.50 D.
10. The subject must have distance best corrected visual acuity of 20/20<sup>-3</sup> or better in each eye.

#### **3.3. Exclusion Criteria**

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

Exclusion Criteria after Screening:

1. Currently pregnant or lactating.
2. Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
3. Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to,

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).

4. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.).
5. A history of amblyopia, strabismus or binocular vision abnormality.
6. Use of any of the following medications within 2 weeks prior to enrollment: oral retinoids, oral tetracyclines, anticholinergics, systemic/topical steroids, oral phenothiazines. See section 9.1 for additional details regarding excluded systemic medications.
7. Use of any ocular medication, with the exception of rewetting drops.
8. History of herpetic keratitis.
9. History of irregular cornea.
10. History of pathological dry eye.
11. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
12. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
13. Any known hypersensitivity or allergic reaction to non-preserved rewetting drop solutions or sodium fluorescein.

**Exclusion Criteria after Baseline:**

14. Clinically significant (Grade 2 or greater) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
15. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions.
16. Any current ocular infection or inflammation.
17. Any current ocular abnormality that may interfere with contact lens wear.

### **3.4. Enrollment Strategy**

Study subjects will be recruited from the Institution/clinical site's subject database and/or utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved materials.

## **4. STUDY DESIGN AND RATIONALE**

### **4.1. Description of Study Design**

This is a 6-visit, subject-masked, multi-site, 2×3 crossover dispensing trial. Approximately 80 subjects will be enrolled with an aim of approximately 70 subjects to complete the study.

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

The study begins with an initial visit (Visit 1). If a subject is found to meet all eligibility criteria, they will be randomized to one of two lens wear sequences (Test/Control/Control or Control/Test/Test) in a bilateral fashion.

If the subject is dispensed study lenses at the initial visit, five additional visits will be conducted. The first follow-up visit (Visit 2) will occur  $3 \pm 1$  days after the initial visit. At visit 2, subjects will undergo lens optimization if necessary. Subjects will wear the study lenses for  $7 \pm 1$  days and then will return for their second follow-up at Visit 3. At Visit 3, subjects will be dispensed their second study lens per the randomization schedule. Subjects will return for their first follow-up visit (Visit 4)  $3 \pm 1$  days after Visit 3, for lens optimization. Subjects will return for their second follow-up visit  $7 \pm 1$  days after Visit 4. At Visit 5, subjects will be dispensed their 3rd study lens per the randomization schedule and wear the lens for ( $7 \pm 1$  days). At the follow-up (Visit 6) the endpoints will again be measured and the subject will be exited from the study.

### **4.2. Study Design Rationale**

Crossover designs are a well-established study design in which subjects are exposed to multiple treatments during different time periods. A  $2 \times 3$  bilateral crossover design was considered to be the optimal design since the study period is relatively short the design can be cost effective and more efficient comparisons between treatments can be made than compared to a parallel study since fewer subjects are required to achieve the same pre-specified statistical power. Each subject will act as their own control to reduce the influence of potential confounding factors such as age, gender and vision correction.

### **4.3. Enrollment Target and Study Duration**

Approximately 80 eligible subjects will be enrolled with the aim of approximately 70 to complete the study. The study will last approximately 2-4 months.

## **5. TEST ARTICLE ALLOCATION AND MASKING**

### **5.1. Test Article Allocation**

The study lenses will be worn in a bilateral and random fashion using a  $2 \times 3$  crossover design. A computer-generated randomization scheme will be used to randomly assign subjects, in blocks of 4, to one of the two possible lens wear sequences: Test/Control/Control or Control/Test/Test. The random scheme will be generated using the PROC PLAN procedure from Statistical Analysis System (SAS) Software Version 9.4 or higher (SAS Institute, Cary, NC)<sup>9</sup>.

The study site must follow the randomization scheme provided and complete enrollment per the randomization list and not pre-select or assign subjects. The randomized assignment of subjects will be performed at the first visit prior to the first fitting. The following must have occurred prior to randomization:

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

- Informed consent has been obtained
- Subject meets all the inclusion / exclusion criteria
- Subject history and baseline information has been collected.

### **5.2. Masking**

This is a single-masked study with the subjects being masked. The term partial masking is being used as subjects will not be told any information regarding the optical designs of the lenses beyond that they are intended to correct for their refractive error and presbyopia, however there are slight differences in the tint of the lenses which is impossible to mask from the subject.

Under normal circumstances, the mask should not be broken until all subjects have completed the study and the database is finalized. Otherwise, the mask should be broken only if specific emergency treatment/course of action would be dictated by knowing the treatment status of the subject. In such cases, the Investigator may, in an emergency, contact the medical monitor. In the event the mask is broken, the Sponsor must be informed as soon as possible. The date, time, and reason for the unmasking must be documented in the subject record. The Investigator is also advised not to reveal the study treatment assignment to the clinical site or Sponsor personnel.

Subjects who have had their treatment assignment unmasked are expected to return for all remaining scheduled evaluations. Subjects who are discontinued may be replaced.

### **5.3. Procedures for Maintaining and Breaking the Masking**

The test articles mask shall not be broken unless information concerning the lens type is necessary for the urgent medical treatment of a subject. The Sponsor must be notified before the mask is broken.

When dispensing test articles, the following steps should be followed to maintain randomization codes:

1. Investigator or designee (documented on the Delegation Log) will consult the lens fitting schedule/randomization scheme to obtain the test article assignment for that subject prior to dispensing.
2. Investigator or designee will record the subject's number on the appropriate line of the randomization scheme if applicable
3. Investigator or designee will pull the appropriate test articles from the study supply. All test articles that are opened, whether dispensed (placed/fit on eye or dispensed outside the clinical site) or not, must be recorded on the Test Article Accountability Log in the "Dispensed" section.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

## 6. STUDY INTERVENTION

### 6.1. Identity of Test Articles

The following contact lenses will be used in this study:

Table 1: Test Articles

	Test	Control
Name	JJVC Investigational Multifocal Contact Lens	Dailies Total 1® Multifocal Contact Lens
Manufacturer	Johnson & Johnson® Vision Care, Inc.	Alcon
		Over-labeled (marketed product)
Lens Material	senofilcon A (C3)	delefilcon A
Nominal Base Curve	8.35 mm	8.5 mm
Nominal Diameter	14.3 mm	14.1 mm
Nominal Distance Powers (D)	+1.00 D to +4.00 D in 0.25 D steps	+1.00 D to +4.25 D in 0.25 D steps
Nominal ADD Powers (D)	LOW, MID, HI	LO, MED, HI
Water Content	38%	33%
Center Thickness @ -3.00 D	0.07 mm @ -3.00 D	0.09 mm @ -1.00 D
Oxygen Permeability (Dk)	103	156 @ -3.00 D
Wear Schedule in Current Study	Daily Wear	Daily Wear
Replacement Frequency	Daily	Daily

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

Packaging Form (vial, blister, etc.)	Blister	Blister
---	---------	---------

### 6.2. Ancillary Supplies/Products

The following solutions will be used in this study:

Table 2: Ancillary Supplies


Single-Use Preservative-Free Rewetting Solutions (any one of these three rewetting solutions options may be supplied)			
Solution Name/Description	Eye-Cept® Rewetting Drops	ScleralFil® Preservative Free Saline Solution	LaciPure Saline Solution
Manufacturer	Optics Laboratory	B&L	Menicon
Preservative	Non-Preserved	Non-preserved	Non-preserved

### 6.3. Administration of Test Articles

Test articles will be dispensed to subjects meeting all eligibility requirements, including any dispensing requirements set forth in this clinical protocol. Subjects will be dispensed an adequate supply of test articles to complete the study. Lost or damaged test articles may be replaced at the discretion of the Investigator and/or the Sponsor.

### 6.4. Packaging and Labeling

The test articles will be packaged in blisters, as the primary packaging. The test article will be over-labeled to mask the subject to the identity of the lens. The test articles will be in investigational cartons sealed with a tamper evident seal, commercial cartons, or in plastic bags as the secondary packaging form. The sample study label is shown below:



# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

### **6.5. Storage Conditions**

Test articles will be maintained at ambient temperatures at the clinical site. Test articles must be kept under secure conditions.

### **6.6. Collection and Storage of Samples**

When possible, any lens or test article associated with an Adverse Event and/or a Product Quality Complaint must be retained and stored in a glass vial with moderate solution pending directions from the sponsor for potential return to JJVC.

### **6.7. Accountability of Test Articles**

JJVC will provide the Investigator with sufficient quantities of study articles and supplies to complete the investigation. The Investigator is asked to retain all lens shipment documentation for the test article accountability records.

Test articles must be kept in a locked storage cabinet, accessible only to those assigned by the Investigator for dispensing. The Investigator may delegate this activity to authorized study site personnel listed on the Site Delegation Log. All test articles must be accounted. This includes:

1. What was dispensed for the subject for trial fitting, to wear out of the office, or issued for the subject to replace appropriately between visits.
2. What was returned to the Investigator unused, including expired or malfunctioning product.
3. The number and reason for unplanned replacements.

The Investigator will collect all unused test articles from the subjects at the end of the subject's participation. Subject returned unused test articles must be separated from the clinical study inventory of un-dispensed test articles and must be labeled with the subject number and date of return. Following final reconciliation of test articles by the monitor, the Investigator or monitor will return all unused test articles to JJVC.

If there is a discrepancy between the shipment documents and the contents, contact the study monitor immediately.



# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### 7. STUDY EVALUATIONS

#### 7.1. Time and Event Schedule

Table 3: Time and Events

Visit Information	Visit 1 Screening, Baseline, Treatment 1	Visit 2 Treatment 1 Follow-up 1 Optimization	Visit 3 Treatment 1 Follow-up 2 Treatment 2	Visit 4 Treatment 2 Follow-up 1 Optimization	Visit 5 Treatment 2 Follow-up 2 Treatment 3	Visit 6 Treatment 3 Follow-up 1
Time Point	Day 0	Day 3±1 from V1	Day 7±1 from V2 Day 0	Day 3±1 from V3	Day 7±1 from V4	Day 7±1 from V5
Estimated Visit Duration	2.5 hours	1.0 hour	2.0 hour	1.0 hour	2.0 hour	1.5 hour
Statement of Informed Consent	x					
Demographics	x					
Medical History/Concomitant Medications	x					
Adverse Events and Concomitant Medications Review		x		x	x	x
Compliance		x	x	x	x	x
Habitual Contact Lens Information	x					

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Visit Information	Visit 1 Screening, Baseline, Treatment 1	Visit 2 Treatment 1 Follow-up 1 Optimization	Visit 3 Treatment 1 Follow-up 2 Treatment 2	Visit 4 Treatment 2 Follow-up 1 Optimization	Visit 5 Treatment 2 Follow-up 2 Treatment 3	Visit 6 Treatment 3 Follow-up 1
Time Point	Day 0	Day 3±1 from V1	Day 7±1 from V2 Day 0	Day 3±1 from V3	Day 7±1 from V4	Day 7±1 from V5
Estimated Visit Duration	2.5 hours	1.0 hour	2.0 hour	1.0 hour	2.0 hour	1.5 hour
Contact Lens History	x					
Wear Time and Comfortable Wear Time with Habitual lenses	x					
Wear Time and Comfortable Wear Time with Study lenses		x	x	x	x	x
Screening Inclusion/Exclusion Criteria	x					
Subject Reported Ocular Symptoms	x	x	x	x	x	x
Baseline PRO (CLUE and MRD) Questionnaire	x					
CLDEQ-8 Questionnaire	x		x		x	x
Distance and Near Entrance Visual Acuity	x	x	x	x	x	x
Lens Removal	x	x	x	x	x	x
Keratometry	x					
Subjective Refraction and Distance Visual Acuity	x					

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Visit Information	Visit 1 Screening, Baseline, Treatment 1	Visit 2 Treatment 1 Follow-up 1 Optimization	Visit 3 Treatment 1 Follow-up 2 Treatment 2	Visit 4 Treatment 2 Follow-up 1 Optimization	Visit 5 Treatment 2 Follow-up 2 Treatment 3	Visit 6 Treatment 3 Follow-up 1
Time Point	Day 0	Day 3±1 from V1	Day 7±1 from V2 Day 0	Day 3±1 from V3	Day 7±1 from V4	Day 7±1 from V5
Estimated Visit Duration	2.5 hours	1.0 hour	2.0 hour	1.0 hour	2.0 hour	1.5 hour
Near ADD Determination	x					
Ocular Dominance	x					
ADD Refinement	x					
Near Visual Acuity	x					
Biomicroscopy	x	x	x	x	x	x
Baseline Inclusion/ Exclusion Criteria	x					
Continuance		x		x	x	x
Lens Selection	x	x (if modified)	x	x (if modified)	x	x
Lens Insertion	x	x	x	x	x	x
10 Minute Settling	x	x (if modified)	x (if modified)	x (if modified)	x	x
Visual Satisfaction / Subjective Acceptance	x	x	x	x	x	x
Study Lens Distance and Near Visual Acuity	x	x	x	x	x	x
Distance Over Refraction and Visual Acuity	x	x	x	x	x	x
Subjective Lens Fit Assessment	x	x	x	x	x	x
Binocular Over Refraction		x	x	x	x	x

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Visit Information	Visit 1 Screening, Baseline, Treatment 1	Visit 2 Treatment 1 Follow-up 1 Optimization	Visit 3 Treatment 1 Follow-up 2 Treatment 2	Visit 4 Treatment 2 Follow-up 1 Optimization	Visit 5 Treatment 2 Follow-up 2 Treatment 3	Visit 6 Treatment 3 Follow-up 1
Time Point	Day 0	Day 3±1 from V1  Day 0	Day 7±1 from V2  Day 0	Day 3±1 from V3	Day 7±1 from V4	Day 7±1 from V5
Estimated Visit Duration	2.5 hours	1.0 hour	2.0 hour	1.0 hour	2.0 hour	1.5 hour
C-Quant Straylight Meter Testing			x		x	x
Corneal Topography and Wavefront measurement			x		x	x
Compliance	x	x	x	x	x	x
Follow-up PRO (CLUE / MRD) Questionnaire	x	x	x	x	x	x
Visual Performance			x		x	x
Modifications	x	x	x	x		
Distance and Near Exit						
Visual Acuity	x	x	x	x	x	x
Dispensing Criteria	x	x	x	x	x	x
Instructions	x	x	x	x	x	x
Schedule Follow-up	x	x	x	x	x	x
Final Evaluation						x

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

## 7.2. Detailed Study Procedures

### VISIT 1

Subjects must report to the visit wearing their habitual contact lenses to accurately assess baseline PRO (CLUE and MRD) performance. If the subject is not wearing their lenses they must be rescheduled.

Visit 1: Screening			
Step	Procedure	Details	
1.1	Statement of Informed Consent	Each subject must read, understand, and sign the Statement of Informed Consent before being enrolled into the study. The Principal Investigator or his/her designee conducting the informed consent discussion must also sign the consent form. <b><u>NOTE:</u></b> <i>The subject must be provided a signed copy of this document.</i>	
1.2	Demographics	Record the subject's age, gender, race and ethnicity.	
1.3	Medical History and Concomitant Medications	Questions regarding the subject's medical history and concomitant medications.	
1.4	Habitual Lenses	Questions regarding the subject's habitual lens type and parameters.	
1.5	Habitual Lens Duration of Wear/Days per week	Questions regarding the subject's duration of contact lens wear and the minimum number of days they wear their lenses per week.	
1.6	Contact Lens History	Record the subject's correction type (i.e. monovision, multifocal, sphere with readers, etc.).	
1.7	Wear time and Comfortable Wear time with Habitual lenses	Record the subject's wear time and comfortable wear time with their habitual contact lenses.	
1.8	Eligibility after Screening	All responses to Screening Inclusion Criteria questions must be answered "yes" and all responses to Exclusion Criteria must be answered "no" for the subject to be considered eligible.  <i>If subject is deemed to be ineligible after screening, proceed to Final Evaluation and complete Subject Disposition. Refraction and Biomicroscopy forms are not required.</i>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Visit 1: Baseline		
Step	Procedure	Details
1.9	Baseline PRO (CLUE and MRD) and CLDEQ-8 Questionnaires	The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of their habitual lenses using the PRO (CLUE and MRD) questions.
1.10	Ocular Symptoms	The subject will respond to a verbal open-ended symptoms questionnaire.
1.11	Entrance Visual Acuity	Distance and near Snellen visual acuity will be measured for each eye with the subject's habitual contact lenses in place.  For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.
1.12	Lens Removal	Have the subject remove their habitual lenses and store in an approved storage solution.
1.13	Keratometry	Keratometry will be performed OD and OS and the steep and flat dioptric power and corresponding meridians recorded.
1.14	Subjective Refraction and Distance Visual Acuity	An optimal, binocular balanced distance spherocylindrical refraction will be performed. Record the refraction and distance visual acuity to the nearest letter.  <b><u>NOTE: Best distance visual acuity with spherocylindrical refraction must be at least 20/20<sup>3</sup> in each eye for the subject to be eligible in the study.</u></b>
1.15	Near ADD Determination	The near reading addition will be determined using the binocular crossed cylinder technique (BCC) at 40 cm.
1.16	Ocular Dominance	Determine the distance ocular dominance with the best distance correction in place using a +1.00-blur test. If the results are equivocal use the sighting dominance test to determine the dominant eye used for the study.
1.17	ADD Refinement	Place the BCC result in the trial frame and refine the near prescription with trial lenses (or flippers) under binocular conditions.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

1.18	Near Visual Acuity	Using the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm. Record the near visual acuity OD, OS and OU at 40 cm.	
1.19	Biomicroscopy	<p>FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility.</p> <p>If any of these slit lamp findings are Grade 2 or higher, the subject will be discontinued. If discontinued a final examination must be completed.</p> <p>If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops may be instilled.</p>	
1.20	Eligibility after Baseline	<p>All responses to Inclusion Criteria questions must be answered “yes” and all responses to Exclusion Criteria questions must be answered “no” for the subject to be considered eligible.</p> <p>If so, proceed to lens fitting.</p> <p><i>If subject is deemed to be ineligible after baseline, proceed to Final Evaluation and complete all forms.</i></p>	

Visit 1: Treatment 1 Lens Fitting			
Step	Procedure	Details	
1.21	Randomization	Record the randomization ID.	
1.22	Lens Selection	Select the lens pair and power based on the randomization scheme, spherical equivalent refraction and fitting guide for each eye. Record the Test lens parameters (power and lot number).	
1.23	Lens Insertion	<p>Subjects will insert the lenses themselves. If the lens is uncomfortable, inspect for damage and remove, reinsert or replace as necessary.</p> <p>Damaged lenses will be stored in labeled vial with sterile saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor. Complete the Product Quality Complaint form.</p>	
1.24	Lens Settling	Allow the study lenses to settle for a minimum of 10 minutes.	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

1.25	Determine Visual Satisfaction	Determine if the subject's vision is acceptable with the lenses. Allow the subject to look down a hallway or out of a window for distance vision assessments, and for them to read a book, magazine or similar for near vision.	
1.26	Study Lens Distance and Near Visual Acuity	Measure the distance and near visual acuity OD, OS and OU. Record the results.  <b>Note:</b> Use the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm to measure the Near visual acuity	[REDACTED]
1.27	Distance Over-Refraction and Distance Visual Acuity	Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination. The distance over-refraction may also be refined under binocular conditions. Record the results. The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.	
1.28	Modifications	If the subject reports unsatisfactory vision or is unable to obtain 20/30 distance visual acuity OU with the lenses, then a modification must be attempted. If the subject reports satisfactory vision with the lenses a modification is not required, however at the Investigator's discretion and based upon their findings on the measured visual acuity and/or over-refraction the investigator may make a modification.  Up to two attempts at modification are permitted, if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.  Follow the fitting guide allowing for at least 10 minutes of settling time between each lens modification attempted.  If modifications are required steps 1.22-1.27 will be repeated for each modification.	[REDACTED] [REDACTED] [REDACTED]
1.29	Lens Fit Assessment	Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).  The subject should not proceed to wear the	[REDACTED]

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<p>lenses if any of the following is observed:</p> <ul style="list-style-type: none"> <li>• presence of limbal exposure (appearance of clear cornea) in any gaze</li> <li>• presence of edge lift</li> <li>• presence of unacceptable movement (excessive or insufficient) in <u>all three</u> movement categories (primary gaze, upgaze, and push-up).</li> </ul> <p><b><i>NOTE: If lens fit is unacceptable subject will be discontinued from the study. Remove the lenses, and complete the Final Evaluation forms.</i></b></p>	
1.30	Distance and Near Exit Visual Acuity	<p>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place.</p> <p>For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</p> <p><b><i>NOTE: The distance visual acuity must be at least 20/30 OU for the lenses to be dispensed.</i></b></p>	
1.31	Dispensing Criteria	<p>The following criteria must be met for lenses to be dispensed and if not all are met subject to be discontinued.</p> <ul style="list-style-type: none"> <li>• Distance Snellen acuity equal to or better than 20/30 OU</li> <li>• Subject must indicate that the vision is acceptable.</li> <li>• Subject must indicate that the comfort of the lenses is acceptable.</li> <li>• Lenses must have an acceptable general lens fit.</li> </ul>	
1.32	Patient Instructions	<p>Instruct the Subject the following:</p> <ul style="list-style-type: none"> <li>• The lenses will be worn on a daily wear basis.</li> <li>• Only enough lenses will be dispensed to the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed.</li> </ul>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<ul style="list-style-type: none"> <li>• A new lens will be opened and worn each day.</li> <li>• Instruct the subject to bring back all unworn study lenses.</li> <li>• Instruct the subject no cleaning or disinfecting solutions will be used for this lens type.</li> <li>• If determined necessary by the Investigator sterile non-preserved rewetting drops may be dispensed to be used as needed for dryness.</li> <li>• Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study.</li> <li>• Subjects will be instructed to wear their glasses when not wearing the study lenses.</li> <li>• A patient instruction booklet will be provided.</li> </ul> <p><b><u>NOTE: In the event a lens is lost or damaged, the subject will return to the clinical site for replacement. As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.</u></b></p>	
1.33	Schedule Follow-up	<p>The subject will be scheduled to return for their follow-up appointment in <math>3\pm1</math> days.</p> <p><b><u>NOTE: To count the follow-up visit as a day of wear the Subject must have worn the study lenses for 6 hours prior to the visit.</u></b></p>	

## VISIT 2

The subjects must present to Visit 2 wearing the study lenses. To be counted as a day of wear the lenses need to have been worn for at least six (6) hours prior to the visit.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Visit 2: Treatment 1 Follow-up 1			
Step	Procedure	Details	
2.1	Adverse Events and Concomitant Medications Review	<p>Review the subject's concomitant medications and record any changes from the previous study visit.</p> <p>Record any adverse events or medical history changes from the previous study visit.</p>	
2.2	Wear time and Comfortable Wear time with Study lenses	Record the hours the subject has worn the study lenses and the comfortable wear time on the day of follow-up.	
2.3	Compliance	<p>Record the subject's compliance with wearing the study lenses.</p> <p><b><i>NOTE: Subjects must have worn lenses for at least 6 hours per day.</i></b></p> <p><b><i>To be counted as a day of wear at this visit the Subject must have worn the study lenses for 6 hours prior to the visit.</i></b></p>	
2.4	Follow-Up PRO (CLUE) Questionnaire	The subject will respond to the Follow-Up PRO (CLUE) Questionnaire.	
2.5	Ocular Symptoms	Subjects will respond to a verbal open-ended symptoms questionnaire.	
2.6	Subjective Acceptance	Record whether the subject's distance and near vision with the lenses is acceptable.	
2.7	Distance and Near Entrance Visual Acuity	<p>Measure the distance and near visual acuity OD, OS and OU. Record the results.</p> <p>Use the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm to measure the Near visual acuity</p>	
2.8	Distance Over-Refraction and Distance Visual Acuity	<p>Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination. The distance over-refraction may also be refined under binocular conditions. Record the results and distance visual acuity OD and OS.</p> <p>The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.</p>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

2.9	Determination of Lens Optimization	<p>If the subject reports unsatisfactory vision or is unable to obtain 20/30 distance visual acuity OU with the lenses, then a modification must be attempted.</p> <p>If the subject reports satisfactory vision with the lenses a modification is not required, however at the Investigator's discretion and based upon their findings on the measured visual acuity and/or over-refraction the investigator may make a modification.</p> <p>Up to two attempts at modification are permitted if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.</p> <p>Follow the fitting guide and steps 1.22-1.27 in Visit 1 Fitting allowing for at least 10 minutes of settling time between each lens modification.</p>	
2.10	Lens Fit Assessment	<p>Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).</p> <ul style="list-style-type: none"> <li>• The subject should not proceed to wear the lenses if any of the following is observed:</li> <li>• presence of limbal exposure (appearance of clear cornea) in any gaze</li> <li>• presence of edge lift</li> <li>• presence of unacceptable movement (excessive or insufficient) in <u>all three</u> movement categories (primary gaze, upgaze, and push-up).</li> </ul> <p><b><u>NOTE: If lens fit is unacceptable subject will be discontinued from the study. Remove the lenses, and complete the Final Evaluation forms.</u></b></p>	
2.11	Collection of unworn lenses (if applicable)	<p>Collect unworn lenses returned by the subject when lens power has been optimized.</p> <p>If lens power was not changed allow the subject to use the unworn lenses dispensed at Visit 1 and dispense enough lenses of the</p>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		same power to last the subject until their next visit.	
2.12	Lens Removal	The study lenses will be removed and discarded.	
2.13	Biomicroscopy	<p>Perform biomicroscopy OD and OS. Slit Lamp Classification Scales will be used to grade the findings.</p> <p>If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops may be instilled.</p>	
2.14	Insertion of Study Lenses	Dispense the subject a new pair of lenses that match the distance and ADD power of the lenses that were removed in Step 2.12 above.	
2.15	Distance and Near Exit Visual Acuity	<p>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place.</p> <p>For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</p> <p><b><u>NOTE: The distance visual acuity must be at least 20/30 OU for the lenses to be dispensed.</u></b></p>	
2.16	Dispensing Criteria	<p>The following criteria must be met for lenses to be dispensed and if not all are met subject to be discontinued.</p> <ul style="list-style-type: none"> <li>• Distance Snellen acuity equal to or better than 20/30 OU</li> <li>• Subject must indicate that the vision is acceptable.</li> <li>• Subject must indicate that the comfort of the lenses is acceptable.</li> <li>• Lenses must have an acceptable general lens fit.</li> </ul>	
2.17	Patient Instructions	<p>Instruct the Subject the following:</p> <ul style="list-style-type: none"> <li>• The lenses will be worn on a daily wear basis.</li> <li>• Only enough lenses will be dispensed to the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed.</li> </ul>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<ul style="list-style-type: none"> <li>• A new lens will be opened and worn each day.</li> <li>• Instruct the subject to bring back all unworn study lenses.</li> <li>• Instruct the subject no cleaning or disinfecting solutions will be used for this lens type.</li> <li>• If determined necessary by the Investigator sterile non-preserved rewetting drops may be dispensed to be used as needed for dryness.</li> <li>• Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study.</li> <li>• Subjects will be instructed to wear their glasses when not wearing the study lenses.</li> </ul> <p><b><u>NOTE:</u></b> <i>In the event a lens is lost or damaged, the subject will return to the clinical site for replacement. As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.</i></p>	
2.18	Schedule Follow-up	<p>The subject will be scheduled to return for their follow-up appointment in <math>7\pm1</math> days.</p> <p><b><u>NOTE:</u></b> <i>To count the follow-up visit as a day of wear the Subject must have worn the study lenses for 6 hours prior to the visit.</i></p>	

### VISIT 3

The subjects must present to Visit 3 wearing the study lenses. To be counted as a day of wear the lenses need to have been worn for at least six (6) hours prior to the visit.

Visit 3: Treatment 1 Follow-up 2

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Step	Procedure	Details	
3.1	Adverse Events and Concomitant Medications Review	Review the subject's concomitant medications and record any changes from the previous study visit. Record any adverse events or medical history changes from the previous study visit.	
3.2	Wear time and Comfortable Wear time with Study lenses	Record the hours the subject has worn the study lenses and the comfortable wear time on the day of follow-up.	
3.3	Compliance	Record the subject's compliance with wearing the study lenses.  <b><u>NOTE: Subjects must have worn lenses for at least 6 hours per day.</u></b> <b><u>To be counted as a day of wear at this visit the Subject must have worn the study lenses for 6 hours prior to the visit.</u></b>	
3.4	PRO (CLUE and MRD) and CLDEQ-8 Questionnaires	The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO (CLUE and MRD) questionnaires.	
3.5	Ocular Symptoms	Subjects will respond to a verbal open-ended symptoms questionnaire	
3.6	Subjective Acceptance	Record whether the subject's distance and near vision with the lenses is acceptable.	
3.7	Distance and Near Entrance Visual Acuity	Measure the distance and near visual acuity OD, OS and OU. Record the results.  For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.	
3.8	Visual Performance Distance (4M) Intermediate (64 cm) Near (40 cm)	Visual performance will be recorded OD, OS, and OU for the following: <b>Distance, Bright Illuminance</b> <i>High and Low Contrast ETDRS Charts</i> 4M- HC#1, HC#2, HC#3 and LC#1, LC#2, LC#3  <b>Near, Bright Illuminance</b> <i>Reduced Guillot-Polking Charts</i> Intermediate (64 cm) High Contrast and Low Contrast Near (40 cm) High Contrast and Low Contrast	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<p><b>Distance, Dim Illuminance (with <u>Distance</u> goggles)</b>  <i>High Contrast ETDRS Charts 4M-HC#4, HC#5, HC#6</i></p> <p><b>Near, Dim Illuminance (with <u>Near</u> goggles)</b>  <i>Reduced Guillot-Polking charts</i>      High Contrast Intermediate (64 cm) and Near (40 cm).</p> <p><b>Note:</b></p> <ul style="list-style-type: none"> <li>• The room illuminance must be between 7.3 and 7.9 EV (394-597 lux).</li> <li>• Distance, HC-1 Chart luminance Acceptable Range 10.5-10.7 EV (181-208 cd/m<sup>2</sup>).</li> <li>• Guillot-Polking, Near Chart Luminance Acceptable Range 10.8-11.1 EV (223-274 cd/m<sup>2</sup>).</li> <li>• Do not use the Mesopic filter for Dim luminance (Dim luminance will be simulated by using the goggles)</li> </ul>	
3.9	Binocular Distance Over-refraction and Distance Visual Acuity	<p>Perform a binocular over-refraction and record the OD and OS results and distance visual acuity.</p> <p>Note: No lens changes are allowed based on the over-refraction.</p>	[REDACTED]
3.10	C-Quant Straylight Meter Testing [REDACTED]	Ocular straylight will be measured using the C-Quant OD and OS and record the log (s), Esd and Q values to two decimal places.	[REDACTED]
3.11	Corneal Topography and Wavefront measurement [REDACTED]	Using the VISIONIX corneal topography and wavefront will be measured over the contact lens OD and OS. The simulated Ks will be recorded.	[REDACTED]
3.12	Lens Fit Assessment	<p>Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).</p> <ul style="list-style-type: none"> <li>• The subject should not proceed to wear the lenses if any of the following is observed:</li> <li>• presence of limbal exposure (appearance of clear cornea) in any gaze</li> </ul>	[REDACTED]

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<ul style="list-style-type: none"> <li>• presence of edge lift</li> <li>• presence of unacceptable movement (excessive or insufficient) in <u>all three</u> movement categories (primary gaze, upgaze, and push-up).</li> </ul> <p><b><u>NOTE: If lens fit is unacceptable subject will be discontinued from the study. Remove the lenses, and complete the Final Evaluation forms.</u></b></p>	
3.13	Collection of unworn lenses (if applicable)	Collect unworn lenses returned by the subject.	
3.14	Lens Removal	Have the subject remove the study lenses and store in saline in a labeled glass vial. <b><u>NOTE: Lenses do not need to be stored in a refrigerator.</u></b>	
3.15	Biomicroscopy	<p>Perform biomicroscopy OD and OS. Slit Lamp Classification Scales will be used to grade the findings.</p> <p>If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops may be instilled.</p>	
3.16	Continuance	Determine whether the subject is eligible to continue in the study based on the examination findings.	

Visit 3: Treatment 2 Lens Fitting		
Step	Procedure	Details
3.19	Lens Selection	Select the lens pair and power based on the randomization scheme, spherical equivalent refraction (measured at Visit 1 baseline) and fitting guide for each eye. Record the Test lens parameters (power and lot number).
3.20	Lens Insertion	<p>Subjects will insert the lenses themselves. If the lens is uncomfortable, inspect for damage and remove, reinsert or replace as necessary.</p> <p>Damaged lenses will be stored in labeled vial with sterile saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor. Complete the Product Quality Complaint form.</p>

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

3.21	Lens Settling	Allow the study lenses to settle for a minimum of 10 minutes.	
3.22	Determine Visual Satisfaction	Determine if the subject's vision is acceptable with the lenses. Allow the subject to look down a hallway or out of a window for distance vision assessments, and for them to read a book, magazine or similar for near vision.	
3.23	Distance and Near Entrance Visual Acuity	<p>Measure the distance and near visual acuity OD, OS and OU. Record the results.</p> <p>For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</p>	████████
3.24	Distance Over-Refraction and Distance Visual Acuity	Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination. The distance over-refraction may also be refined under binocular conditions. Record the results. The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.	
3.25	Modifications	<p>If the subject reports unsatisfactory vision or is unable to obtain 20/30 distance visual acuity OU with the lenses, then a modification must be attempted. If the subject reports satisfactory vision with the lenses a modification is not required, however at the Investigator's discretion and based upon their findings on the measured visual acuity and/or over-refraction the investigator may make a modification.</p> <p>Up to two attempts at modification are permitted, if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type. Follow the fitting guide allowing for at least 10 minutes of settling time between each lens modification attempted.</p> <p>If modifications are required steps 3.19-3.25 will be repeated for each modification.</p>	████████ ████████ ████████ ████████
3.26	Lens Fit Assessment	Evaluate overall lens fit acceptance (acceptable or unacceptable) based on	████████

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<p>centration, movement and other fitting characteristics.</p> <p>The subject should not proceed to wear the lenses if any of the following is observed:</p> <ul style="list-style-type: none"> <li>• presence of limbal exposure (appearance of clear cornea) in any gaze</li> <li>• presence of edge lift</li> <li>• presence of unacceptable movement (excessive or insufficient) in <u>all three</u> movement categories (primary gaze, upgaze, and push-up).</li> </ul> <p><b><u>NOTE: If lens fit is unacceptable subject will be discontinued from the study. Remove the lenses, and complete the Final Evaluation forms.</u></b></p>	
3.27	Distance and Near Exit Visual Acuity	<p>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place.</p> <p>For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</p> <p><b><u>NOTE: The distance visual acuity must be at least 20/30 OU for the lenses to be dispensed.</u></b></p>	
3.28	Dispensing Criteria	<p>The following criteria must be met for lenses to be dispensed and if not all are met subject to be discontinued.</p> <ul style="list-style-type: none"> <li>• Distance Snellen acuity equal to or better than 20/30 OU</li> <li>• Subject must indicate that the vision is acceptable.</li> <li>• Subject must indicate that the comfort of the lenses is acceptable.</li> <li>• Lenses must have an acceptable general lens fit.</li> </ul>	
3.29	Patient Instructions	<p>Instruct the Subject the following:</p> <ul style="list-style-type: none"> <li>• The lenses will be worn on a daily wear basis.</li> </ul>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<ul style="list-style-type: none"><li>• Only enough lenses will be dispensed to the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed.</li><li>• A new lens will be opened and worn each day.</li><li>• Instruct the subject to bring back all unworn study lenses.</li><li>• Instruct the subject no cleaning or disinfecting solutions will be used for this lens type.</li><li>• If determined necessary by the Investigator sterile non-preserved rewetting drops may be dispensed to be used as needed for dryness.</li><li>• Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study.</li><li>• Subjects will be instructed to wear their glasses when not wearing the study lenses.</li><li>• A patient instruction booklet will be provided.</li></ul> <p><b><i>NOTE: In the event a lens is lost or damaged, the subject will return to the clinical site for replacement. As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.</i></b></p>	
3.30	Schedule Follow-up	The subject will be scheduled to return for their follow-up appointment in 3±1 days.	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<p><b><u>NOTE:</u></b> <i>To count the follow-up visit as a day of wear the Subject must have worn the study lenses for 6 hours prior to the visit.</i></p>	
--	--	---	--

## VISIT 4

The subjects must present to Visit 4 wearing the study lenses. To be counted as a day of wear the lenses need to have been worn for at least six (6) hours prior to the visit.

Visit 4: Treatment 2 Follow-up 1			
Step	Procedure	Details	
4.1	Adverse Events and Concomitant Medications Review	Review the subject's concomitant medications and record any changes from the previous study visit.  Record any adverse events or medical history changes from the previous study visit.	[REDACTED]
4.2	Wear time and Comfortable Wear time with Study lenses Wear Time	Record the hours the subject has worn the study lenses and the comfortable wear time on the day of follow-up.	[REDACTED]
4.3	Compliance	Record the subject's compliance with wearing the study lenses.  <b><u>NOTE:</u></b> <i>Subjects must have worn lenses for at least 6 hours per day To be counted as a day of wear at this visit the Subject must have worn the study lenses for 6 hours prior to the visit.</i>	[REDACTED]
4.4	Follow-Up PRO (CLUE) Questionnaire	The subject will respond to the Follow-Up PRO (CLUE) Questionnaire.	[REDACTED]
4.5	Ocular Symptoms	Subjects will respond to a verbal open-ended symptoms questionnaire.	[REDACTED]
4.6	Subjective Acceptance	Record whether the subject's distance and near vision with the lenses is acceptable.	[REDACTED]
4.7	Distance and Near Entrance Visual Acuity	Measure the distance and near visual acuity OD, OS and OU. Record the results.  Use the ETDRS 2000 Series Chart 1 or 2 near card placed at 40 cm to measure the Near visual acuity	[REDACTED]
4.8	Distance Over-Refraction and	Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination.	[REDACTED]

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

	Distance Visual Acuity	<p>The distance over-refraction may also be refined under binocular conditions. Record the results and distance visual acuity OD and OS.</p> <p>The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.</p>	
4.9	Determination of Lens Optimization	<p>If the subject reports unsatisfactory vision or is unable to obtain 20/30 distance visual acuity OU with the lenses, then a modification must be attempted.</p> <p>If the subject reports satisfactory vision with the lenses a modification is not required, however at the Investigator's discretion and based upon their findings on the measured visual acuity and/or over- refraction the investigator may make a modification.</p> <p>Up to two attempts at modification are permitted, if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.</p> <p>Follow the fitting guide and steps 3.20-3.25 in Visit 3 Fitting allowing for at least 10 minutes of settling time between each lens modification.</p>	   
4.10	Lens Fit Assessment	<p>Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).</p> <ul style="list-style-type: none"> <li>• The subject should not proceed to wear the lenses if any of the following is observed:</li> <li>• presence of limbal exposure (appearance of clear cornea) in any gaze</li> <li>• presence of edge lift</li> <li>• presence of unacceptable movement (excessive or insufficient) in <u>all three</u> movement categories (primary gaze, upgaze, and push-up).</li> </ul> <p><b><u>NOTE: If lens fit is unacceptable subject will be discontinued from the study. Remove</u></b></p>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<i>the lenses, and complete the Final Evaluation forms.</i>	
4.11	Collection of unworn lenses (if applicable)	<p>Collect unworn lenses returned by the subject when lens power has been optimized.</p> <p>If lens power was not changed allow the subject to use the unworn lenses dispensed at Visit 3 and dispense enough lenses of the same power to last the subject until their next visit.</p>	
4.12	Lens Removal	The study lenses will be removed and discarded.	
4.13	Biomicroscopy	<p>Perform biomicroscopy OD and OS. Slit Lamp Classification Scales will be used to grade the findings.</p> <p>If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops may be instilled.</p>	
4.14	Insertion of Study Lenses	Dispense the subject a new pair of lenses that match the distance and ADD power of the lenses that were removed in Step 4.12 above.	
4.15	Distance and Near Exit Visual Acuity	<p>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place.</p> <p>For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</p> <p><b><u>NOTE: The distance visual acuity must be at least 20/30 OU for the lenses to be dispensed.</u></b></p>	
4.16	Dispensing Criteria	<p>The following criteria must be met for lenses to be dispensed and if not all are met subject to be discontinued.</p> <ul style="list-style-type: none"> <li>• Distance Snellen acuity equal to or better than 20/30 OU</li> <li>• Subject must indicate that the vision is acceptable.</li> <li>• Subject must indicate that the comfort of the lenses is acceptable.</li> </ul>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<ul style="list-style-type: none"> <li>• Lenses must have an acceptable general lens fit.</li> </ul>	
4.17	Patient Instructions	<p>Instruct the Subject the following:</p> <ul style="list-style-type: none"> <li>• The lenses will be worn on a daily wear basis.</li> <li>• Only enough lenses will be dispensed to the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed.</li> <li>• A new lens will be opened and worn each day.</li> <li>• Instruct the subject to bring back all unworn study lenses.</li> <li>• Instruct the subject no cleaning or disinfecting solutions will be used for this lens type.</li> <li>• If determined necessary by the Investigator sterile non-preserved rewetting drops may be dispensed to be used as needed for dryness.</li> <li>• Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study.</li> <li>• Subjects will be instructed to wear their glasses when not wearing the study lenses.</li> <li>• Subjects will be instructed to bring their habitual contacts or spectacles to the next visit.</li> </ul> <p><b><u>NOTE: In the event a lens is lost or damaged, the subject will return to the clinical site for replacement. As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn</u></b></p>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<i><b>lenses that will be shipped back to the Sponsor.</b></i>	
4.18	Schedule Follow-up	<p>The subject will be scheduled to return for their follow-up appointment in 7±1 days.</p> <p><b><u>NOTE: To count the follow-up visit as a day of wear the Subject must have worn the study lenses for 6 hours prior to the visit.</u></b></p>	

## VISIT 5

The subjects must present to Visit 5 wearing the study lenses. To be counted as a day of wear the lenses need to have been worn for at least six (6) hours prior to the visit.

Visit 5: Treatment 2 Follow-up 2			
Step	Procedure	Details	
5.1	Adverse Events and Concomitant Medications Review	<p>Review the subject's concomitant medications and record any changes from the previous study visit.</p> <p>Record any adverse events or medical history changes from the previous study visit.</p>	
5.2	Wear time and Comfortable Wear time with Study lenses	Record the hours the subject has worn the study lenses and the comfortable wear time on the day of follow-up.	
5.3	Compliance	<p>Record the subject's compliance with wearing the study lenses.</p> <p><b><u>NOTE: Subjects must have worn lenses for at least 6 hours per day</u></b>  <b><u>To be counted as a day of wear at this visit the Subject must have worn the study lenses for 6 hours prior to the visit.</u></b></p>	
5.4	PRO (CLUE and MRD) and CLDEQ-8 Questionnaires	The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO (CLUE and MRD) questionnaires.	
5.5	Ocular Symptoms	Subjects will respond to a verbal open-ended symptoms questionnaire	
5.6	Subjective Acceptance	Record whether the subject's distance and near vision with the lenses is acceptable.	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

5.7	Distance and Near Entrance Visual Acuity	<p>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place.</p> <p>For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</p>	
5.8	Visual Performance Distance (4M) Intermediate (64 cm) Near (40 cm)	<p>Visual performance will be recorded OD, OS, and OU for the following:</p> <p><b>Distance, Bright Illuminance</b>  <i>High and Low Contrast ETDRS Charts</i>          4M- HC#1, HC#2, HC#3 and LC#1, LC#2, LC#3</p> <p><b>Near, Bright Illuminance</b>  <i>Reduced Guillon-Poling Charts</i> Intermediate (64 cm) High Contrast and Low Contrast          Near (40 cm) High Contrast and Low Contrast</p> <p><b>Distance, Dim Illuminance (with <u>Distance</u> goggles)</b>  <i>High Contrast ETDRS Charts</i> 4M-HC#4, HC#5, HC#6</p> <p><b>Near, Dim Illuminance (with <u>Near</u> goggles)</b>  <i>Reduced Guillon-Poling charts</i>          High Contrast Intermediate (64 cm) and Near (40 cm).</p> <p><b>Note:</b></p> <ul style="list-style-type: none"> <li>• The room illuminance must be between 7.3 and 7.9 EV (394-597 lux).</li> <li>• Distance, HC-1 Chart luminance Acceptable Range 10.5-10.7 EV (181-208 cd/m<sup>2</sup>).</li> <li>• Guillon-Poling, Near Chart Luminance Acceptable Range 10.8-11.1 EV (223-274 cd/m<sup>2</sup>).</li> <li>• Do not use the Mesopic filter for Dim luminance (Dim luminance will be simulated by using the goggles)</li> </ul>	  

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

5.9	Binocular Distance Over-refraction and Distance Visual Acuity	<p>Perform a binocular over-refraction and record the OD and OS results and distance visual acuity.</p> <p>Note: No lens changes are allowed based on the over-refraction.</p>	[REDACTED]
5.10	C-Quant Straylight Meter Testing [REDACTED]	<p>Ocular straylight will be measured using the C-Quant OD and OS and record the log (s), Esd and Q values to two decimal places.</p>	[REDACTED]
5.11	Corneal Topography and Wavefront measurement [REDACTED]	<p>Using the VISIONIX corneal topography and wavefront will be measured over the contact lens OD and OS. The simulated Ks will be recorded.</p>	[REDACTED]
5.12	Lens Fit Assessment	<p>Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).</p> <p>The subject should not proceed to wear the lenses if any of the following is observed:</p> <ul style="list-style-type: none"> <li>• presence of limbal exposure (appearance of clear cornea) in any gaze</li> <li>• presence of edge lift</li> <li>• presence of unacceptable movement (excessive or insufficient) in <u>all three</u> movement categories (primary gaze, upgaze, and push-up).</li> </ul> <p><b><u>NOTE: If lens fit is unacceptable subject will be discontinued from the study. Remove the lenses, and complete the Final Evaluation forms.</u></b></p>	[REDACTED]
5.13	Collection of unworn lenses (if applicable)	<p>Collect unworn lenses returned by the subject.</p>	
5.14	Lens Removal	<p>Have the subject remove the study lenses and store in saline in a labeled glass vial.</p> <p><b><u>NOTE: Lenses do not need to be stored in a refrigerator.</u></b></p>	
5.15	Biomicroscopy	<p>Perform biomicroscopy OD and OS. Slit Lamp Classification Scales will be used to grade the findings.</p> <p>If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops may be instilled.</p>	[REDACTED]

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

5.16	Continuance	Determine whether the subject is eligible to continue in the study based on the examination findings.	
------	-------------	---	--

Visit 5: Treatment 3 Lens Fitting			
Step	Procedure	Details	
5.19	Lens Selection	Select the same lens pair and power that was dispensed at Visit 4.  Record the Test lens parameters (power and lot number).	
5.20	Lens Insertion	Subjects will insert the lenses themselves. If the lens is uncomfortable, inspect for damage and remove, reinsert or replace as necessary.  Damaged lenses will be stored in labeled vial with sterile saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor. Complete the Product Quality Complaint form.	
5.21	Lens Settling	Allow the study lenses to settle for a minimum of 10 minutes.	
5.22	Determine Visual Satisfaction	Determine if the subject's vision is acceptable with the lenses. Allow the subject to look down a hallway or out of a window for distance vision assessments, and for them to read a book, magazine or similar for near vision.	
5.23	Distance and Near Entrance Visual Acuity	Measure the distance and near visual acuity OD, OS and OU. Record the results.  For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.	
5.24	Distance Over-Refraction and Distance Visual Acuity	Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination. The distance over-refraction may also be refined under binocular conditions. Record the results. The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.	
5.25	Lens Fit Assessment	Evaluate overall lens fit acceptance (acceptable or unacceptable) based on	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		<p>centration, movement and other fitting characteristics.</p> <p>An unacceptable fit is deemed by one of the following criteria:</p> <ul style="list-style-type: none"> <li>• limbal exposure at primary gaze or with extreme eye movement;</li> <li>• edge lift;</li> <li>• excessive movement in primary and up gaze; or</li> <li>• insufficient movement in all three of the following conditions: primary gaze, up gaze, and Josephson push up.</li> </ul> <p><b><u>NOTE: If lens fit is unacceptable subject will be discontinued from the study. Remove the lenses, and complete the Final Evaluation forms.</u></b></p>	
5.26	Distance and Near Exit Visual Acuity	<p>Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place.</p> <p>For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</p> <p><b><u>NOTE: The distance visual acuity must be at least 20/30 OU for the lenses to be dispensed.</u></b></p>	
5.27	Dispensing Criteria	<p>The following criteria must be met for lenses to be dispensed and if not all are met subject to be discontinued.</p> <ul style="list-style-type: none"> <li>• Distance Snellen acuity equal to or better than 20/30 OU</li> <li>• Subject must indicate that the vision is acceptable.</li> <li>• Subject must indicate that the comfort of the lenses is acceptable.</li> <li>• Lenses must have an acceptable general lens fit.</li> </ul>	
5.28	Patient Instructions	Instruct the Subject the following:	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

	<ul style="list-style-type: none"><li>• The lenses will be worn on a daily wear basis.</li><li>• Only enough lenses will be dispensed to the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed.</li><li>• A new lens will be opened and worn each day.</li><li>• Instruct the subject to bring back all unworn study lenses.</li><li>• Instruct the subject no cleaning or disinfecting solutions will be used for this lens type.</li><li>• If determined necessary by the Investigator sterile non-preserved rewetting drops may be dispensed to be used as needed for dryness.</li><li>• Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study.</li><li>• Subjects will be instructed to wear their glasses when not wearing the study lenses.</li><li>• A patient instruction booklet will be provided.</li><li>• Subjects will be instructed to bring their habitual contacts or glasses to the next visit.</li></ul> <p><b><u>NOTE: In the event a lens is lost or damaged, the subject will return to the clinical site for replacement. As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.</u></b></p>	
--	--	--

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

5.29	Schedule Follow-up	<p>The subject will be scheduled to return for their follow-up appointment in 7±1 days.</p> <p><b><u>NOTE:</u></b> <i>To count the follow-up visit as a day of wear the Subject must have worn the study lenses for 6 hours prior to the visit.</i></p>	
------	--------------------	---	--

## VISIT 6

The subjects must present to Visit 6 wearing the study lenses. To be counted as a day of wear the lenses need to have been worn for at least six (6) hours prior to the visit.

Visit 6: Treatment 2 Follow-up 1			
Step	Procedure	Details	
6.1	Adverse Events and Concomitant Medications Review	<p>Review the subject's concomitant medications and record any changes from the previous study visit.</p> <p>Record any adverse events or medical history changes from the previous study visit.</p>	
6.2	Wear time and Comfortable Wear time with Study lenses	Record the hours the subject has worn the study lenses and the comfortable wear time on the day of follow-up.	
6.3	Compliance	<p>Record the subject's compliance with wearing the study lenses.</p> <p><b><u>NOTE:</u></b> <i>Subjects must have worn lenses for at least 6 hours per day</i>  <i>To be counted as a day of wear at this visit the Subject must have worn the study lenses for 6 hours prior to the visit.</i></p>	
6.4	PRO (CLUE and MRD) and CLDEQ-8 Questionnaires	The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO (CLUE and MRD) questionnaires.	
6.5	Ocular Symptoms	Subjects will respond to a verbal open-ended symptoms questionnaire	
6.6	Subjective Acceptance	Record whether the subject's distance and near vision with the lenses is acceptable.	
6.7	Distance and Near Entrance Visual Acuity	Distance and near Snellen visual acuity will be measured for each eye with the study contact lenses in place.	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

		For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.	
6.8	Visual Performance Distance (4M) Intermediate (64 cm) Near (40 cm)	<p>Visual performance will be recorded OD, OS, and OU for the following:</p> <p><b>Distance, Bright Illuminance</b>  <i>High and Low Contrast ETDRS Charts</i>          4M- HC#1, HC#2, HC#3 and LC#1, LC#2, LC#3</p> <p><b>Near, Bright Illuminance</b>  <i>Reduced Guillon-Poling Charts</i> Intermediate (64 cm) High Contrast and Low Contrast</p> <p>Near (40 cm) High Contrast and Low Contrast</p> <p><b>Distance, Dim Illuminance (with <u>Distance</u> goggles)</b>  <i>High Contrast ETDRS Charts</i> 4M-HC#4, HC#5, HC#6</p> <p><b>Near, Dim Illuminance (with <u>Near</u> goggles)</b>  <i>Reduced Guillon-Poling charts</i>          High Contrast Intermediate (64 cm) and Near (40 cm).</p> <p><b>Note:</b></p> <ul style="list-style-type: none"> <li>• The room illuminance must be between 7.3 and 7.9 EV (394-597 lux).</li> <li>• Distance, HC-1 Chart luminance Acceptable Range 10.5-10.7 EV (181-208 cd/m<sup>2</sup>).</li> <li>• Guillon-Poling, Near Chart Luminance Acceptable Range 10.8-11.1 EV (223-274 cd/m<sup>2</sup>).</li> <li>• Do not use the Mesopic filter for Dim luminance (Dim luminance will be simulated by using the goggles)</li> </ul>	
6.9	Binocular Distance Over-refraction and Distance Visual Acuity	<p>Perform a binocular over-refraction and record the OD and OS results and distance visual acuity.</p> <p>Note: No lens changes are allowed based on the over-refraction.</p>	

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

6.10	C-Quant Straylight Meter Testing [REDACTED]	Ocular straylight will be measured using the C-Quant OD and OS and record the log (s), Esd and Q values to two decimal places.	[REDACTED]
6.11	Corneal Topography and Wavefront measurement [REDACTED]	Using the VISIONIX corneal topography and wavefront will be measured over the contact lens OD and OS. The simulated Ks will be recorded.	[REDACTED]
6.12	Lens Fit Assessment	<p>Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).</p> <p>The subject should not proceed to wear the lenses if any of the following is observed:</p> <ul style="list-style-type: none"> <li>• presence of limbal exposure (appearance of clear cornea) in any gaze</li> <li>• presence of edge lift</li> <li>• presence of unacceptable movement (excessive or insufficient) in <u>all three</u> movement categories (primary gaze, upgaze, and push-up).</li> </ul> <p><b><u>NOTE: If lens fit is unacceptable subject will be discontinued from the study. Remove the lenses, and complete the Final Evaluation forms.</u></b></p>	[REDACTED]
6.13	Collection of unworn lenses (if applicable)	Collect unworn lenses returned by the subject.	
6.14	Lens Removal	<p>Have the subject remove the study lenses and store in saline in a labeled glass vial.</p> <p><b><u>NOTE: Lenses do not need to be stored in a refrigerator.</u></b></p>	
6.15	Biomicroscopy	<p>Perform biomicroscopy OD and OS. Slit Lamp Classification Scales will be used to grade the findings.</p> <p>If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops may be instilled.</p>	[REDACTED]

#### **FINAL EVALUATION**

The final evaluation will ordinarily take place immediately following the last scheduled follow-up visit per the study protocol. It may also take place at any point the subject discontinues the study or is terminated from the study.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Final Evaluation			
Step	Procedure	Details	
F.1	Distance Subjective Sphero-cylindrical Refraction and Distance Exit Visual Acuity	<p>An optimal, binocular balanced distance sphero-cylindrical refraction will be performed.</p> <p>Record the refraction and distance visual acuity to the nearest letter.</p>	[REDACTED]
F.2	Subject Disposition	Indicate if the subject completed the study successfully. If subject discontinued from the study indicate the reason.	

### **7.3. Unscheduled Visits**

If, during the investigation, a subject requires an unscheduled visit to the clinical site, the following information will be collected at a minimum:

- Chief complaint prompting the visit. If the reason is an adverse event, the applicable eCRF for the adverse event must be completed and subject record completed as appropriate.
- Date and time of the visit and all procedures completed at the unscheduled visit.
- Review of adverse event and concomitant medications.
- Documentation of any test article dispensed or collected from the subject, if applicable.
- Slit lamp findings (using the Slit Lamp Classification Scale).

If the Investigator withdraws a subject from the study, the final study visit case report forms must be completed indicating the reason(s) why the subject was withdrawn. The subject record must be completed documenting the date and primary reason for withdrawal and the study CRA notified.

Any ocular and non-ocular Adverse Events that are ongoing at the time of the study visit will be followed by the Investigator, within licensure, until they have resolved, returned to pre-treatment status, stabilized, or been satisfactorily explained. If further treatment i.e., beyond licensure is required, the subject will be referred to the appropriate health care provider.

The following information will be collected during an unscheduled visit.

Unscheduled Visit			
Step	Procedure	Details	
U.1	Chief Complaints	Record the subject's chief complaints for reasons for the unscheduled visit	[REDACTED]

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Unscheduled Visit			
U.2	Adverse Events and Concomitant Medications Review	Review the subject's concomitant medications and record any changes from the previous study visit.	
U.3	Subject Reported Ocular Symptoms	Subjects will respond to a verbal open-ended symptoms questionnaire.	████████
U.4	Entrance VA	Record the entrance distance and near visual acuity (OD, OS and OU) to the nearest letter.  For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.	████████
U.5	Subjective Sphero-cylindrical Refraction	An optimal, binocular balanced distance sphero-cylindrical refraction will be performed.  Record the refraction and distance visual acuity to the nearest letter.	████ ████████
U.6	Biomicroscopy	FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility.  For the conjunctival redness █████ 0.5 unit increments will be used in the grading. Corneal Staining Assessment █████ will be graded in 1.0 increments.  If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops may be instilled.	████ ████████ ████████
U.7	Lens Dispensing	Additional study lenses may be dispensed when required.	
U.8	Lens Fit Assessment	Evaluate and grade lens centration, primary gaze movement, upgaze movement and tightness (push-up test).  The subject should not proceed to wear the lenses if any of the following is observed: <ul style="list-style-type: none"> <li>• presence of limbal exposure (appearance of clear cornea) in any gaze</li> <li>• presence of edge lift</li> </ul>	████████

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

Unscheduled Visit			
		<ul style="list-style-type: none"><li>presence of unacceptable movement (excessive or insufficient) in <u>all three</u> movement categories (primary gaze, upgaze, and push-up).</li></ul> <p><b><i>NOTE: If lens fit is unacceptable subject will be discontinued from the study. Remove the lenses, and complete the Final Evaluation forms.</i></b></p>	
U.9	Exit Visual Acuity	<p>Record the subject's exit distance and near visual acuity (OD, OS and OU) to the nearest letter.</p> <p>For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.</p>	[REDACTED]

#### **7.4. Laboratory Procedures**

Not Applicable

### **8. SUBJECTS COMPLETION/WITHDRAWAL**

#### **8.1. Completion Criteria**

Subjects are considered to have completed the study if they:

- provided informed consent.
- they are eligible.
- completed all study visits

#### **8.2. Withdrawal/Discontinuation from the Study**

A subject will be withdrawn from the study for any of the following reasons:

- Subject death during the study period
- Subject withdrawal of consent
- Subject not compliant to protocol
- Subject lost to follow-up
- Subject no longer meets eligibility criteria (e.g. the subject becomes pregnant)
- Subject develops significant or serious adverse events causing discontinuation of study lens wear
- Subjects who have experienced a Corneal Infiltrative Event (CIE)

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

- Investigator's clinical judgment regarding the subject safety reasons (that it is in the best interest of the subject to stop treatment)
- Subject missed any study visits
- Subject not compliant with study lens wear schedule
- Subject not successfully dispensed due to lack of efficacy and safety including poor vision, poor comfort or unacceptable fit

For discontinued subjects, the Investigator will:

- Complete the current visit (scheduled or unscheduled).
- Complete the Final Evaluation, indicating the reason that the subject was discontinued from the study.
- Record the spherocylindrical refraction with best corrected distance visual acuity.
- Collect used test article(s) (worn or brought to the visit) from the subject and discard them, unless otherwise stated in Section 7.2.
- Collect all unused test article(s) from the subject.
- Make arrangements for subject care, if needed, due to their study participation

An additional subject may be enrolled if a subject discontinues from the study prematurely.

In cases where a subject is lost to follow-up, every possible effort must be made to contact the subject and determine the reason for discontinuation/withdrawal. The measures taken to follow up must be documented including two written attempts and a certified letter (or equivalent) as the final attempt.

## **9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION**

Concomitant medications will be documented during screening and updated during the study. Disallowed medications and therapies are medications or therapies that contraindicate contact lens wear.

### **9.1. Systemic Medications**

A summary of disallowed medications is shown in Table 4.

Table 4: Disallowed systemic medications.

Class of Drug	Common Indication(s)	Common Examples
Anticholinergics	Irritable bowel syndrome, Parkinson's disease, peptic ulcer, cystitis, nasal congestion, cold symptoms, overactive bladder, COPD	Bentyl, Spiriva, Atrovent, Hyosyne, Levsin, Symax Fastab, Symax SL, Homax SL, Cogentin, Transderm Scop, etc.
Oral Phenothiazines	Antipsychotic disorders (schizophrenia, mania)	Compazine, Mellaril, Thorazine, Phenagran, etc.

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

Class of Drug	Common Indication(s)	Common Examples
Systemic/Topical Corticosteroids	Arthritis, colitis, asthma, bronchitis, allergic or inflammatory conditions	Cortisone, Prednisone, Hydrocortisone, Medrol, Kenalog etc.
Oral Retinoids	Seborrhea, acne	Isotretinoin, Acitretin, Alitretinoin, etc.
Oral Tetracycline	Urinary Tract Infection, acne, chlamydia, gonorrhea	Sumcytin, Acitsite, Achromycin V, etc.

## **10. DEVIATIONS FROM THE PROTOCOL**

Investigator will notify study sponsor upon identification of a protocol deviation. Protocol deviations must be reported to the sponsor within 24 hours after discovery of the protocol deviation. The Investigator will report deviations per IRB/IEC requirements. All deviations will be tracked and corrective actions implemented as appropriate.

If it becomes necessary for the Investigator to implement a deviation in order to eliminate an immediate hazard to the trial subject, the Investigator may implement the deviation immediately without notification to the sponsor. Within 24 hours after the implemented deviation, the Investigator must notify and provide the rationale to the Sponsor and, as required, the IEC/IRB.

If the deviation potentially impacts the safety of patient or changes the technical integrity of the study then it must be reported to IEC/IRB. This is a "Major Deviation".

Minor deviations have no substantive effect on patient safety or technical integrity of the study. They are often logistical in nature. The informed consent must also not be contradicted by the deviation.

Protocol waivers are prohibited.

## **11. STUDY TERMINATION**

The occurrence of one or more Unanticipated Serious Adverse Device Effect (USADE), or any SAE where the relationship to study agent cannot be ruled out, may result in stopping further dispensing of test article. In the event of a USADE or SAE, the Sponsor may unmask the treatment regimen for the subject(s) and will discuss this with the Investigator before any further subjects are enrolled.

The Sponsor will determine when a study will be stopped. The Principal Investigator always has the discretion to initiate stopping the study based on patient safety or if information indicates the study's results are compromised.

JJVC reserves the right to terminate the study at any time for any reason. Additionally, the IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

study can be terminated by the Principal Investigator at the individual clinical site due to specific clinical observations, if in their opinion, after a discussion with JJVC, it is determined that it would be unwise to continue at the clinical site.

JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is determined that an adverse event presents an unreasonable risk, the investigation, or that part of the investigation presenting the risk, will be terminated as soon as possible.

Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulatory Authority as required by local regulatory requirements.

## **12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS**

A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness or performance of test articles after they have been released for clinical trial use.

Potential complaints may come from a variety of sources including but not limited to subjects, clinical research associates (CRA), clinical operations managers (COM), medical monitors, and site personnel, etc. The following are not considered product quality complaints:

- Subject satisfaction inquiries reported via “Subjective Questionnaires” and “Patient Reported Outcomes (PRO).”
- Clinical test articles that are stored improperly or damaged after receipt at the investigational site.
- Lens replacements that occur due to drops/fall-outs.
- Damage deemed by clinicians or clinical staff to be caused by handling by the user, and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where there is no deficiency alleged by the subject.

Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be recorded in the EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use is not configured to send automatic notifications or when an EDC system is not used, the COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.

Upon receipt of the EDC notification, the COM/CRA will contact the study site to collect additional information which will include:

- Date the complaint was received/recorded in the EDC System (Date of Sponsor Awareness).
- Who received the complaint.
- Study number.
- Clinical site information (contact name, site ID, telephone number).
- Lot number(s).
- Unique Subject Identifier(s).
- Indication of who first observed complaint (site personnel or subject).

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

- OD/OS indication, along with whether the lens was inserted.
- Any related AE number if applicable.
- Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, resolution of symptoms, etc.).
- Eye Care Provider objective (slit lamp) findings if applicable.
- Confirmation of product availability for return (and tracking information, if available), or rationale if product is not available for return

Once a complaint is received, it will be assessed by the COM, CRA, or trained site personnel to determine if it is an Adverse Event/Serious Adverse Event (AE/SAE). If the complaint results in an AE/SAE, the COM/CRA, or trained site personnel will follow Section 13 of this protocol. If the AE/SAE was potentially the result of a product quality related deficiency, these procedures also applies and will be executed in parallel.

In some cases, a PQC form may be generated in EDC by the site in error. In this event, the PQC forms will be marked “Intentionally Left Blank” or “ILB”. Justification for ILB must be documented.

### 13. ADVERSE EVENTS

#### 13.1. Definitions and Classifications

**Adverse Event (AE)** – An AE is “any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device.

*This definition includes events related to the investigational medical device or the comparator, and to the procedures involved. For users or other persons, this definition is restricted to events related to investigational medical devices<sup>1</sup>*

An AE includes any condition (including a pre-existing condition) that:

1. Was not present prior to the study, but appeared or reappeared following initiation of the study.
2. Was present prior to the study, but worsened during the study. This would include any condition resulting from concomitant illnesses, reactions to concomitant medications, or progression of disease states.
3. Pregnancy must be documented as an adverse event and must be reported to the clinical monitor and to the Sponsor immediately upon learning of the event.

**Serious Adverse Event (SAE)** – An SAE is any adverse event that led to any of the following:

- Death
- Serious deterioration in the health of the subject that resulted in any of the following:
- Life-threatening illness or injury
- Permanent or persistent impairment of a body structure or a body function
- Hospitalization or prolongation of patient hospitalization

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

- Medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
- Chronic disease
- Fetal distress, fetal death or a congenital physical or mental impairment of birth defect.

Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not limited to:

- Microbial Keratitis (MK)
- Iritis (including cells in the anterior chamber)
- Permanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines or greater
- Central Corneal Opacity
- Central Corneal Neovascularization
- Uveitis
- Endophthalmitis
- Hypopyon
- Hyphemia
- Penetration of Bowman's Membrane
- Persistent Epithelial Defect
- Limbal cell Damage leading to Conjunctivalization

**Significant Adverse Events** – are defined as events that are symptomatic and warrant discontinuation (temporary or permanent) of the contact lens wear

Diagnoses and conditions that are considered Ocular Significant Adverse Events include, but not limited to the following:

- Contact Lens Induced Peripheral Ulcer (CLPU)
- Significant Infiltrative Events (SIE)
- Superior Epithelial Arcuate Lesions (SEALs)
- Any Temporary Loss of > 2 Lines of BSCVA
- Other grade 3 or higher corneal findings, such as abrasions or edema
- Non-contact lens related corneal events - e.g. Epidemic Keratoconjunctivitis (EKC)
- Asymptomatic Corneal Scar
- Any corneal event which necessitates temporary lens discontinuation > 2 weeks

**Non-Significant Adverse Events** – are defined as those events that are usually asymptomatic and usually do not warrant discontinuation of contact lens wear but may cause a reduction in wear time. However, the Investigator may choose to prescribe treatment as a precautionary measure.

Diagnoses and conditions that are considered Ocular Non-Significant Adverse Events include, but not limited to the following:

- Non-significant Infiltrative Event (NSIE)
- Contact Lens Papillary Conjunctivitis (CLPC)

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

- Superficial Punctate Keratitis (SPK)
- Conjunctivitis: Bacterial, Viral, Allergic
- Blepharitis
- Meibomianitis
- Contact Dermatitis
- Localized Allergic Reactions
- Any corneal event not explicitly defined as serious or significant adverse event, which necessitates temporary lens discontinuation < 2 weeks

**Adverse Device Effect (ADE)** – An ADE is an “adverse event related to the use of an investigational medical device.

**NOTE 1: to entry:** This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.

**NOTE 2 to entry:** This definition includes any event resulting from use error or from intentional misuse of the investigational medical device.”<sup>1</sup>

**Unanticipated Adverse Device Effect (UADE)** – Any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, the test article, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan, Investigator’s Brochure or protocol, or any other unanticipated serious problem associated with the test article that relates to the rights, safety and welfare of subjects.

### 13.2. Assessing Adverse Events

In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are categorized correctly. Elements of categorization will include:

- Seriousness/Classifications (see definition in Section 13.1).
- Causality or Relatedness – i.e. the relationship between the test article, study treatment or study procedures and the adverse event (not related; unlikely related; possibly related; related - see definition in Section 13.2.1).
- Adverse Event Severity – Adverse event severity is used to assess the degree of intensity of the adverse event (mild; moderate; severe for all events - see definition in Section 0).
- Outcome – not recovered or not resolved; recovering or resolving; recovered or resolved with sequelae; recovered or resolved; death related to adverse event; unknown.
- Actions Taken – none; temporarily discontinued; permanently discontinued; other.

#### 13.2.1. Causality Assessment

**Causality Assessment** – A determination of the relationship between an adverse event and the test article. The test article relationship for each adverse event should be determined by the investigator using these explanations:

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

- Not Related- An adverse event that is not related to the use of the test article, study treatment or study procedures.
- Unlikely Related – An adverse event for which an alternative explanation is more likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time suggests that a causal relationship is not likely.
- Possibly Related – An adverse event that might be due to the use of the test article, or to the study treatment or study procedures. An alternative explanation, e.g. concomitant treatment, concomitant disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship cannot be excluded.
- Related – An adverse event that is listed as a possible adverse effect (device) or adverse reaction (drug) and cannot be reasonably explained by an alternative explanation, e.g. concomitant treatment of concomitant disease(s). The relationship in time is very suggestive, e.g. it is confirmed by de-challenge and re-challenge.

### **13.2.2. Severity Assessment**

**Severity Assessment** – A qualitative assessment of the degree of intensity of an adverse event as determined by the Investigator or reported to him/her by the subject. The assessment of severity is made irrespective of test article, study treatment or study procedure relationship or seriousness of the event and should be evaluated according to the following scale:

- Mild – Event is noticeable to the subject, but is easily tolerated and does not interfere with the subject's daily activities.
- Moderate – Event is bothersome, possible requiring additional therapy, and may interfere with the subject's daily activities.
- Severe – Event is intolerable, necessitates additional therapy or alteration of therapy and interferes with the subject's daily activities.

### **13.3. Documentation and Follow-Up of Adverse Events**

The recording and documenting of adverse events (ocular and non-ocular) begin when the subjects are exposed to the test article, study treatment or study procedure. Adverse events reported before the use of test article, start of study treatment, or study procedures will be recorded as medical history. However, if the condition deteriorates at any time during the study it will be recorded and reported as an AE. Untoward medical events reported after the subject's exit from the study will be recorded as adverse events at the discretion of the Investigator.

Upon finding an adverse event, the Principal Investigator will document the condition in the subject record and in the eCRFs. He/she will complete the Adverse Event /eCRF.

Complete descriptions of all adverse events must be available in the subject record. All Adverse Events including local and systemic reactions not meeting the criteria for "serious adverse events" shall be captured on the appropriate case report form or electronic data system. All adverse events occurring while the subject is enrolled in the study must be documented appropriately regardless of relationship.

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

It is the Investigator's responsibility to maintain documentation of each reported adverse event. All adverse events will be followed in accordance with applicable licensing requirements. Such documentation will include the following:

- Adverse event (diagnosis not symptom).
- Drawings or photographs (where appropriate) that detail the finding (e.g., size, location, and depth, etc.).
- Date the clinical site was notified.
- Date and time of onset.
- Date and time of resolution.
- Adverse event classification, severity, and relationship to test articles, as applicable.
- Treatment regimen instituted, including concomitant medications prescribed, in accordance with applicable licensing requirements.
- Any referral to another health care provider if needed.
- Outcome, ocular damage (if any).
- Likely etiology.
- Best corrected visual acuity at the discovery of the event and upon conclusion of the event.

In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature. If cultures are collected, the date of culture collection and laboratory utilized will be recorded.

Changes in the severity of an AE shall be documented to allow an assessment of the duration of the event at each level of intensity to be performed. Adverse events characterized as intermittent require documentation of the onset and duration of each episode. Changes in the assessment of relationship to the Test Article shall also be clearly documented.

Subjects who present with an adverse event shall be followed by the Investigator, within licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or been satisfactorily resolved. If further treatment beyond licensure is required, the patient will be referred to the appropriate health care provider. The Investigator will use his/her clinical judgment as to whether a subject reporting with an adverse event will continue in the study. If a subject is discontinued from the study, it will be the responsibility of the Investigator to record the reason for discontinuation. The Investigator will also document the adverse event appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse events related to the test article, study treatment or study procedures, as of the final study visit date, should be followed to resolution of the adverse event or until referral to an appropriate health care provider, as recommended by the Investigator. Non-ocular adverse events that are not related to the test article, study treatment, or study procedures may be recorded as "ongoing" without further follow-up.

### **13.4. Reporting Adverse Events**

The Investigator will notify the Sponsor of an adverse event by e-mail, facsimile, or telephone as soon as possible and no later than 24 hours from discovery for any serious /significant

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

adverse events, and 2 days from discovery for any non-significant adverse event. In addition, a written report will be submitted by the Principal Investigator to the IEC/IRB according to their requirements (Section 13.4.2). The report will comment whether the adverse event was considered to be related to the test article, study treatment or study procedures.

### **13.4.1. Reporting Adverse Events to Sponsor**

#### **Serious/Significant Adverse Events**

The Investigator will inform the sponsor of all serious/significant adverse events occurring during the study period as soon as possible by e-mail, fax, or telephone, but no later than 24 hours following discovery of the event. The Investigator is obligated to pursue and obtain information requested by the Sponsor in addition to that information reported on the eCRF. All subjects experiencing a serious/significant adverse event must be followed up and all outcomes must be reported.

When medically necessary, the Investigator may break the randomization code to determine the identity of the treatment that the subject received. The Sponsor and study monitor should be notified prior to unmasking the test articles.

In the event of a serious/significant adverse event, the Investigator must:

- Notify the Sponsor immediately.
- Obtain and maintain in the subject's records all pertinent medical information and medical judgment for colleagues who assisted in the treatment and follow-up of the subject.
- Provide the Sponsor with a complete case history which includes a statement as to whether the event was or was not related to the use of the test article.
- Notify the IEC/IRB as required by the IEC/IRB reporting procedure according to national regulations.

#### **Unanticipated (Serious) Adverse Device Effect (UADE)**

In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later than 24 hours after the Investigator first learns of the effect. This report is in addition to the immediate notification mentioned above.

The Sponsor must conduct an evaluation of the UADE and must report the results of the evaluation to FDA, the IEC/IRB and participating Investigators within 10 working days after the Sponsor first receives notification of the effect.

#### **Non-Serious Adverse Events**

All non-serious adverse events, including non-serious adverse device effects, will be reported to the sponsor by the Investigator no later than 2 days from discovery.

### **13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities**

Adverse events that meet the IEC/IRB requirements for reporting must be reported within the IEC/IRB's written guidelines. Each clinical site will refer to and follow any guidelines set forth

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

by their Approving IEC/IRB. Each clinical site will refer to and follow any guidelines set forth by their local governing Health Authorities.

The Sponsor will report applicable Adverse Events to the local health authorities according the written guidelines, including reporting timelines.

### **13.4.3. Event of Special Interest**

None

### **13.5. Reporting of Pregnancy**

Subjects reporting pregnancy (by self-report) during the study will be discontinued after the event is recorded as an Adverse Event. Once discontinued, pregnant participants and their fetuses will not be monitored for study related purposes. Pregnant participants are not discontinued from contact lens or solution related studies for safety concerns, but due to general concerns relating to pregnancy and contact lens use. Specifically, pregnant women are discontinued due to fluctuations in refractive error and/or visual acuity that occur secondary to systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.

## **14. STATISTICAL METHODS**

### **14.1. General Considerations**

Statistical Analysis will be undertaken by the sponsor or under the authority of the sponsor. A general description of the statistical methods to be implemented in this clinical trial is outlined below.

All data summaries and statistical analyses will be performed using the SAS software Version 9.4 or higher (SAS Institute, Cary, NC). Throughout the analysis of data, the results for each subject/eye will be used when available for summarization and statistical analysis. Unscheduled visits will be summarized separately and will be excluded from the statistical analysis.

Summary tables (descriptive statistics and/or frequency tables) will be provided for all baseline variables, efficacy variables and safety variables as appropriate. Continuous variables will be summarized with descriptive statistics (n, mean, standard deviation [SD], median, minimum and maximum). Frequency count and percentage of subjects or eyes within each category will be provided for categorical data.

Summaries will be presented by study lens type (Test and Control) and will be performed separately by completion status (Safety Population, Per-Protocol Population or Intent-to-Treat Population).

### **14.2. Sample Size Justification**

This study was designed and powered to demonstrate that the binocular high luminance high contrast, visual performance (logMAR) of the Test lens at distance (4 meters) is statistically

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

lower than 0.00 logMAR and statistically lower than 0.17 logMAR at intermediate (64 cm) and near (40 cm) after 1-weeks of lens wear. Historical data for the Test lens with respect to visual acuity is presented in the Table below.

Table 5: [REDACTED] Binocular High Luminance High Contrast Visual Performance – 1-Week Follow-up

Position	Mean	SD*	Minimum	Maximum
Distance (4 m)	-0.104	0.0712	-0.240	-0.040
Intermediate (64 cm)	-0.067	0.0688	-0.200	-0.080
Near (40 cm)	0.058	0.0812	-0.060	-0.260

\* SD: Standard Deviation

**Visual Performance (logMAR)**

Sample size calculation for Visual performance (logMAR) was carried out using Monte Carlo simulation methods using PROC IML. One-thousand boot strap samples were simulated based on the historical data in Table 5 above for each Position separately. An interclass correlation of 0.5 was assumed for the correlation between period 1 and period 2 and period 2 and period 3. An intraclass correlation of 0.3 was assumed for the correlation between period 1 and period 3. For this sample size calculation, we assumed that there was no period or sequence effect since the Test and Control have not be evaluated together in the same clinical study. For each replicated sample a linear mixed model was used; lens was included as the only fixed effect. A variance component (VC) covariance structure was used to model measurements from the same subject across study periods. Seventy subjects to complete provides at least 90% power to meet all primary hypotheses (Distance, Intermediate and Near) associated with visual performance.

Historical CLUE vision scores for the Control lens (Dailies Total 1® Multifocal Contact Lenses manufactured in deleficon A material) from [REDACTED] at the 1-week follow-up for the hyperopic population only, was utilized in the power analysis. The mean and standard deviation for the Control was 54.35 and 16.52, respectively. However, a conservative estimate of 20 points for the standard deviation was considered for the power calculation. Assuming the Test and Control will have similar performance with respect to subjective vision scores (CLUE), the table below provide the power for different scenarios of effect size and intra-class correlation.

Table 6: Statistical Power Analysis for Non-inferiority of the Test relative to the Control at the 1-Week Follow-up Evaluation

Effect Size	Intra-class correlation	Power
0	0.3	0.542
0	0.6	0.749
0	0.8	0.984
1	0.3	0.676
1	0.6	0.872

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

1	0.8	0.989
2	0.3	0.790
2	0.6	0.945
2	0.8	0.998
3	0.3	0.876
3	0.6	0.980
3	0.8	>.999

The plan is to enroll 80 eligible subjects with a target completion of 70 subjects. During the enrollment period, the subject drop-out rate will be closely monitored, if an unexpectedly high dropout rate is observed, then the targeted total enrollment number maybe be increased accordingly to ensure that a minimum of 70 subjects complete the study.

### 14.3. Analysis Populations

#### Safety Population:

All subjects who were administered any test article excluding subjects who drop out prior to administering any test article. At least one observation should be recorded.

#### Per-Protocol Population:

All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hard lock (Per-Protocol Population). Justification of excluding subjects with protocol deviations in the Per-Protocol Population set will be documented in a memo to file.

#### Intent-to-Treat (ITT) Population:

All subjects regardless of actual treatment and subsequent withdrawal from study or deviation from protocol. At least one observation should be recorded.

### 14.4. Level of Statistical Significance

All planned analysis for this study will be conducted with an overall type I error rate of 5%.

### 14.5. Primary Analysis

All primary analysis will be conducted on the Intent-to-Treat Population. A sensitivity analysis will be conducted on the Per-Protocol population.

#### Visual Performance (logMAR)

Binocular, high luminance, high contrast visual performance (logMAR) will be analyzed using a linear mixed model. Sequence of lens wear, study period, lens type, distance (4 m, 64 cm and 40 cm) and the lens by distance interaction as fixed effects. Other characteristics including, age, gender and race and ADD power may be included when appropriate. Site will be included as a random effect (G-side). The covariance between residual errors from the same subject and distance across study periods will be modeled using either homogenous compound symmetry (CS) or unstructured (UN) covariance structure. The structure that returns the lowest finite-

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

sample corrected Akaike's Information criterion<sup>7</sup> will be selected as the structure that best fits the model. The Kenward and Roger method<sup>8</sup> will be used for the denominator degrees of freedom.

Comparisons between the Test and Control lenses will be carried out at each distance (4 m, 64 cm and 40 cm) using 2-sided 95% confidence intervals constructed of least square means (LSM) differences (Test minus Control) at the 1-week follow-up evaluation.

Secondary hypothesis 1:

The null and alternative hypothesis for binocular distance HLHC visual performance to test for superiority of the Test lens relative to the pre-defined threshold of 0.0 logMAR is as follows:

$$\begin{aligned} H_0: \mu_{Test} &\geq 0 \text{ logMAR} \\ H_A: \mu_{Test} &< 0 \text{ logMAR} \end{aligned}$$

Superiority will be declared if the upper limit of the 95% confidence interval of the adjusted mean for the Test lens is below 0 logMAR. i.e.  $P(\mu_{Test} < 0) \geq 0.975$ .

Secondary hypothesis 2:

The null and alternative hypothesis for binocular near HLHC visual performance to test for superiority of the Test lens relative to the pre-defined threshold of 0.17 logMAR is as follows:

$$\begin{aligned} H_0: \mu_{Test} &\geq 0.17 \text{ logMAR} \\ H_A: \mu_{Test} &< 0.17 \text{ logMAR} \end{aligned}$$

Superiority will be declared if the upper limit of the 95% confidence interval of the adjusted mean for the Test lens is below 0.17 logMAR. i.e.  $P(\mu_{Test} < 0.17) \geq 0.975$ .

Secondary hypothesis 3:

The null and alternative hypothesis for binocular distance HLHC visual performance to test for superiority of the Test lens relative to the pre-defined threshold of 0.17 logMAR is as follows:

$$\begin{aligned} H_0: \mu_{Test} &\geq 0.17 \text{ logMAR} \\ H_A: \mu_{Test} &< 0.17 \text{ logMAR} \end{aligned}$$

Superiority will be declared if the upper limit of the 95% confidence interval of the adjusted mean for the Test lens is below 0.17 logMAR. i.e.  $P(\mu_{Test} < 0.17) \geq 0.975$ .

### 14.6. Secondary Analysis

#### CLUE Vision

CLUE vision scores at the 1-week follow-up will be analyzed using a linear mixed model adjusting for baseline values as a covariate. Sequence of lens wear, study period, lens type will

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

be included as fixed effects. Other factors such as, race, gender or ADD power may be included in the model as covariates when appropriate. Site will be included as a random effect (G-side). The covariance between residual errors from the same subject across study periods will be modeled using either homogenous compound symmetry (CS) or unstructured (UN). The structure that returns the lowest finite-sample corrected Akaike's Information criterion<sup>7</sup> will be selected as the structure that best fits the model. The Kenward and Roger method, (Kenward and Roger, 1997)<sup>8</sup> will be used for the denominator degrees of freedom.

Comparisons between the Test and Control lenses at the 1-week follow-up evaluation will be carried out using two-sided 95% confidence intervals constructed for the least-square mean difference (Test minus Control).

Primary hypothesis 1:

The null and alternative hypothesis for CLUE vision to test for superiority of the Test lens relative to the pre-defined threshold of 32 is as follows:

$$H_0: \mu_{Test} \leq 32$$
$$H_A: \mu_{Test} > 32$$

Superiority will be declared if the lower limit of the 95% confidence interval of the adjusted mean for the Test lens is greater than 32. i.e.  $P(\mu_{Test} > 32) \geq 0.975$ .

Primary Hypothesis 2:

The null and alternative hypothesis for CLUE vision to test for non-inferiority of the Test lens relative the Control lens is as follows:

$$H_0: \mu_{Test} - \mu_{Control} \leq -5$$
$$H_A: \mu_{Test} - \mu_{Control} > -5$$

Non-inferiority will be declared if the lower limit of the 95% confidence interval for the least-square mean difference is greater than -5. i.e.  $P(\mu_{Test} - \mu_{Control} > -5) \geq 0.975$

### 14.7. Other Exploratory Analyses

CLUE™ comfort and handling scores will be descriptively summarized for each timepoint and lens type.

Further exploratory analysis may be undertaken at the discretion of the study responsible clinician.

### 14.8. Interim Analysis

There will not be an interim analysis performed on this study.

### 14.9. Procedure for Handling Missing Data and Drop-Outs

Missing or spurious values will not be imputed. The count of missing values will be included in the summary tables and listings.

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

Subject dropout is expected to be one of the main reasons of missing data in this clinical trial. Past clinical trials don't provide the evidence that subject dropout is systematic or not-at-random. To evaluate the impact of missing data, sensitivity analysis will be conducted using multiple imputation methods if the proportion of subject dropout is greater than the 15%. The SAS/STAT procedures PROC MI and PROC MIANALYZE will be utilized with a parametric regression method used to make at least 15 imputations.

### **14.10. Procedure for Reporting Deviations from Statistical Plan**

The analysis will be conducted according to that specified in above sections. There are no known reasons for which it is planned to deviate from these analysis methods. If for any reason a change is made, the change will be documented in the study report along with a justification for the change.

## **15. DATA HANDLING AND RECORD KEEPING/ARCHIVING**

### **15.1. Electronic Case Report Form/Data Collection**

The data for this study will be captured on electronic case report forms (eCRFs) using an EDC system (Bioclinica). An authorized data originator will enter study data into the eCRFs using the EDC system. Data collected on equipment that is not captured in EDC will be formatted to the specification of the JJVC database manager and sent to JJVC for analysis.

External Date Sources for this study include:

Not Applicable

The clinical data will be recorded on dedicated eCRFs specifically designed to match the study procedures for each visit. Only specifically delegated staff can enter data on a CRF. Once completed, the eCRFs will be reviewed for accuracy and completeness and signed by the Investigator. The sponsor or sponsor's representatives will be authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study.

Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and complete data collection. Data will be transmitted from the clinical site to a secure central database as forms are completed or updated, ensuring information accuracy, security, and confidentiality. After the final database lock, the Investigator will be provided with Individual Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of the study data. The IPP must be retained in the study files as a certified copy of the source data for the study.

The content and structure of the eCRFs are compliant with ISO14155:2011.<sup>1</sup>

### **15.2. Subject Record**

At a minimum, subject record should be available for the following:

- subject identification
- eligibility

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

- study identification
- study discussion
- provision of and date of informed consent
- visit dates
- results of safety and efficacy parameters as required by the protocol
- a record of all adverse events
- follow-up of adverse events
- medical history and concomitant medication
- test article receipt/dispensing/return records
- date of study completion
- reason for early discontinuation of test article or withdrawal from the study, if applicable

The subject record is the eCRF or an external record. The author of an entry in the subject record must be identifiable. The first point of entry is considered to be the source record.

Adverse event notes must be reviewed and initialed by the Investigator.

### **15.3. ClinicalTrials.gov**

This study will be registered on ClinicalTrials.gov.

## **16. DATA MANAGEMENT**

### **16.1. Access to Source Data/Document**

The Investigator/Institution will permit trial-related monitoring, audits, IEC/IRB review and regulatory inspection(s) by providing direct access to source data/documents. Should the clinical site be contacted for an audit by an IEC/IRB or regulatory authority, JJVC must be contacted and notified in writing within 24 hours.

### **16.2. Confidentiality of Information**

Information concerning the investigational product and patent application processes, scientific data or other pertinent information is confidential and remains the property of JJVC. The Investigator may use this information for the purposes of the study only. It is understood by the Investigator that JJVC will use information developed in this clinical study in connection with the development of the investigational product and therefore may disclose it as required to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands that he/she has an obligation to provide complete test results and all data developed during this study to the Sponsor.

### **16.3. Data Quality Assurance**

Steps will be taken to ensure the accuracy and reliability of data, include the selection of qualified investigators and appropriate clinical sites and review of protocol procedures with

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site personnel are familiar with the protocol and all study-specific procedures and have appropriate knowledge of the study article.

Training on case report form completion will be provided to clinical site personnel before the start of the study. The Sponsor will review case report forms for accuracy and completeness remotely during the conduct of the study, during monitoring visits, and after transmission to data management. Any data discrepancies will be resolved with the Investigator or designee, as appropriate.

Quality Assurance representatives from JJVC may visit clinical sites to review data produced during the study and to assess compliance with applicable regulations pertaining to the conduct of clinical trials. The clinical sites will provide direct access to study-related source data/documents and reports for the purpose of monitoring and auditing by JJVC and for inspection by local and regulatory authorities.

## **17. CLINICAL MONITORING**

The study monitors will maintain close contact with the Principal Investigator and the Investigator's designated clinical site personnel. The monitor's responsibilities will include:

- Ensuring that the investigation is being conducted according to the protocol, any subsequent versions, and regulatory requirements are maintained.
- Ensuring the rights and wellbeing of subjects are protected.
- Ensuring adequate resources, including facilities, laboratories, equipment, and qualified clinical site personnel.
- Ensuring that protocol deviations are documented with corrective action plans, as applicable.
- Ensuring that the clinical site has sufficient test article and supplies.
- Clarifying questions regarding the study.
- Resolving study issues or problems that may arise.
- Reviewing of study records and source documentation verification in accordance with the monitoring plan.

## **18. ETHICAL AND REGULATORY ASPECTS**

### **18.1. Study-Specific Design Considerations**

Potential subjects will be fully informed of the risks and requirements of the study and, during the study, subjects will be given any new information that may affect their decision to continue participation. Subjects will be told that their consent to participate in the study is voluntary and may be withdrawn at any time with no reason given and without penalty or loss of benefits to which they would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and potential adverse events of the study, and provide their consent voluntarily will be enrolled.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### **18.2. Investigator Responsibility**

The Principal Investigator is responsible for ensuring that the clinical study is performed in accordance with the signed agreement, the investigational plan, Section 4 of the ICH E6 guidelines on Good Clinical Practice (GCP),<sup>2</sup> and applicable regulatory requirements. GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting studies that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of study subjects are protected, consistent with the principles of the Declaration of Helsinki 64<sup>th</sup> WMA General Assembly 2013<sup>3</sup> and that the clinical study data are credible. The Investigator must maintain clinical study files in accordance with Section 8 of the ICH E6 guidelines on Good Clinical Practice (GCP),<sup>2</sup> and applicable regulatory requirements.

### **18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB)**

Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copies of the following documents (where applicable):

- Final protocol.
- Sponsor-approved informed consent form (and any other written materials to be provided to the subjects)
- Investigator's Brochure (or equivalent information).
- Sponsor-approved subject recruitment materials.
- Information on compensation for study-related injuries or payment to subjects for participation in the study.
- Investigator's curriculum vitae, clinical licenses, or equivalent information (unless not required, as documented by IEC/IRB).
- Information regarding funding, name of the Sponsor, institutional affiliations, other potential conflicts of interest, and incentives for subjects.
- Any other documents that the IEC/IRB requests to fulfill its obligation.

This study will be undertaken only after IEC/IRB has given full approval of the final protocol, the informed consent form, applicable recruiting materials, and subject compensation programs, and the Sponsor has received a copy of this approval. This approval letter must be dated and must clearly identify the documents being approved.

During the study, the Investigator (or Sponsor when applicable) will send the following documents to the IEC/IRB for their review and approval, where appropriate:

- Protocol revisions
- Revision(s) to informed consent form and any other written materials to be provided to subjects
- If applicable, new or revised subject recruitment materials approved by the Sponsor
- Revisions to compensation for study-related injuries or payment to subjects for participation in the study
- Investigator's Brochure revisions
- Summaries of the status of the study (at least annually or at intervals stipulated in guidelines of the IEC/IRB)

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

- Reports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRB's requirements
- New information that may adversely affect the safety of the subjects or the conduct of the study
- Major protocol deviations as required by the IEC/IRB
- Report of deaths of subjects under the Investigator's care
- Notification if a new Investigator is responsible for the study at the clinical site
- Any other requirements of the IEC/IRB

For protocol revisions that increase subject risk, the revisions and applicable informed consent form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s).

At least once a year, the IEC/IRB will review and reapprove this clinical study. This request should be documented in writing.

At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB about the study completion. Documentation of this notification must be retained at the clinical site and a copy provided to the CRO or Sponsor as applicable.

### **18.4. Informed Consent**

Each subject or their representative, must give written consent according to local requirements after the nature of the study has been fully explained. The consent form must be signed before performance of any study-related activity. The consent form that is used must be approved by both the Sponsor and by the reviewing IEC/IRB. The informed consent is in accordance with principles that originated in the Declaration of Helsinki,<sup>3</sup> current ICH<sup>2</sup> and ISO 14155<sup>1</sup> guidelines, applicable regulatory requirements, and Sponsor Policy.

Before entry into the study, the Investigator or an authorized member of the clinical site personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, and potential hazards of the study, and any discomfort it may entail. Subjects will be informed that their participation is voluntary and that they may withdraw consent to participate at any time.

The subject will be given sufficient time to read the informed consent form and the opportunity to ask questions. After this explanation and before entry into the study, consent should be appropriately recorded by means of the subject's dated signature. After having obtained the consent, a copy of the informed consent form must be given to the subject.

### **18.5. Privacy of Personal Data**

The collection, processing and disclosure of personal data and medical information related to the Study Subject, and personal data related to Principal Investigator and any clinical site personnel (e.g., name, clinic address and phone number, curriculum vitae) is subject to compliance with the Health Information Portability and Accountability Act (HIPAA) in the United States<sup>5</sup> and other applicable personal data protection and security laws and regulations.

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

Appropriate measures will be employed to safeguard these data, to maintain the confidentiality of the person's related health and medical information, to properly inform the concerned persons about the collection and processing of their personal data, to grant them reasonable access to their personal data and to prevent access by unauthorized persons.

All information obtained during the course of the investigation will be regarded as confidential. All personal data gathered in this trial will be treated in strictest confidence by Investigators, monitors, Sponsor's personnel and IEC/IRB. No data will be disclosed to any third party without the express permission of the subject concerned, with the exception of Sponsor personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their investigation related activities that, as part of the investigation will have access to the CRFs and subject records.

The collection and processing of personal data from subjects enrolled in this study will be limited to those data that are necessary to investigate the efficacy, safety, quality, and utility of the investigational product(s) used in this study.

These data must be collected and processed with adequate precautions to ensure confidentiality and compliance with applicable data privacy protection laws and regulations.

The Sponsor ensures that the personal data will be:

- processed fairly and lawfully.
- collected for specified, explicit, and legitimate purposes and not further processed in a way incompatible with these purposes.
- adequate, relevant, and not excessive in relation to said purposes.
- accurate and, where necessary, kept current.

Explicit consent for the processing of personal data will be obtained from the participating subject before collection of data. Such consent should also address the transfer of the data to other entities and to other countries.

The subject has the right to request through the Investigator access to his personal data and the right to request rectification of any data that are not correct or complete. Reasonable steps should be taken to respond to such a request, taking into consideration the nature of the request, the conditions of the study, and the applicable laws and regulations.

Appropriate technical and organizational measures to protect the personal data against unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. Sponsor personnel whose responsibilities require access to personal data agree to keep the identity of study subjects confidential.

### **19. STUDY RECORD RETENTION**

In compliance with the ICH/GCP guidelines,<sup>2</sup> the Investigator/Institution will maintain all CRFs and all subject records that support the data collected from each subject, as well as all study documents as specified in ICH/GCP<sup>2</sup> and all study documents as specified by the

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

applicable regulatory requirement(s). The Investigator/Institution will take measures to prevent accidental or premature destruction of these documents.

Essential documents must be retained until at least two (2) years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least two (2) years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents will be retained for a longer period if required by the applicable regulatory requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained.

If the responsible Investigator retires, relocates, or for other reasons withdraws from the responsibility of keeping the study records, custody must be transferred to a person who will accept the responsibility. The Sponsor must be notified in writing of the name and address of the new custodian. Under no circumstance shall the Investigator relocate or dispose of any study documents before having obtained written approval from the Sponsor.

If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any documentation relating to this study, the Investigator must permit access to such reports. If the Investigator has a question regarding retention of study records, he/she should contact JJVC.

## **20. FINANCIAL CONSIDERATIONS**

Remuneration for study services and expenses will be set forth in detail in the Clinical Research Agreement. The Research Agreement will be signed by the Principal Investigator and a JJVC management representative prior to study initiation.

JJVC reserves the right to withhold remuneration for costs associated with protocol violations such as:

- Continuing an ineligible subject in the study.
- Scheduling a study visit outside the subject's acceptable visit range.

JJVC reserves the right to withhold final remuneration until all study related activities have been completed, such as:

- Query resolution.
- Case Report Form signature.
- Completion of any follow-up action items.

## **21. PUBLICATION**

This study will be registered on ClinicalTrials.gov by the Sponsor.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**22. REFERENCES**

1. ISO 14155:2011: Clinical Investigation of Medical Devices for Human Subjects — Good Clinical Practice. Available at: <https://www.iso.org/standard/45557.html>
2. International Conference on Harmonization Good Clinical Practice E6 (ICH-GCP). Available at: <http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html>
3. Declaration of Helsinki - Ethical principles for Medical Research Involving Human Subjects. Available at: <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>
4. United States (US) Code of Federal Regulations (CFR). Available at: <https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR>
5. Health Information Portability and Accountability Act (HIPAA). Available at: <https://www.hhs.gov/hipaa/for-professionals/privacy/index.html>
6. Wirth RJ, et al. Development of the Contact Lens User Experience: CLUE Scales. *Optom Vis Sci.* 2016;93(8):801-808.
7. Keselman HJ, Algina J, Kowalchuk RK, Wolfinger RD. A Comparison of Two Approaches for Selecting Covariance Structures in the Analysis of Repeated Measures. *Communications in Statistics—Simulation and Computation.* 1998;27:591-604.
8. Kenward MG, Roger JH. Small Sample Inference for Fixed Effects from Restricted Maximum Likelihood. *Biometrics.* 1997;53:983–997.
9. SAS Institute Inc: SAS® 9.4 Statements: Reference, Third Edition. Cary, NC: SAS Institute Inc; 2014.

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)**

# Clinical Study Protocol


Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

1

















# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

9





# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

11







# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

15

# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

16



# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

17



# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

19

# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

20








# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

23




# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

24




# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

25




# Clinical Study Protocol

Protocol 6392    Johnson & Johnson Vision Care, Inc.

Confidential

26



**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**APPENDIX B: PATIENT INSTRUCTION GUIDE (TO BE PROVIDED  
SEPERATLEY)**

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)**

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

**Alcon®**  
a Novartis company

### DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal (delefilcon A) Soft Contact Lenses for Daily Disposable Wear

W900038292

**IMPORTANT:** This package insert is effective as of March 2016 and applicable to the delefilcon A contact lenses described below. Please read carefully and keep this information for future use. This package insert is intended for the eye care professional, but should be made available to patients upon request. The eye care professional should provide the patient with appropriate instructions that pertain to the patient's prescribed lenses. Copies of this package insert are available without charge from Alcon by calling Customer Service at 1-800-241-5999 or download from our website at [www.alcon.com](http://www.alcon.com). In addition, a Patient Instruction Booklet is available which is recommended to be given to patients.

**Rx only**

**CAUTION: Federal law (United States) restricts this device to sale by or on the order of a licensed eye care professional.**

#### PRODUCT DESCRIPTION

DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal (delefilcon A) soft contact lenses are made from a lens material that is 33% water and 67% (delefilcon A) polymer, a silicone containing hydrogel with added phosphatidylcholine. The core lens material containing 33% water transitions through a water gradient to a hydrogel surface layer that exceeds 80% water. Lenses contain the color additive copper phthalocyanine, a light blue tint, which makes them easier to see when handling.

#### Lens Properties

- Refractive Index hydrated: 1.42
- Light Transmittance: 93% (@ 610 nm, -1.00D)
- Oxygen Permeability (Dk):  $140 \times 10^{-11} \text{ (cm}^2/\text{sec)(ml O}_2/\text{ml x mm Hg)}$ , measured at 35°C (intrinsic Dk-Coulometric method)
- Water Content: 33% by weight in normal saline
- Surface Water Content:  $\geq 80\%$

#### Lens Parameters

- Diameter Range: 13.0 to 15.0 mm
- Spherical Power Range: -20.00 to +20.00D
- Base Curve Range: 8.0 to 9.2 mm

#### Lens Parameters Available<sup>1</sup>

##### DAILIES TOTAL1\* (delefilcon A) spherical

- Chord Diameter: 14.1 mm
- Center Thickness: 0.09 mm @ -3.00D (varies with power)
- Base Curve: 8.5 mm
- Powers: -0.50 to -6.00D (0.25D steps); -6.50 to -12.00D (0.50D steps) +0.50 to +6.00D (0.25D steps)

##### DAILIES TOTAL1\* Multifocal (delefilcon A)

- Chord Diameter: 14.1 mm
- Center Thickness: 0.09 mm @ -3.00D (varies with power)
- Base Curve: 8.5 mm
- Powers: +6.00 to -10.00D (0.25D steps) ADD: LO, MED, HI

**NOTE:** Hereafter, DAILIES TOTAL1\* spherical lenses and DAILIES TOTAL1\* Multifocal contact lenses will simply be referred to as delefilcon A contact lenses unless product distinction is necessary.

#### ACTIONS

When hydrated and placed on the cornea, delefilcon A contact lenses act as a refracting medium to focus light rays on the retina.

#### INDICATIONS (USES)

DAILIES TOTAL1\* (delefilcon A) spherical soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.

DAILIES TOTAL1\* Multifocal (delefilcon A) soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) and/or presbyopia in phakic or aphakic persons with non-diseased eyes who may require a reading addition of +3.00 (D) or less and who may have up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.

The lenses are to be prescribed for single use, daily disposable wear. The lenses are not intended to be cleaned or disinfected and should be discarded after a single use.

#### CONTRAINDICATIONS (REASONS NOT TO USE)

**DO NOT use delefilcon A contact lenses when any of the following exists:**

- Inflammation or infection of the anterior chamber of the eye

- Active disease, injury or abnormality affecting the cornea, conjunctiva, or eyelids
- Microbial infection of the eye
- Insufficiency of lacrimal secretion (dry eye) that interferes with contact lens wear
- Corneal hypoesthesia (reduced corneal sensitivity)
- Use of any medication that is contraindicated or interferes with contact lens wear, including eye medications
- Any systemic disease which may be exacerbated by or interferes with contact lens wear
- Allergic reactions or ocular irritation of the ocular surfaces or adnexa that may be caused by or exaggerated by the wearing of contact lenses
- Patient history of recurring eye or eyelid infections, adverse effects associated with contact lens wear, intolerance or abnormal ocular response to contact lens wear
- If eyes become red or irritated

#### WARNINGS

**Advise patients of the following warnings pertaining to contact lens wear:**

- Problems with contact lenses and lens care products could result in serious injury to the eye. It is essential that patients follow their eye care professional's directions and all labeling instructions for proper use of lenses and lens care products. **Serious eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision.**
- Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping. Clinical study results have shown that the risk of serious adverse reactions is increased when contact lenses are worn overnight<sup>2</sup>.
- Studies<sup>2</sup> have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers.
- If a patient experiences eye discomfort, foreign body sensation, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her eye care professional. It is recommended that contact lens wearers see their eye care professional regularly as directed.

#### PRECAUTIONS

To prevent damage to the eyes or to the contact lenses, the following precautions should be taken:

##### Special Precautions for the Eye Care Professional:

Due to the small number of patients enrolled in the clinical investigation of lenses, all refractive powers, design configurations, or lens parameters available in the lens material are not evaluated in significant numbers. Consequently when selecting an appropriate lens design and parameters, the eye care professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, central and peripheral thickness and optic zone diameter. The potential impact of these factors on the patient's ocular health should be carefully weighed against the patient's need for refractive correction; therefore the continuing ocular health of the patient and lens performance on the eye should be carefully evaluated on initial dispensing and monitored on an ongoing basis by the prescribing eye care professional.

- Fluorescein, a yellow dye, should not be used while the lenses are on the patient's eyes. The lenses absorb this dye and become discolored. Whenever fluorescein is used, the eyes should be flushed thoroughly with sterile saline solution that is recommended for in eye use prior to inserting lenses. Avoid dispensing saline from an aerosol can directly into the eye.
- Patients who wear contact lenses to correct presbyopia may not achieve the best possible corrected visual acuity for either far or near vision. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
- Before leaving the eye care professional's office, the patient should be able to promptly remove their lenses or should have someone else available who can remove their lenses for them.
- Eye care professionals should instruct the patient to remove the lenses immediately if the eye becomes red or irritated.
- Routine eye examinations are necessary to help assure the continued health of the patient's eyes. Eye care professionals should make arrangements with the patient for appropriate

follow-up visits. Alcon recommends that patients see their eye care professional once each year, or more often, as recommended by the eye care professional.

- Diabetics may have reduced corneal sensitivity and thus are more prone to corneal injury and do not heal as quickly or completely as non-diabetics.
- Visual changes or changes in lens tolerance may occur during pregnancy or use of oral contraceptives. Caution patients accordingly.

**Eye Care Professionals should carefully instruct patients about the following safety precautions:**

##### Handling Precautions:

- Be sure that before leaving the eye care professional's office the patient is able to promptly remove lenses or have someone else available to remove them.
- Good hygiene habits help promote safe and comfortable lens wear. **Always wash, rinse and thoroughly dry hands with a lint-free towel before handling lenses.**
- REMOVE A LENS IMMEDIATELY** if an eye becomes red or irritated.
- Always handle lenses carefully. Never use tweezers or other sharp objects such as fingernails to remove lenses from the lens container unless specifically indicated for that use.
- Do not use if blister package is damaged or not sealed completely. This may result in product contamination which can lead to a serious eye infection.
- Ensure that the correct lens for each eye is available. Shake the blister pack gently prior to opening. Remove the lens from the blister pack by carefully pouring the lens onto the palm of your clean hand. Ensure the lens is right side out. Inspect lenses prior to insertion. Do not insert damaged lenses.
- To insert lenses:
  - Wash and rinse hands thoroughly and dry completely with a clean, lint free towel before handling lenses.
  - Place a lens on the tip of your clean and dry right or left index finger, place the middle finger of the same hand close to lower eyelashes and pull down the lower eyelid.
  - Use the fingers of the other hand to lift the upper eyelid.
  - Place the lens directly on the eye (cornea) and gently roll finger away from the lens.
  - Look down and slowly remove the hand, releasing the lower lid.
  - Look straight ahead and slowly remove the other hand, releasing the upper lid.
  - Blink gently.
- To remove lenses:
  - Wash and rinse hands thoroughly and dry completely with a clean, lint free towel before handling lenses. **Make sure hands are clean and completely dry.**
  - Blink fully several times.
  - While looking up, slide the lens down onto the white part of the eye.
  - Remove the lens by pinching gently between the thumb and forefinger. Do not pinch the eye tissue.
  - If the lens is difficult to grasp, dry fingers once more and try again. Do not use rewetting drops in this instance.
- If a lens decenters on the eye, it may be possible to recenter it by:
  - Closing the eye and massaging the lens into place, or
  - Looking in the direction of the lens and blinking gently, or
  - Gently pushing the off-centered lens onto the cornea with light finger pressure on the edge of the upper or lower eyelid.
- If a lens tears in the eye it will feel uncomfortable. Advise wearers it is impossible to lose a contact lens or part of a contact lens behind the eye and to remain calm. Lens pieces may be removed by pinching them as for normal lens removal, carefully avoiding pinching the eye tissue. If the lens pieces do not seem to remove easily, rinsing with saline is recommended. If this does not help, the wearer should contact an eye care professional for assistance.

**Lens Wearing Precautions:**

- Patients should never exceed the prescribed wearing schedule regardless of how comfortable the lenses feel. Doing so may increase the risk of adverse effects.
- The lens should move freely on the eye at all times. If the lens sticks (stops moving) on the eye, follow the recommended directions in the **Care for a Sticking Lens** section. If non-movement of the lens continues, the patient should be instructed to consult their eye care professional immediately.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

- The eye care professional should be consulted about wearing lenses during water sports and water related activities. Exposure to water or other non-sterile liquids while wearing contact lenses in activities such as swimming, water skiing, and hot tubs may increase the risk of ocular infection, including but not limited to *Acanthamoeba* keratitis.
- Never allow contact lenses to come into contact with non-sterile liquids (including tap water and saliva) as microbial contamination can occur, which may lead to permanent eye damage.
- Eye irritation, infection, or lens damage may result if cosmetics, lotion, soap, cream, hair spray, deodorant, aerosol products or foreign particles come in contact with lenses.
- Environmental fumes, smoke, and vapors should be avoided in order to reduce the chance of lens contamination or physical trauma to the cornea.
- Lenses should be disposed of each day upon removal from the eye.
- Discard any lens which has become dehydrated or damaged. Replace with a sterile, fresh, new lens.
- Note the correct lens power for each eye to prevent getting them mixed up.
- Always carry spare lenses with you or have back-up spectacles available.
- Do not share lenses with anyone as this may spread micro-organisms which could result in serious eye health problems.
- Do not use lenses beyond their expiration date.

### Other Topics to Discuss with Patients:

- Periodic eye examinations are extremely important for contact lens wearers. Schedule and conduct appropriate follow-up examinations to determine ocular response. Alcon recommends that patients see their eye care professional once each year or as recommended by the eye care professional.
- Certain medications may cause dryness of the eye, increased lens awareness, lens intolerance, and blurred vision or visual changes. These include, but are not limited to, antihistamines, decongestants, diuretics, muscle relaxants, tranquilizers, and those for motion sickness. Caution patients using such medications accordingly and prescribe proper remedial measures.
- Visual changes or changes in lens tolerance may occur during pregnancy or use of oral contraceptives. Caution patients accordingly.

### Who Should Know that the Patient is Wearing Contact Lenses:

- Patients should inform their health care practitioners that they are wearing contact lenses.
- Patients should inform their employers that they are wearing contact lenses. Some jobs may require the use of eye protection equipment or may require that contact lenses not be worn.

It is strongly recommended that patients be provided with a copy of the **DAILIES TOTAL1\*** and **DAILIES TOTAL1\* Multifocal Contact Lenses** (delefilcon A) Patient Instruction Booklet available from Alcon and understand its contents prior to dispensing the lenses.

### ADVERSE EFFECTS

**Patients should be instructed to check eyes regularly to make sure they look well, feel comfortable and vision is clear.**

**Potentially serious complications are usually accompanied by one or more of the following signs or symptoms:**

- Moderate to severe eye pain not relieved by removing the lens
- Foreign body sensation
- Excessive watering or other eye secretions including mucopurulent discharge
- Redness of the eyes
- Photophobia (light sensitivity)
- Burning, stinging or itching or other pain associated with the eyes
- Comfort is less compared to when the lens was first placed on eye
- Poor visual acuity (reduced sharpness of vision)
- Blurred vision, rainbows or halos around objects
- Feeling of dryness

### WHAT TO DO IF A PROBLEM OCCURS

**Patients should be instructed that if any of the above signs or symptoms are noticed, he or she should:**

- IMMEDIATELY REMOVE THE LENSES.**
- If the discomfort or problem stops, discard the lens and replace it with a new one.
- If the discomfort or problem continues after removing lens(es) or upon insertion of a new lens, **IMMEDIATELY remove the lens(es) and contact the eye care professional for identification of the problem and prompt treatment to avoid serious eye damage.**
- The patient should be informed that a serious condition such as corneal ulcer, infection, corneal vascularization, or

iritis may be present, and may progress rapidly. Less serious reactions such as abrasions, infiltrates, and bacterial conjunctivitis must be managed and treated carefully to avoid more serious complications.

- Additionally, contact lens wear may be associated with ocular changes that require consideration of discontinuation or restriction of wear. These include but are not limited to local or generalized corneal edema, epithelial microcysts, epithelial staining, infiltrates, neovascularization, endothelial polymegathism, tarsal papillary changes, conjunctival injection or irritation.

### ADVERSE EFFECT REPORTING

If a patient experiences any serious adverse effects associated with the use of **DAILIES TOTAL1\*** brand (delefilcon A) contact lenses, please notify: Alcon Medical Safety in the USA at 1-800-757-9780.

### FITTING GUIDE AND PATIENT BOOKLET

Conventional methods of fitting contact lenses apply to delefilcon A contact lenses. For a detailed description of the fitting techniques, refer to the **DAILIES TOTAL1\*** and **DAILIES TOTAL1\* Multifocal Contact Lenses** (delefilcon A) Professional Fitting and Information Guide. Both the professional fitting guide and a patient instruction booklet are available free of charge from:

Alcon Laboratories, Inc.  
6201 South Freeway  
Fort Worth, TX, USA 76134-2099  
1-800-241-5999

### LENS WEAR & REPLACEMENT SCHEDULES

#### DAILY WEAR (less than 24 hours, while awake):

- To avoid tendency of the daily wear patient to overwear the lenses initially, stress the importance of adhering to a proper, initial wearing schedule. Normal daily wear of lenses assumes a minimum of 6 hours of non-lens wear per 24 hour period.
- It may be advisable for patients who have never worn contact lenses previously to be given a wearing schedule that gradually increases wearing time over a few days. This allows more gradual adaptation of the ocular tissues to contact lens wear.
  - The maximum daily wearing time should be determined by the eye care professional based upon the patient's physiological eye condition because individual responses to contact lenses vary. There may be a tendency for patients to overwear the lenses initially. The eye care professional should stress the importance of adhering to the initial maximum wearing schedule. Studies have not been conducted to show that delefilcon A contact lenses are safe to wear during sleep, therefore patients should be advised to remove their lenses while sleeping. Normal daily wear of lenses assumes a minimum of 6 hours of non-lens wear per 24 hour period. Optimum individual wearing schedule will vary.
  - Delefilcon A contact lenses are intended to be worn once (daily disposable wear) and then discarded at the end of each wearing period. The patient should be instructed to start the next wearing period with a fresh new lens.

### EMERGENCY LENS CARE

Cleaning and disinfection of daily disposable lenses is not recommended. The patient should be reminded to have replacement lenses or back-up spectacles available at all times.

### CARE FOR A STICKING LENS

If the lens sticks (stops moving) or begins to dry on the eye, instruct the patient to apply several drops of a recommended lubricating solution (used in accordance with package labeling). The patient should wait until the lens begins to move freely on the eye before attempting to remove it. It is important that the patient wash and dry their hands thoroughly before removing the lens. If the lens continues to stick, the patient should IMMEDIATELY consult the eye care professional.

### IN OFFICE USE OF TRIAL LENSES

Eye care professionals should educate contact lens technicians concerning proper use of trial lenses.

Each contact lens is shipped sterile in a blister pack containing phosphate buffered saline solution. Hands should be thoroughly washed and rinsed and dried with a lint-free towel prior to handling a lens. In order to ensure sterility, the blister pack should not be opened until immediately prior to use. For fitting and diagnostic purposes lenses should be disposed of after a single use and not be re-used from patient to patient.

### EMERGENCIES

The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should:

**Flush eyes immediately with tap water or fresh saline solution and immediately contact the eye care professional or visit a hospital emergency room without delay.**

### HOW SUPPLIED

Each lens is packaged in a foil-sealed plastic container containing phosphate buffered saline solution with approximately 0.3% of polymeric wetting agents consisting of copolymers of polyamidoamine and poly(acrylamide-acrylic) acid and is steam sterilized . The package is marked with the base curve, diameter, dioptric power and ADD power (multifocal lenses), manufacturing lot number and expiration date.

The following may appear on the labels or cartons:

Symbols/Signs/ Abbreviations	Description
 Rx only	CAUTION: Federal law (United States) restricts this device to sale by or on the order of a licensed eye care professional.
 STERILE	Steam sterilized
 EXP	Use by date (Expiry date)
 LOT	Batch code
 (X)	Do not reuse
 (X)	Do not use if blister package is damaged
 en	Example of two letter language code (English)
 DIA	Diameter
 BC	Base curve
 PWR	Power
 D	Diopter (lens power)
 ADD	Addition power
 CE 0086	European conformity sign
 Caution	Caution
 (i)	See product instructions
 (i)	Authorized Representative European Community
 Manufacturer	Manufacturer
 (i)	Packaging waste license sign

\* a trademark of Novartis

© 2016 Novartis

Manufacturer:  
Alcon Laboratories, Inc.  
6201 South Freeway  
Fort Worth, TX, USA 76134-2099  
www.alcon.com  
1-800-241-5999

March 2016

W900038292-0316

<sup>1</sup> Check for actual product availability as additional parameters may be introduced over time

<sup>2</sup> Schein, OD, Glynn RJ, Poggio EC, Seddon JM, Kenyon KR. The Relative Risk of Ulcerative Keratitis Among Users of Daily Wear and Extended Wear Soft Contact Lenses. *N Eng J Med.* 1989; 323(12):773-783

**Alcon**  
a Novartis company

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**APPENDIX D: BINOCULAR OVER REFRACTION**

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]  
■ [REDACTED]  
■ [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

## APPENDIX E: PRESBYOPIC SYMPTOMS QUESTIONNAIRE

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or [research@iastate.edu](mailto:research@iastate.edu).

Term	Percentage
GMOs	85%
Organic	75%
Natural	70%
Artificial	45%
Organic	80%
Natural	78%
Artificial	55%
Organic	88%
Natural	82%
Artificial	50%
Organic	72%
Natural	68%
Artificial	40%

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**APPENDIX F: OCULAR DOMINANCE**



## **Clinical Study Protocol**

### **Johnson & Johnson Vision Care, Inc.**

## APPENDIX G: LENS FITTING GUIDE

1

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or [research@iastate.edu](mailto:research@iastate.edu).

100% of the time.

1. *What is the primary purpose of the study?* (check all that apply)

a. To describe the characteristics of a population  
 b. To test a hypothesis  
 c. To compare two groups  
 d. To evaluate a treatment  
 e. To predict an outcome  
 f. To describe a process  
 g. To evaluate a diagnostic test  
 h. To compare three or more groups

© 2019 Pearson Education, Inc.

[REDACTED]

© 2013 Pearson Education, Inc.

www.english-test.net

Digitized by srujanika@gmail.com

Digitized by srujanika@gmail.com

10 of 10

1000

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

A horizontal bar chart with 10 categories on the y-axis and a single data series represented by black bars. The categories are: '1', '2', '3', '4', '5', '6', '7', '8', '9', and '10'. The length of each bar corresponds to the number of countries in that category. The data shows that category 10 has the most countries (approximately 80), followed by category 2 (approximately 60), and category 1 (approximately 50). Categories 3, 4, 5, 6, 7, 8, and 9 each contain a single country.

Category	Number of Countries
1	~50
2	~60
3	1
4	1
5	1
6	1
7	1
8	1
9	1
10	~80

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**APPENDIX H: CONTROL LENS FITTING GUIDE**

# Professional Fitting and Information Guide

**DAILIES TOTAL1\***  
and  
**DAILIES TOTAL1\* Multifocal**  
**(delefilcon A) Soft Contact Lenses**  
**For Single-Use, Daily Disposable Wear**  
**Water Gradient One-Day Contact Lenses**

**Rx only**

**CAUTION: Federal law (United States)  
restricts this device to sale by or on the  
order of a licensed eye care professional.**

**Alcon®**  
a Novartis company

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

This page intentionally left blank

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### Table of Contents

Introduction.....	5
Product Description.....	5
Lens Properties.....	6
Available Lens Parameters.....	6
Actions.....	6
Indications (Uses).....	6
Contraindications, Warnings, Precautions, Adverse Effects.....	7
Adverse Effect Reporting.....	7
Fitting Guidelines (Spherical Lenses).....	8
Patient Selection.....	8
Pre-fitting Examination.....	8
Trial Lens Evaluation.....	8
• Lens Base Curve Selection.....	8
• Initial Lens Power Selection.....	8
• Lens Fit Assessment.....	9
• Final Lens Power Determination.....	10
Fitting Guidelines (Multifocal Lenses).....	11
Pre-Fitting Examination.....	11
Patient Selection.....	11
Initial Lens Selection.....	13
Initial Lens Fitting Evaluation.....	14
Initial Lens Visual Evaluation.....	15
Fitting Procedures.....	16
Fitting Guidelines (Monovision).....	18
Patient Selection.....	18
Eye Selection.....	18
Special Fitting Considerations.....	19
Near Add Determination.....	20
Trial Lens Fitting.....	20
Adaptation.....	20
Other Suggestions.....	21
Dispensing Visit.....	21
Follow-Up Examinations.....	23
Follow-up Examination Procedures.....	23
Lens Handling Hints.....	23
Lens Insertion.....	23
Lens Removal.....	24
Care for a Sticking Lens.....	25
In Office Care of Trial Lenses.....	25
Additional Information.....	25
Vertex Distance Conversion Chart.....	26
Product Package Insert.....	29

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

This page intentionally left blank

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### Introduction

Thank you for prescribing DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal (delefilcon A) daily disposable soft contact lenses. The benefits of a high oxygen transmissible and wettable lens material with a state of the art manufacturing process are combined to make DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal (delefilcon A) lenses. This guide contains important information regarding fitting procedures and aftercare of the DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal (delefilcon A) contact lens patient.

### Daily Disposability:

By eliminating the need for lens care, daily disposable lenses offer your patients a major advancement in wearing convenience. The next time you prescribe lenses consider the health and comfort benefits of beginning each wearing period with a new pair of fresh, sterile lenses that are worn once and then discarded.

### LightStream® Lens Technology:

DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal (delefilcon A) contact lenses are made from a proprietary silicone hydrogel material with a water content of approximately 33% water. The use of process automation, precision glass and quartz molds and photolithographic edge forming help ensure every lens has the same crisp optics, smooth surface finish and consistent edge quality from lens to lens. Delefilcon A contact lenses are produced under strictly controlled process conditions and inspected to exacting quality tolerances. As a result, you can be confident your patients will experience consistent vision, comfort, and ease of handling every day.

### PRODUCT DESCRIPTION

DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal soft contact lenses are made a silicone containing hydrogel that is approximately 33% water and 67% delefilcon A polymer with added phosphatidylcholine. The core lens material containing 33% water transitions through a water gradient to a hydrogel surface layer that exceeds 80% water. This structure enables a silicone hydrogel lens with a water gradient that has:

- Over 80% water at the surface of the lens to mimic the water content of the cornea.
- High level of oxygen transmissibility through the lens.
- Excellent overall comfort.

The lenses contain and release phosphatidylcholine (DMPC), a phospholipid found naturally in the tears. In addition, lenses contain the color additive copper phthalocyanine, a light blue tint which makes them easier to see when handling.

The lenses are packaged in strips of 5 individual blisters containing buffered saline with approximately 0.3% of polymeric wetting agents consisting of copolymers of polyamidoamine and poly(acrylamide-acrylic acid).

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### Lens Properties

- Refractive Index (hydrated): 1.42
- Light Transmittance:  $\geq 93\% (@610\text{ nm}, -1.00\text{D})$
- Oxygen Permeability (Dk):  $140 \times 10^{-11} (\text{cm}^2/\text{sec})$   
(ml O<sub>2</sub>/ml x mm Hg), measured at 35°C,  
(intrinsic Dk - Coulometric method)
- Water Content 33% by weight in normal saline
- Surface Water Content  $\geq 80\%$

### Available Lens Parameters<sup>1</sup>

#### DAILIES TOTAL1\* (delefilcon A)

- Chord Diameter Available: 14.1 mm
- Center Thickness: 0.09 mm @ -3.00D (varies with power)
- Base Curve: 8.5 mm
- Powers Available: -0.50 to -6.00D (0.25D steps); -6.50 to -12.00D (0.50D steps)  
+0.50 to +6.00D (0.25D steps)

#### DAILIES TOTAL1\* Multifocal (delefilcon A)

- Chord Diameter: 14.1 mm
- Center Thickness: 0.09 mm @ -3.00D (varies with power)
- Base Curve: 8.5 mm
- Powers: -0.25 to -10.00D (0.25D steps); plano to +6.00D (0.25D steps)  
ADD: LO, MED, HI

<sup>1</sup>Check for actual product availability as additional parameters may be introduced over time.

### Actions

When hydrated and placed on the cornea delefilcon A soft contact lenses act as a refracting medium to focus light rays on the retina.

### INDICATIONS (USES)

**DAILIES TOTAL1\*** (delefilcon A) spherical soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.

**DAILIES TOTAL1\* Multifocal** (delefilcon A) soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) and/or presbyopia in phakic or aphakic persons with non-diseased eyes who may require a reading addition of +3.00 (D) or less and who may have up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.

The lenses are to be prescribed for single use, daily disposable wear. The lenses are not intended to be cleaned or disinfected and should be discarded after a single use.

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

**See WARNINGS for information about the relationship between wearing schedule and corneal complications.**

### **CONTRAINdications, WARNINGS, PRECAUTIONS AND ADVERSE EFFECTS**

For additional important prescribing and safety information, refer to the Package Insert that is printed in the back of this guide.

### **ADVERSE EFFECT REPORTING**

If a patient experiences any serious adverse effects associated with the use of DAILIES TOTAL1\* or DAILIES TOTAL1\* Multifocal (delefilcon A) contact lenses, in the USA please **contact Alcon Medical Safety at 1-800-757-9780**.

### **FITTING GUIDELINES**

Please see the appropriate sections of this booklet that contain guidelines for spherical, multifocal and monovision fitting techniques.

## **Clinical Study Protocol**

### **Johnson & Johnson Vision Care, Inc.**

## FITTING GUIDELINES (Spherical Lenses)

## 1. Patient Selection

The patient characteristics necessary to achieve success with DAILIES TOTAL1\* (delefilcon A) spherical lenses are similar to those for other spherical soft contact lenses. A thorough pre-fitting examination should be conducted to ensure the patient is a suitable candidate for soft contact lens wear.

The following procedures should be followed when fitting DAILIES TOTAL1\* (delefilcon A) spherical lenses. For additional tips on fitting the monovision patient refer to the section *Monovision Fitting Guidelines*.

## 2. Pre-fitting Examination

**A pre-fitting examination is necessary to:**

- assess the patient's motivation, physical state and willingness to comply with instructions regarding hygiene and wear schedule
- make ocular measurements for initial contact lens parameter selection
- collect baseline clinical information to which post-fitting examination results can be compared

### **A pre-fitting examination should include:**

- a thorough case history
- a spherocylindrical refraction
- keratometry
- tear film assessment
- biomicroscopy

### 3. Trial Lens Evaluation

### **A. Lens Base Curve Selection**

A well-fitted lens provides good movement, centration and comfort. An optimal fit can be achieved for the vast majority of patients with the single 8.5 mm base curve.

### ***B. Initial Lens Power Selection***

The initial power selection should be as close as possible to the patient's prescription after taking into account spherical equivalent and vertex calculations, if necessary.

## Spherical Equivalent Calculation

To determine initial lens power, convert the spherocylindrical spectacle Rx to its spherical equivalent as follows:

**Spherical Equivalent = Sphere power + 1/2 (Cylinder Power)**

## Vertex Distance Conversion

If the spherical equivalent is greater than  $\pm 4.00\text{D}$ , a vertex distance correction is necessary (see *Vertex Distance Conversion Chart*) to determine the lens power required at the corneal plane.

<b>Example:</b>	<b>Spectacle Rx:</b>	<b>-4.50D -1.00 x 180</b>
	<b>Spherical equivalent:</b>	<b><math>-4.50D + (-0.50D) = -5.00D</math></b>
	<b>Vertex compensation:</b>	<b>-4.75 (initial lens power)</b>

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### C. Lens Fit Assessment

Allow the lenses to settle on the eyes for approximately 10 minutes. This allows time for the patient to adapt to the lenses and time for the lens to equilibrate.

Evaluate the fit and movement of the lenses on the eye in primary and up gaze positions. The **Push-up Test**, as described below, is an additional test of the lens evaluation. The following guidelines will be helpful in fit evaluation:

#### **Characteristics of a Well-fitted Lens**

A well-fitted DAILIES TOTAL1\* (delefilcon A) spherical contact lens satisfies the following criteria:

1. **Good centration and full corneal coverage** in all fields of gaze.
2. **Sufficient lens movement to allow tear exchange** under the lens during a blink in primary or upward gaze.
3. **Satisfactory Push-up Test**
  - This test is a reliable indicator of a good fit. With the patient looking straight ahead, place your index finger on the patient's lower lid and nudge the edge of the lens upward while observing lens movement. Then pull the lid back down and observe the return of the lens.
  - A well fitted lens will move freely upward, stopping shortly after passing the limbus and then return freely to its original position.
4. **Good comfort and stable visual response** (with over refraction).

#### **Characteristics of a Tight (Steep) Lens Fit**

A tight or steep lens fit would display some or all of the following characteristics:

1. Insufficient or no lens movement during a blink in primary or upward gaze.
2. **Unsatisfactory Push-up Test**
  - **A tight fitting lens will resist movement.** If successfully nudged upward, the lens may remain decentered or return slowly to its original position.
3. Good centration.
4. Good comfort.
5. Fluctuating vision between blinks.

#### **Characteristics of a Loose (Flat) Lens Fit**

A loose lens fit would display some or all of the following characteristics:

1. **Reduced comfort**, usually accompanied by lower lid sensation.
2. **Poor centration** with limbal exposure on exaggerated eye movement.
3. **Lens edge standoff.**
4. **Excessive lens movement** during the blink in primary or upward gaze.
5. **Unsatisfactory Push-up Test**
  - A loose fitting lens will move easily but may remain decentered or slip under the upper lid.
6. **Vision may be blurred** after the blink.

An inverted lens may mimic the characteristics of a loose lens. If any of

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

the above signs occur remove the lens and check to make sure it is not inverted.

### **General Fitting Tips**

- Trial fitting of the individual eye is recommended.
- A well fitting lens will show movement of 0.1 to 0.5 mm.

### **D. Final Lens Power Determination**

After the characteristics of a well fitted lens have been satisfied, conduct a **spherical over-refraction** to determine the proper lens power to be dispensed.

<b>Example:</b>	<b>Diagnostic lens:</b>	<b>-4.50</b>
	<b>Over-refraction:</b>	<b>-0.25</b>
	<b>Final lens power:</b>	<b>-4.75</b>

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### FITTING GUIDELINES (Multifocal)

The **DAILIES TOTAL1\* Multifocal** (delefilcon A) soft contact lens is a progressive aspheric simultaneous vision soft contact lens, intended to correct presbyopia with or without additional ammetropia, available in three ADD powers; low (LO), medium (MED) and high (HI). For each lens the near and intermediate powers are concentrated primarily in the central portion of the optical zone while the distance power is contained in the surrounding portion. The continuous changes in power across the surface of the lens allow patients requiring a reading addition of up to + 3.00D to see clearly at far, intermediate, and near distances.

Achieving high success with DAILIES TOTAL1\* Multifocal (delefilcon A) contact lenses is dependent on several factors, including the patient's motivation, expectations and visual wearing environment, as well as your skill in optimizing the lens powers to balance binocular performance at distance and near. The information in this guide is designed to provide you with the tools to manage your presbyopic patients through each stage of the process from the initial case history to post-fitting follow-up.

#### 1. *Pre-fitting Examination*

##### **A pre-fitting examination is necessary to:**

- determine whether a patient is a suitable candidate for DAILIES TOTAL1\* Multifocal (delefilcon A) contact lenses
- make ocular measurements and assessments for initial contact lens parameter selection
- collect baseline clinical information to which post-fitting examination results can be compared

##### **A pre-fitting examination should include:**

- a thorough case history
- detailed assessment of patient's individual visual demands
- understanding of patient's objectives for lens wear and expectations
- a distance spherocylindrical refraction, near add determination and measurement of pupil diameter
- keratometry
- tear assessment
- biomicroscopy

Note: The importance of a thorough case history should not be underestimated. The information gained through careful listening and probing will help greatly in satisfying each patient's unique needs.

#### 2. *Patient Selection*

The eye care professional should weigh several factors when considering patient selection for a DAILIES TOTAL1\* Multifocal (delefilcon A) soft contact lens fitting. When fitting a lens intended to correct for presbyopia, it is especially important to evaluate the particular visual needs, objectives, lifestyle and expectations of the individual patient. Prospective candidates may include current contact lens wearers, former wearers, and persons with no previous wear history. For former wearers it is important to determine the cause for discontinuation.

There are two general categories of candidates based on anticipated usage: those who seek to wear their lenses as their principal means

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

of vision correction, and those who wish to integrate the use of their contact lenses with spectacles. The integrative user often seeks to wear their lenses for sports or other occasional activities while reverting to spectacles under poor lighting or otherwise demanding vision conditions. In general, even the part-time user does not require more than a few moments re-adaptation time following an interval of no lens wear.

While candidates with greater than 1.00 diopter of refractive error have often been thought of as better candidates than those with low error or emmetropia, this is a generalization that often does not hold true for a given individual. Success is influenced by many factors and the eye care professional is encouraged to offer DAILIES TOTAL1\* Multifocal (delefilcon A) contact lenses to all interested presbyopic patients who satisfy the standard requirements for soft contact lens wear.

To summarize patient selection, the characteristics of “ideal candidates” and those that will be more difficult to fit” are listed below:

### ***Ideal Candidates***

- Refractive cylinder < 1.00D.
- Attainable visual demands that do not depend upon resolving very fine (smaller than 20/20 letters) details at *both* distance and near for extended periods while wearing DAILIES TOTAL1\* Multifocal contact lenses.
- Emphasis on tasks where it is advantageous to have objects simultaneously in focus over a large range of viewing distances.
- Expectations consistent with actual everyday visual demands.
- Motivated to wear lenses and understands that vision may not always be as sharp as with spectacles for some distances or lighting conditions.
- Unable to adapt to monovision correction.

### ***Less than Ideal Candidates***

- Critical or very fine visual demands at both distance and near.
- Refractive cylinder  $\geq$  1.00D (any axis) in one or both eyes or against-the-rule refractive cylinder  $>$  1.00D in one or both eyes.
- Monocular distance acuities poorer than 20/20 with spherical equivalent refractive correction.
- Myopic anisometropia where the refractive error for one of the two eyes is low ( $\leq$ 1.50D) and has not been habitually corrected.
- Pupil size larger ( $>$  4 mm) or smaller ( $<$ 3 mm) than norm for presbyopic population under natural illumination conditions.
- Abnormal binocular sensory function (e.g., amblyopia or strabismus).
- Expectation to discard and never use spectacles again, including reading glasses, even for special tasks or viewing conditions.
- Highly satisfied monovision wearers.
- Any other contraindications to successful contact lens wear such as tear abnormality or lid margin disease.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### 3. Initial Lens Selection

#### A. Initial Base Curve Selection

DAILIES TOTAL1\* Multifocal (delefilcon A) contact lenses are available in a single 8.5 mm base curve.

#### B. Initial Lens Power Selection

**Note:** A careful maximum plus spherocylindrical refraction and nearpoint add determination should be conducted prior to selecting a DAILIES TOTAL1\* Multifocal (delefilcon A) trial lens. Autorefraction findings should be refined manually to rule out effects of instrument myopia and ensure proper control of residual accommodation.

The DAILIES TOTAL1\* Multifocal lens design makes selecting the initial lens power easy. You need only manipulate the distance power. **The optimum starting point is with a power that is equal to or more plus or less minus than the vertex corrected spherical equivalent spectacle refraction.**

#### C. Initial ADD Selection

**Note:** A careful nearpoint ADD determination should be conducted prior to selecting a DAILIES TOTAL1\* Multifocal (delefilcon A) trial lens

The DAILIES TOTAL1\* Multifocal (delefilcon A) 3 ADD SYSTEM allows personalized fitting for presbyopic patients. The table below makes initial ADD selection easy.

### DAILIES TOTAL1\* MULTIFOCAL ADD SELECTION

SPECTACLE ADD	BOTH EYES
Up to +1.25	LO
+1.50 to +2.00	MED
+2.25 to +2.50	HI

Example 1:	OD	OS
Spherical Rx:	-4.50 -0.75 x 90	-4.00D
Spherical equivalent (least minus);	-4.75D	-4.00D
Vertex corrected power:	-4.50D	-4.00D
Spectacle Add:		+0.75D
Eye Dominance:		OD
Initial Trial Lens:	-4.50 LO	-4.00 LO

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

<b>Example 2:</b>	<b>OD</b>	<b>OS</b>
<b>Spherical Rx:</b>	<b>+4.25 -0.25 x 180</b>	<b>+4.00 D -0.50 x 180</b>
<b>Spherical equivalent (least minus):</b>	<b>+4.25D</b>	<b>+3.75D</b>
<b>Vertex corrected power:</b>	<b>+4.50D</b>	<b>+3.75D</b>
<b>Spectacle Add:</b>		<b>+2.00D</b>
<b>Eye Dominance:</b>		<b>OS</b>
<b>Initial Trial Lens:</b>	<b>+4.50 MED</b>	<b>+3.75 MED</b>

**4. Initial Lens Fitting Evaluation**

- a) Insert the lenses selected in Section 3 (above). If the exact power is not available, choose the next closest least minus/most plus lens power in your trial set.
- b) Allow the lenses to settle on the eyes for approximately **10 minutes**. This allows time for the patient to adapt to the lenses and time for the lens to equilibrate with the patient's tears.
- c) Evaluate the fit of the lenses on the eye. The **Push-up Test** as described below is an important part of the lens evaluation. The following guidelines will be helpful in evaluating the physical fit of the lens:

**Characteristics of a Well-fitted Lens**

A well-fitted DAILIES TOTAL1\* Multifocal (delefilcon A) contact lens satisfies the following criteria:

1. Full corneal coverage and good centration (no limbal exposure). A lens that is decentered > 1 mm, particularly temporal, is less likely to give adequate vision.
2. Lens movement of 0.1 to 0.5 mm should be present to allow tear exchange under the lens during a blink in primary gaze or upward gaze and to avoid variable vision.

**Push-up Test:**

- This test is a reliable indicator of a good fit. With the patient looking straight ahead, place your index finger on the patient's lower lid and nudge the edge of the lens upward while observing lens movement. Then pull the lid back down and observe the return of the lens.
- A well fitted lens will move freely upward, stopping shortly after passing the limbus and then return freely to its original position.

3. Good comfort.
4. Acceptable visual acuity with over-refraction.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### Characteristics of a Tight (Steep) Lens Fit

A tight or steep fit should not be dispensed. If a lens fit is judged to be too steep a flatter lens (larger base curve), if available, should be evaluated. A tight or steep lens fit would display some or all of the following characteristics:

1. Good centration.
2. Insufficient or no lens movement during a blink in primary gaze or upward gaze.
3. Excessive conjunctival drag (visible movement of the conjunctival vessels when the lens moves during a blink or during the push-up test). Note: presbyopes often have loose conjunctiva, some conjunctival movement is occasionally seen and may not be a sign of a tight fit. See Push-up Test below.

#### Push-up Test:

- **A tight fitting lens will resist movement. If successfully nudged upward, the lens may remain decentered or return slowly to its original position.**

4. Good comfort.
5. Blurred vision between blinks.

### Characteristics of a Loose (Flat) Lens Fit

If a lens fit is judged to be too flat a steeper lens (smaller base curve), if available, should be evaluated. A loose lens fit would display some or all of the following characteristics:

1. Decentration.
2. Excessive lens movement during the blink in primary or upward gaze.

#### Push-up Test:

- **A loose fitting lens will move very easily, well beyond the limbus and possibly encroaching upon or going beyond the pupil. It will then return very quickly to its original position and often times return lower than its original position.**

3. Reduced comfort.
4. Lens edge standoff.
5. Blurred vision immediately after the blink.

### 5. Initial Lens Visual Evaluation

While lenses are settling, it is helpful to take the patient from the exam room to a "real-world" setting such as a room with an outside view. Once an acceptable fit has been achieved, the visual performance of the lenses may be evaluated. Visual acuity is tested at distance. If necessary, a spherical over-refraction should be performed using a trial frame or hand held lenses rather than a phoropter. This technique is essential when fitting multifocal lenses because it allows the patient to maintain the head posture and direction of gaze (relationship between eye and head) that he or she would naturally use during everyday tasks. This ensures that the visual performance of the lens is being assessed under conditions where the on-eye positioning matches that which will occur when the lens is being used, for example, for near work activities. In addition, pupil size will not be artificially increased

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

by the reduction in light associated with looking through the aperture of the phoropter cells, or decreased by proximal cues associated with the nearness of the instrument.

### 6. Fitting Procedures

Step 1. After the trial lenses have settled for approximately 10 minutes, measure distance acuity while the patient is viewing the chart binocularly (i.e., simultaneously with both eyes). Next, evaluate the patient's subjective impression of the near vision when trying to read typical everyday material (e.g., a newspaper, magazine, and cell phone). Lighting and reading distance should be what is normal for the patient.

Step 2. If distance or near vision is unsatisfactory, perform a **binocular distance** over-refraction, as follows. Use hand-held trial lenses and encourage plus. For example, if a Plano and +0.25D over-refraction yields the same results, use the +0.25D endpoint. Re-check visual acuity and visual quality as described in Step 1 above. If over-refraction is other than plano, go immediately to new trial lenses, keeping ADD the same.

Step 3. If distance and near vision are satisfactory, dispense lenses and remind patient to use good light when reading fine print or use additional reading glasses if needed. It is helpful to let the patient experience the lenses in their natural environment before further procedures for enhancing vision are performed.

Step 4. **Enhanced Near Vision.** If near vision is unsatisfactory, determine the dominant eye by the following method. Determine the eye with **greatest plus acceptance** by placing +1.50 handheld trial lens over each eye alternately while patient views in the distance with both eyes open. Consider the eye for which binocular vision blurs **least** with the +1.50 to be the non-dominant eye. Other methods to determine the dominant eye are appropriate.

**Step 4A:** Check the patient's binocular acuity with +0.50 over the non-dominant eye to determine if near vision is improved and distance vision is still acceptable. If so, place a new trial lens with the same ADD on the non-dominant eye, **adjusting the distance power by +0.50.**

Enhanced near vision, Step A		
SPECTACLE ADD	DOMINANT EYE	NON-DOMINANT EYE (PLUS ACCEPTED)
Up to +1.25	LO	LO with additional +0.50
+1.50 to +2.00	MED	MED with additional +0.50
+2.25 to +2.50	HI	HI with additional +0.50

Next, re-check visual acuity and visual quality as described in Step 1 above. If satisfactory, dispense new distance lens power for the non-dominant eye. If near vision is still unsatisfactory, proceed to Step B:

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Step 4B:** If near vision is still unsatisfactory, adjust ADD as shown below.

Enhanced near vision, Step B		
SPECTACLE ADD	DOMINANT EYE	NON-DOMINANT EYE (PLUS ACCEPTED)
Up to +1.25	MED	MED
+1.50 to +2.00	MED	HI
+2.25 to +2.50	HI	MED

Note: It is common to question the rather non-intuitive step we suggest for enhancing vision at near in the HI ADD range, where the suggestion is to "back off" to a MED ADD for the non-dominant eye, the same suggestion we make for enhancing distance vision (below). The reason for this is that after establishing (in Step A) that increasing plus is not helpful, the next most common reason for blur at near (or distance) is unacceptable ghosting that degrades the image quality. Backing down to the MED ADD in one eye can often relieve that and actually improve vision at near.

**Step 5: Enhanced Distance Vision.** If distance over-refraction did not improve visual acuity, adjust ADD according to the chart below.

SPECTACLE ADD	DOMINANT EYE	NON-DOMINANT EYE (PLUS ACCEPTED)
+1.50 to +2.00	LO	MED
+2.25 to +2.50	HI	MED

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### FITTING GUIDELINES (Monovision)

#### Patient Selection

##### **A. Monovision Needs Assessment**

For a good prognosis, the patient should have adequately corrected distance and near visual acuity in each eye. Patients with reduced visual acuity, such as the amblyopic patient, may not be a good candidate for monovision.

Occupational and environmental visual demands should be considered. If the patient requires critical vision (visual acuity and stereopsis), it must be determined by trial whether this patient can function adequately with monovision. Monovision contact lens wear may not be optimal for such activities as:

1. visually demanding situations such as operating potentially dangerous machinery or performing other potentially hazardous activities; and
2. driving automobiles (e.g., driving at night). Patients who cannot pass requirements for a driver's license with monovision correction should not drive with this correction. An additional over-correction can be prescribed to improve vision.

##### **B. Patient Education**

All patients do not function equally well with monovision correction. Patients may not perform as well for certain tasks with this correction as they have with bifocal reading glasses. Each patient must understand that monovision, as well as other presbyopic contact lenses, or other alternatives, can create a vision compromise that may reduce visual acuity and depth perception for distance and near tasks. During the fitting process, it is necessary for the patient to realize the disadvantages as well as the advantages of clear near vision in straight-ahead and upward gaze that monovision contact lenses provide compared to spectacle bifocals.

#### Eye Selection

Generally, the non-dominant eye is corrected for near vision. The following test for eye dominance can be used:

##### **A. Ocular Preference Determination Methods**

- Method 1 - Determine which eye is the "sight eye". Have the patient point to an object at the far end of the room. Cover one eye. If the patient is still pointing directly at the object, the eye being used is the dominant (sighting) eye.
- Method 2 - Determine which eye will accept the added power for near with the least reduction in distance vision. Place a trial spectacle near ADD lens in front of one eye and then the other while the distance refractive error correction is in place for both eyes. Determine whether the patient functions best with the near ADD lens over the right or left eye.

##### **B). Refractive Error Method**

- For anisometropic corrections, it is generally best to fit the more hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### C). Visual Demands Method

- Consider the patient's occupation during the eye selection process to determine the critical vision requirements. If a patient's gaze for near tasks is usually in one direction, correct the eye on that side for near.

#### **Example:**

A person who places copy to the left side of the desk will usually function best with the near lens on the left eye.

### Special Fitting Considerations

#### ***Unilateral Lens Correction***

There are circumstances where only one contact lens is required. As an example, an emmetropic patient would only require a near lens while a bilateral myope may require only a distance lens.

- **Examples:**

- **Emmetrope:** A presbyopic emmetropic patient who requires a +1.75 diopter ADD would have a +1.75 lens on the near eye and the other eye left without a lens.
- **Bilateral myope:** A presbyopic patient requiring a +1.50 diopter ADD who is -2.50 diopters myopic in the right eye and -1.50 diopters myopic in the left eye may have the right eye corrected for distance and the left uncorrected for near.
- **Unilateral astigmat:**

- a) Emmetropic in one eye, astigmatic in the other

<u>Spectacle Rx</u>	<u>Potential Monovision Rx</u>
O.D. Plano	Uncorrected for distance
O.S. -1.00 -1.00 x 090	+0.50 -1.00 x 090 for near
Add: +1.50	

- b) Myopic in one eye, astigmatic in the other

<u>Spectacle Rx</u>	<u>Potential Monovision Rx</u>
O.D. -1.50	Uncorrected for near
O.S. -2.00 -1.75 x 090	-2.00 -1.75 x 090 for distance

#### ***Amblyopia***

The amblyopic patient may not be a good candidate for monovision.

#### ***Astigmatism***

Patients with less than 1.50 diopters of astigmatism might be successfully fit in DAILIES TOTAL1\* (delefilcon A) spherical lenses.

- Determine which eye to use for the near prescription (see Eye Selection, A-C, above)
- Add the appropriate near add power to the spherical component of the astigmatic prescription for that eye.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

Example: <u>Spectacle Rx</u>	<u>Potential Monovision Rx</u>
O.D.: -2.50 -0.75 x 180	-2.50 -0.75 x 180 for distance
O.S.: -3.00 -1.75 x 165	-2.00 -1.75 x 165 for near
Add: +1.00	
Dominant eye: O.D.	

### Near Add Determination

Always prescribe the lens power for the near eye that provides optimal near acuity at the midpoint of the patient's habitual reading distance. However, when more than one power provides optimal reading performance, prescribe the least plus (most minus) of the powers.

### Trial Lens Fitting

A trial lens fitting is performed in the office to allow the patient to experience monovision correction. Lenses are fit according to the directions in the *General Fitting Guidelines and Base Curve Selection* described earlier in the guide.

Case history and standard clinical evaluation procedures should be used to determine the suitability of monovision. Determine which eye is to be corrected for distance and which eye is to be corrected for near. Next determine the near ADD. With trial lenses of the proper power in place, observe the reaction to this mode of correction.

Immediately after the correct power lenses are in place, walk across the room and have the patient look at you. Assess the patient's reaction to distance vision under these circumstances. Then have the patient look at familiar near objects such as a watch face or fingernails. Again assess the reaction. As the patient continues to look around the room at both near and distance objects, observe the reactions. Only after these vision tasks are completed, should the patient be asked to read print. Evaluate the patient's reaction to large print (e.g., typewritten copy) at first and then graduate to news print and finally smaller type sizes.

After evaluating the patient's performance under the above conditions, tests of visual acuity and reading ability under conditions of moderately dim illumination should be attempted.

An initial unfavorable response in the office, while indicative of a less favorable prognosis, should not immediately rule out a more extensive trial under the usual conditions in which a patient functions.

### Adaptation

Visually demanding situations should be avoided during the initial wearing period. A patient may at first experience some mild blurred vision, dizziness, headaches, and feeling of slight imbalance. You should explain the adaptational symptoms to the patient. These symptoms may last for a few minutes or for several weeks. The longer these symptoms persist, the poorer the chance for successful adaptation. To help in the adaptation process, the patient can be advised to first use the lenses in a comfortable, familiar environment such as in the home.

Some patients feel that automobile driving performance may not be optimal during the adaptation process. This is particularly true when driving at night. Before driving a motor vehicle, it is recommended that patients be a passenger first to make sure that their vision is satisfactory for operating an automobile. During the first several

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

weeks of wear (when adaptation is occurring), it may be advisable for the patient to only drive under optimal driving conditions. After adaptation, and success with these activities, the patient should be able to drive under other conditions with caution.

### Other Suggestions

The success of the monovision technique may be further improved by having your patient follow the suggestions below:

- Have a third contact lens (distance power) to use when critical distance viewing is needed.
- Have a third contact lens (near power) to use when critical near viewing is needed.
- Have supplemental spectacles to wear over the monovision contact lenses for specific visual tasks. This is particularly applicable for those patients who cannot meet driver's licensing requirements with a monovision correction.
- Make use of proper illumination when carrying out visual tasks.

Success in fitting monovision can be improved by the following suggestions:

- Reverse the distance and near eyes if a patient is having trouble adapting.
- Refine the lens powers if there is trouble with adaptation. Accurate lens power is critical for presbyopic patients.
- Emphasize the benefits of the clear near vision in straight ahead and upward gaze with monovision.

The decision to fit a patient with a monovision correction is most appropriately left to the eye care professional in conjunction with the patient after carefully considering the patient's needs. All patients should be supplied with a copy of the **Patient Instruction Booklet**, which contains important instructions for the monovision wearer. You can obtain copies of the instruction book by calling customer service **in the USA at (800) 241- 5999**.

### DISPENSING VISIT

To help ensure patient success the following steps should be conducted with each patient, even if they have previously worn contact lenses. Even experienced wearers are prone to develop bad habits over time.

DAILIES TOTAL1\* brand (delefilcon A) lenses are supplied sterile in foil sealed blister pack containers. Open the foil pack by peeling back the foil lidding material and gently slide the lens out of the container with your finger, or pour the lens onto the palm of your clean hand.

Conduct the following steps with each patient, even if they have previously worn contact lenses:

#### **A. Verification of Lens Fit**

Evaluate lens fit and visual response with the lens on the eye. The criteria of a well-fitted lens should be met and the patient's visual acuity should be acceptable. If not, the patient should be refitted with a more appropriate lens.

#### **B. Hygiene and Lens Handling Instructions**

Good hygiene and proper lens handling are important factors in achieving safe, comfortable lens wear. Instruct the patient on hygiene and handling of lenses. Patients who are unable to place and remove lenses should not be provided with them.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### **C. Lens Wear and Replacement Schedules (see Package Insert)**

Prescribe and explain the daily disposable wear schedule. Explain that lenses are to be discarded after each daily wearing period. Determine the maximum suggested daily wearing period based on the patient's physiological eye condition. There may be a tendency for the patient to overwear their lenses initially. For some patients who have never worn contact lenses consider a wearing schedule that allows for a gradual increase in wearing time.

### **D. Lens Care Directions (see Package Insert)**

The lenses are not intended to be cleaned or disinfected and should be discarded after a single use. The eye care professional may recommend lens rewetting drops, as needed.

### **E. Specific Instructions for Presbyopic Patients**

Specific instructions, explanations and demonstrations are important for optimizing patient success with multifocal contact lenses. The following information and instructions have proven useful in advising patients who wear DAILIES TOTAL1\* Multifocal (delefilcon A) soft contact lenses.

- A contact lens that contains different powers for distance and near involves greater technological and optical complexity than does a bifocal or multifocal spectacle lens. This is because the contact lens moves with the eye, rather than having the eye move up and down while the lens remains suspended in a frame. While the contact lens therefore gives an unobstructed field of view and greater freedom regarding where to look, these advantages may mean that the sharpness of vision may not always be exactly the same as what would be experienced with spectacles.
- Although many individuals use DAILIES TOTAL1\* Multifocal (delefilcon A) contact lenses for full-time wear, it is not unusual to find that there may be some activities where one prefers to wear spectacles, or where the disadvantages associated with spectacles are outweighed by other issues. This is an entirely normal and natural response to the challenges presented by presbyopia.
- Situations where vision with multifocal contact lenses may be less sharp or otherwise "different" than what is experienced with spectacles often involve low illumination (e.g., a semi-dark room), reduced visibility (e.g., outdoor conditions of fog or heavy rain), or isolated sources of very bright light (e.g., headlights of an oncoming vehicle on a narrow country road). **Patients should be instructed to make use of good light when reading fine print.**
- Patients should be aware that it might be advisable to refrain from wearing their lenses while driving, flying an airplane or operating heavy machinery while wearing their lenses until they gain some experience with the lenses in a similar visual environment.
- Small changes in lens power can often make a significant difference in the quality of the vision experienced with multifocal contact lenses. Such changes can be best tailored to

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

individual needs and environmental conditions that the patient will personally encounter on a day-to-day basis. Confidence and assurance that such refinements, if needed, can be achieved are important for patient motivation during the initial period of lens wear.

### **F. Additional Instructions**

#### **• Review the Package Insert**

Provide the patient with all relevant information and precautions on the proper use of the lenses that are prescribed.

#### **• Provide the Patient Instruction Booklet for DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal (delefilcon A) Contact Lenses.**

Give the patient a copy of the **Patient Instruction Booklet** for DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal (delefilcon A) soft contact lenses. Review the contents so the patient clearly understands the prescribed lens wear, care, and replacement schedule. In the USA you can obtain copies of the instruction book by calling Alcon customer service at **(800) 241-5999**.

## **Follow-Up Examinations**

Follow-up care is extremely important for continued successful contact lens wear. Follow-up care should include:

- Case history, including questions to identify any problems related to contact lens wear
- Management of specific problems, if any, and
- A review with the patient of the lens wearing schedule, replacement schedule and handling procedures.

## **Follow-up Examination Procedures**

- Patients should be instructed to wear lenses prior to a follow-up examination.
- Record patient's symptoms, if any.
- Measure visual acuity monocularly and binocularly with the contact lenses in place.
- Perform an over-refraction to check for residual refractive error.
- With a biomicroscope, evaluate lens fitting.
- Remove the lenses and conduct a thorough biomicroscopic examination with fluorescein. Rinse eyes with saline before re-inserting lenses.
- Evert upper lids to determine condition of tarsal conjunctiva.
- Periodically perform keratometry and spectacle refractions. These results should be recorded to compare to the initial measurements.
- If any observations are abnormal, use professional judgment to manage the problem and restore the eye to optimal conditions. If visual requirements are not satisfied during any follow-up examination, the patient should be re-fitted with a more appropriate lens.

## **LENS HANDLING HINTS**

### **Lens Insertion**

- When about to place the lens on the eye, make sure the lens sits up on the placement finger. The finger should be dry so surface tension does


# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

- not cause the lens to adhere to the finger.
- Check to see that the lens is right side out. A lens that is placed on the eye inside out may not feel comfortable or provide good vision.


One way to do this is to perform the 'taco test' by placing the lens between your thumb and index finger and squeeze the edges together gently.

- If the edges come together, the lens is right side out.
- If the edges turn outward, the lens is wrong side out. Carefully reverse it with your fingers.



Another way is to place the lens on the tip of your index finger and check its shape.

- If the edge appears bowl-shaped, it is right side out.
- If the edge has a lip or flares outward, it is wrong side out and must be reversed.
- Place the lens directly onto the cornea (placing it on the lower sclera can lead to the lens folding after a blink). While continuing to hold both lids in place, the patient should look down to seat the lens. The lids may then be released.



### Lens Removal

- Wash hands thoroughly** with soap that does not have any oils, lotions or perfumes.
- Carefully dry hands** with a clean, lint-free towel.

It is important to remind patients to **dry their hands thoroughly** prior to removing their lenses. The surface of DAILIES TOTAL1® brand lenses is designed to stay very wet and lubricious, or slippery while on the eye. If their fingertips are wet they are likely to slip across the surface of the lens making removal more difficult.

- Slide the lens off the cornea (down or to the side) onto the sclera. This produces a fold in the lens, which assists in removal. With the index finger and thumb, gently pinch the lens off the eye.
- Discard lenses.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

### Care for a Sticking Lens

- In the unlikely event that the lens sticks (stops moving) or begins to dry on the eye, instruct the patient to apply several drops of a recommended lubricating solution (used in accordance with package labeling). The patient should wait until the lens begins to move freely on the eye before attempting to remove it. If the lens continues to stick, the patient should **immediately** consult the eye care professional.

### IN OFFICE CARE OF TRIAL LENSES

Eye care professionals should understand and educate contact lens technicians concerning proper use of trial lenses.

- Each contact lens is shipped sterile in a sealed blister pack containing phosphate buffered saline with additives. Hands should be thoroughly washed and rinsed and dried with a lint-free towel prior to handling a lens. In order to insure sterility, the blister pack should not be opened until immediately prior to use.
- Delefilcon A lenses are for daily disposable wear only and should be discarded after a single use. The **lenses should be disposed of after a single use and not be re-used from patient to patient.**

### ADDITIONAL INFORMATION

For assistance with fitting or clinical questions regarding DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal contact lenses eye care professionals having questions or problems should contact Medical Information Systems in the USA at (800) 241-7468. To order DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal contact lenses contact your Alcon sales representative or call Customer Service, in the USA at (800) 241-5999.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**VERTEX DISTANCE CONVERSION CHART**

For minus lenses, read left to right; for plus lenses, read right to left.  
(12 mm Vertex Distance)

-	+	-	+	-	+	-	+
4.00	3.87	7.50	6.87	12.00	10.37	19.00	15.50
4.25	4.00	7.62	7.00	12.50	10.75	19.25	15.62
4.50	4.25	7.75	7.12	12.75	11.00	19.25	15.75
4.75	4.50	7.87	7.25	13.00	11.25	19.75	16.00
5.00	4.75	8.00	7.37	13.50	11.50	20.00	16.12
5.12	4.87	8.12	7.50	13.75	11.75	20.25	16.25
5.37	5.00	8.25	7.62	14.00	12.00	20.50	16.50
5.50	5.12	8.50	7.75	14.25	12.25	20.75	16.62
5.62	5.25	8.75	8.00	14.75	12.50	21.00	16.75
5.75	5.37	9.00	8.25	15.00	12.75	21.25	17.00
5.87	5.50	9.25	8.37	15.50	12.75	21.75	17.25
6.00	5.62	9.50	8.62	15.75	13.25	22.25	17.50
6.12	5.75	9.75	8.75	16.25	13.50	22.50	17.75
6.37	5.87	10.00	9.00	16.75	13.75	23.00	18.00
6.50	6.00	10.25	9.12	17.00	14.00	23.50	18.25
6.62	6.12	10.50	9.25	17.25	14.25	23.75	18.50
6.75	6.25	10.75	9.37	17.62	14.37	24.25	18.75
6.87	6.37	11.00	9.62	18.00	14.50	24.75	19.00
7.00	6.50	11.25	9.75	18.12	14.75	25.00	19.25
7.12	6.62	11.50	10.00	18.50	15.00	25.50	19.50
7.37	6.75	11.75	10.25	18.75	15.25	26.00	19.75

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

This page intentionally left blank

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

 a Novartis company	<b>DAILIES TOTAL1* and DAILIES TOTAL1* Multifocal (delefilcon A) Soft Contact Lenses for Daily Disposable Wear</b>	900038292
---	--	-----------

**IMPORTANT:** This package insert is effective as of March 2016 and applicable to the delefilcon A contact lenses described below. Please read carefully and keep this information for future use. This package insert is intended for the eye care professional, but should be made available to patients upon request. The eye care professional should provide the patient with appropriate instructions that pertain to the patient's prescribed lenses. Copies of this package insert are available without charge from Alcon by calling Customer Service at 1-800-241-5899 or download from our website at [www.alcon.com](http://www.alcon.com). In addition, a Patient Instruction Booklet is available which is recommended to be given to patients.

**Rx only**

**CAUTION: Federal law (United States) restricts this device to sale by or on the order of a licensed eye care professional.**

### PRODUCT DESCRIPTION

**DAILIES TOTAL1\* and DAILIES TOTAL1\* Multifocal (delefilcon A)** soft contact lenses are made from a lens material that is 33% water and 67% (delefilcon A) polymer, a silicone containing hydrogel with added phosphotrichlorine. The core lens material containing 33% water transitions through a water gradient to a hydrogel surface layer that exceeds 80% water. Lenses contain the color additive copper phthalocyanine, a light blue tint, which makes them easier to see when handling.

### Lens Properties

• Refractive Index hydrated:	1.42
• Light Transmittance:	93% (@ 610 nm, -1.00D)
• Oxygen Permeability (Dk):	140 x 10 <sup>-11</sup> (cm <sup>2</sup> /sec)(ml O <sub>2</sub> / ml x mm Hg), measured at 35° C (intrinsic Dk-Coulometric method)
• Water Content:	33% by weight in normal saline
• Surface Water Content:	≥ 80%

### Lens Parameters

• Diameter Range	13.0 to 15.0 mm
• Spherical Power Range	-20.00 to +20.00
• Base Curve Range	8.0 to 9.2 mm

### Lens Parameters Available\*

• Chord Diameter:	14.1 mm
• Center Thickness:	0.09 mm @ -3.00D (varies with power)
• Base Curve:	8.5 mm
• Powers:	-0.50 to +6.00D (0.25D steps); -6.50 to +12.00D (0.50D steps) +0.50 to +6.00D (0.25D steps)

### DAILIES TOTAL1\* (delefilcon A) spherical

• Chord Diameter:	14.1 mm
• Center Thickness:	0.09 mm @ -3.00D (varies with power)
• Base Curve:	8.5 mm
• Powers:	+6.00D to -10.00D (0.25D steps) ADD: LO, MED, HI

NOTE: Hereafter, **DAILIES TOTAL1\* spherical lenses** and **DAILIES TOTAL1\* Multifocal contact lenses** will simply be referred to as delefilcon A contact lenses unless product distinction is necessary.

### ACTIONS

When hydrated and placed on the cornea, delefilcon A contact lenses act as a refracting medium to focus light rays on the retina.

### INDICATIONS (USES)

**DAILIES TOTAL1\* (delefilcon A) spherical** soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.

**DAILIES TOTAL1\* Multifocal (delefilcon A) soft contact lenses** are indicated for the optical correction of refractive ametropia (myopia and hyperopia) and/or presbyopia in phakic or aphakic persons with non-diseased eyes who may require a reading addition of +3.00 (D) or less and who may have up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.

The lenses are to be prescribed for single use, daily disposable wear. The lenses are not intended to be cleaned or disinfected and should be discarded after a single use.

### CONTRAINDICATIONS (REASONS NOT TO USE)

**DO NOT use delefilcon A contact lenses when any of the following exists:**

- Inflammation or infection of the anterior chamber of the eye

- Active disease, injury or abnormality affecting the cornea, conjunctiva, or eyelids
- Microbial infection of the eye
- Insufficiency of lacrimal secretion (dry eye) that interferes with contact lens wear
- Corneal hypothesia (reduced corneal sensitivity)
- Use of any medication that is contraindicated or interferes with contact lens wear, including eye medications
- Any systemic disease which may be exacerbated by or interferes with contact lens wear
- Allergic reactions or ocular irritation of the ocular surfaces or adnexa that may be caused by or exaggerated by the wearing of contact lenses
- Patient history of recurring eye or eyelid infections, adverse effects associated with contact lens wear, intolerance or abnormal ocular response to contact lens wear
- If eyes become red or irritated

### WARNINGS

**Advise patients of the following warnings pertaining to contact lens wear:**

- **Problems with contact lenses and lens care products could result in serious injury to the eye.** It is essential that patients follow their eye care professional's directions and all labeling instructions for proper use of lenses and lens care products. **Serious eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision.**
- Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping. Clinical study results have shown that the risk of serious adverse reactions is increased when contact lenses are worn overnight<sup>2</sup>.
- Studies<sup>2</sup> have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers.
- If a patient experiences eye discomfort, foreign body sensation, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her eye care professional. It is recommended that contact lens wearers see their eye care professional regularly as directed.

### PRECAUTIONS

To prevent damage to the eyes or to the contact lenses, the following precautions should be taken:

#### Special Precautions for the Eye Care Professional:

Due to the small number of patients enrolled in the clinical investigation of lenses, all refractive powers, design configurations, or lens parameters available in the lens material are not evaluated in significant numbers. Consequently when selecting an appropriate lens design and parameters, the eye care professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, central and peripheral thickness and optic zone diameter. The potential impact of these factors on the patient's ocular health should be carefully weighed against the patient's need for refractive correction; therefore the continuing ocular health of the patient and lens performance on the eye should be carefully evaluated on initial dispensing and monitored on an ongoing basis by the prescribing eye care professional.

- Fluorescein, a yellow dye, should not be used while the lenses are on the patient's eyes. The lenses absorb this dye and become discolored. Whenever fluorescein is used, the eyes should be flushed thoroughly with sterile saline solution that is recommended for in eye use prior to inserting lenses. Avoid dispensing saline from an aerosol can directly into the eye.
- Patients who wear contact lenses to correct presbyopia may not achieve the best possible corrected visual acuity for either far or near vision. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
- Before leaving the eye care professional's office, the patient should be able to promptly remove their lenses or should have someone else available who can remove their lenses for them.
- Eye care professionals should instruct the patient to remove the lenses immediately if the eye becomes red or irritated.
- Routine eye examinations are necessary to help assure the continued health of the patient's eyes. Eye care professionals should make arrangements with the patient for appropriate

follow-up visits. Alcon recommends that patients see their eye care professional once each year, or more often, as recommended by the eye care professional.

- Diabetics may have reduced corneal sensitivity and thus are more prone to corneal injury and do not heal as quickly or completely as non-diabetics.
- Visual changes or changes in lens tolerance may occur during pregnancy or use of oral contraceptives. Caution patients accordingly.

**Eye Care Professionals should carefully instruct patients about the following safety precautions:**

#### Handling Precautions:

- Be sure that before leaving the eye care professional's office the patient is able to promptly remove lenses or have someone else available to remove them.
- Good hygiene habits help promote safe and comfortable lens wear. Always wash, rinse and thoroughly dry hands with a lint-free towel before handling lenses.
- **REMOVE A LENS IMMEDIATELY** if an eye becomes red or irritated.
- Always handle lenses carefully. Never use tweezers or other sharp objects such as fingernails to remove lenses from the lens container unless specifically indicated for that use.
- Do not use if blister package is damaged or not sealed completely. This may result in product contamination which can lead to a serious eye infection.
- Ensure that the correct lens for each eye is available. Shake the blister pack gently prior to opening. Remove the lens from the blister pack by carefully pouring the lens onto the palm of your clean hand. Ensure the lens is right side out. Inspect lens prior to insertion. Do not insert damaged lenses.
- To insert lenses:
  - Wash and rinse hands thoroughly and dry completely with a clean, lint free towel before handling lenses.
  - Place a lens on the tip of your clean and dry right or left index finger, place the middle finger of the same hand close to lower eyelashes and pull down the lower eyelid.
  - Use the fingers of the other hand to lift the upper eyelid.
  - Place the lens directly on the eye (cornea) and gently roll finger away from the lens.
  - Look down and slowly remove the hand, releasing the lower lid.
  - Look straight ahead and slowly remove the other hand, releasing the upper lid.
  - Blink gently.

#### To remove lenses:

- Wash and rinse hands thoroughly and dry completely with a clean, lint free towel before handling lenses.
- Make sure hands are clean and completely dry.
- Blink fully several times.
- While looking up, slide the lens down onto the white part of the eye.
- Remove the lens by pinching gently between the thumb and forefinger. Do not pinch the eye tissue.
- If the lens is difficult to grasp, dry fingers once more and try again. Do not use rewetting drops in this instance.
- If a lens decenters on the eye, it may be possible to recenter it by:
  - Closing the eye and massaging the lens into place, or
  - Looking in the direction of the lens and blinking gently, or
  - Gently pushing the off-centered lens onto the cornea with light finger pressure on the edge of the upper or lower eyelid.
- If a lens tears in the eye it will feel uncomfortable. Advise wearers it is impossible to lose a contact lens or part of a contact lens behind the eye and to remain calm. Lens pieces may be removed by pinching them as for normal lens removal, carefully avoiding pinching the eye tissue. If the lens pieces do not seem to remove easily, rinsing with saline is recommended. If this does not help, the wearer should contact an eye care professional for assistance.

#### Lens Wearing Precautions:

- Patients should never exceed the prescribed wearing schedule regardless of how comfortable the lenses feel. Doing so may increase the risk of adverse effects.
- The lens should move freely on the eye at all times. If the lens sticks (stops moving) on the eye, follow the recommended directions in the **Care for a Sticking Lens** section. If non-movement of the lens continues, the patient should be instructed to consult their eye care professional immediately.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

- The eye care professional should be consulted about wearing lenses during water sports and water related activities. Exposure to water or other non-sterile liquids while wearing contact lenses in activities such as swimming, water skiing, and hot tubs may increase the risk of ocular infection, including but not limited to *Acanthamoeba* keratitis.
- Never allow contact lenses to come into contact with non-sterile liquids (including tap water and saliva) as microbial contamination can occur, which may lead to permanent eye damage.
- Eye irritation, infection, or lens damage may result if cosmetics, lotion, soap, cream, hair spray, deodorant, aerosol products or foreign particles come in contact with lenses.
- Environmental fumes, smoke, and vapors should be avoided in order to reduce the chance of lens contamination or physical trauma to the cornea.
- Lenses should be disposed of each day upon removal from the eye.
- Discard any lens which has become dehydrated or damaged. Replace with a sterile, fresh, new lens.
- Note the correct lens power for each eye to prevent getting them mixed up.
- Always carry spare lenses with you or have back-up spectacles available.
- Do not share lenses with anyone as this may spread micro-organisms which could result in serious eye health problems.
- Do not use lenses beyond their expiration date.

#### Other Topics to Discuss with Patients:

- Periodic eye examinations are extremely important for contact lens wearers. Schedule and conduct appropriate follow-up examinations to determine ocular response. Alcon recommends that patients see their eye care professional once each year or as recommended by the eye care professional.
- Certain medications may cause dryness of the eye, increased lens awareness, lens intolerance, and blurred vision or visual changes. These include, but are not limited to, antihistamines, decongestants, diuretics, muscle relaxants, tranquilizers, and those for motion sickness. Caution patients using such medications accordingly and prescribe proper remedial measures.
- Visual changes or changes in lens tolerance may occur during pregnancy or use of oral contraceptives. Caution patients accordingly.

#### Who Should Know that the Patient is Wearing Contact Lenses:

- Patients should inform their health care practitioners that they are wearing contact lenses.
- Patients should inform their employers that they are wearing contact lenses. Some jobs may require the use of eye protection equipment or may require that contact lenses not be worn.

It is strongly recommended that patients be provided with a copy of the **DAILIES TOTAL1®** and **DAILIES TOTAL1® Multifocal Contact Lenses** (delefilcon A) Patient Instruction Booklet available from Alcon and understand its contents prior to dispensing the lenses.

#### ADVERSE EFFECTS

Patients should be instructed to check eyes regularly to make sure they look well, feel comfortable and vision is clear. Potentially serious complications are usually accompanied by one or more of the following signs or symptoms:

- Moderate to severe eye pain not relieved by removing the lens
- Foreign body sensation
- Excessive watering or other eye secretions including mucopurulent discharge
- Redness of the eyes
- Photophobia (light sensitivity)
- Burning, stinging or itching or other pain associated with the eyes
- Comfort is less compared to when the lens was first placed on eye
- Poor visual acuity (reduced sharpness of vision)
- Blurred vision, rainbows or halos around objects
- Feeling of dryness

#### WHAT TO DO IF A PROBLEM OCCURS

Patients should be instructed that if any of the above signs or symptoms are noticed, he or she should:

- IMMEDIATELY REMOVE THE LENSES.**
- If the discomfort or problem stops, discard the lens and replace it with a new one.
- If the discomfort or problem continues after removing lens(es) or upon insertion of a new lens, **IMMEDIATELY** remove the lens(es) and contact the eye care professional for identification of the problem and prompt treatment to avoid serious eye damage.
- The patient should be informed that a serious condition such as corneal ulcer, infection, corneal vascularization, or

iritis may be present, and may progress rapidly. Less serious reactions such as abrasions, infiltrates, and bacterial conjunctivitis must be managed and treated carefully to avoid more serious complications.

- Additionally, contact lens wear may be associated with ocular changes that require consideration of discontinuation or restriction of wear. These include but are not limited to local or generalized corneal edema, epithelial microcysts, epithelial staining, infiltrates, neovascularization, endothelial polymegathism, tarsal papillary changes, conjunctival injection or irritis.

#### ADVERSE EFFECT REPORTING

If a patient experiences any serious adverse effects associated with the use of **DAILIES TOTAL1®** brand (delefilcon A) contact lenses, please notify: Alcon Medical Safety in the USA at 1-800-757-9780.

#### FITTING GUIDE AND PATIENT BOOKLET

Conventional methods of fitting contact lenses apply to delefilcon A contact lenses. For a detailed description of the fitting techniques, refer to the **DAILIES TOTAL1®** and **DAILIES TOTAL1® Multifocal Contact Lenses** (delefilcon A) Professional Fitting and Information Guide. Both the professional fitting guide and a patient instruction booklet are available free of charge from:

Alcon Laboratories, Inc.  
6201 South Freeway  
Fort Worth, TX, USA 76134-2099  
1-800-241-5999

#### LENS WEAR & REPLACEMENT SCHEDULES

##### DAILY WEAR (less than 24 hours, while awake):

- To avoid tendency of the daily wear patient to overwear the lenses initially, stress the importance of adhering to a proper initial wearing schedule. Normal daily wear of lenses assumes a minimum of 6 hours of non-lens wear per 24 hour period.
- It may be advisable for patients who have never worn contact lenses previously to be given a wearing schedule that gradually increases wearing time over a few days. This allows more gradual adaptation of the ocular tissues to contact lens wear.
- The maximum daily wearing time should be determined by the eye care professional based upon the patient's physiological eye condition because individual responses to contact lenses vary. There may be a tendency for patients to overwear the lenses initially. The eye care professional should stress the importance of adhering to the initial maximum wearing schedule. Studies have not been conducted to show that delefilcon A contact lenses are safe to wear during sleep, therefore patients should be advised to remove their lenses while sleeping. Normal daily wear of lenses assumes a minimum of 6 hours of non-lens wear per 24 hour period. Optimum individual wearing schedule will vary.
- Delefilcon A contact lenses are intended to be worn once (daily disposable wear) and then discarded at the end of each wearing period. The patient should be instructed to start the next wearing period with a fresh new lens.

#### EMERGENCY LENS CARE

Cleaning and disinfection of daily disposable lenses is not recommended. The patient should be reminded to have replacement lenses or back-up spectacles available at all times.

#### CARE FOR A STICKING LENS

If the lens sticks (stops moving) or begins to dry on the eye, instruct the patient to apply several drops of a recommended lubricating solution (used in accordance with package labeling). The patient should wait until the lens begins to move freely on the eye before attempting to remove it. It is important that the patient wash and dry their hands thoroughly before removing the lens. If the lens continues to stick, the patient should IMMEDIATELY consult the eye care professional.

#### IN OFFICE USE OF TRIAL LENSES

Eye care professionals should educate contact lens technicians concerning proper use of trial lenses.

Each contact lens is shipped sterile in a blister pack containing phosphate buffered saline solution. Hands should be thoroughly washed and rinsed and dried with a lint-free towel prior to handling a lens. In order to ensure sterility, the blister pack should not be opened until immediately prior to use. For fitting and diagnostic purposes lenses should be disposed of after a single use and not be re-used from patient to patient.

#### EMERGENCIES

The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should:

Flush eyes immediately with tap water or fresh saline solution and immediately contact the eye care professional or visit a hospital emergency room without delay.

#### NOW SUPPLIED

Each lens is packaged in a foil-sealed plastic container containing phosphate buffered saline solution with approximately 0.3% of polymeric wetting agents consisting of copolymers of poly(ami)odiamine and poly(acrylamide-acrylic) acid and is steam sterilized . The package is marked with the base curve, diameter, dioptric power and ADD power (multifocal lenses), manufacturing lot number and expiration date.

The following may appear on the labels or cartons:

Symbol/Sign/ Abbreviations	Description
	CAUTION: Federal law (United States) restricts this device to sale by or on the order of a licensed eye care professional.
	STERILE
	EXP Use by date (Expiry date)
	LOT Batch code
	Do not reuse
	Do not use if package is damaged
	Example of two letter language code (English)
	DIA Diameter
	BC Base curve
	PWR Power
	D Diopter (lens power)
	ADD Addition power
	CE European conformity sign
	Caution
	See product instructions
	Authorized Representative European Community
	Manufacturer
	Packaging waste license sign

\* a trademark of Novartis

© 2016 Novartis

Manufacturer:  
Alcon Laboratories, Inc.  
6201 South Freeway  
Fort Worth, TX, USA 76134-2099  
www.alcon.com  
1-800-241-5999

March 2016

900038292-0316

<sup>1</sup> Check for actual product availability as additional parameters may be introduced over time

<sup>2</sup> Schein OD, Glynn RJ, Poggio EC, Seddon JM, Kenyon KR. The Relative Risk of Ulcerative Keratitis Among Users of Daily Wear and Extended Wear Soft Contact Lenses. *N Eng J Med*, 1989; 323(12):773-783

**Alcon®**  
a Novartis company

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

This page intentionally left blank

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

This page intentionally left blank

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**



Manufacturer:  
Alcon Laboratories, Inc.  
6201 South Freeway  
Fort Worth, TX  
76134-2099, USA

© 2016 Novartis  
\*a trademark of Novartis

March 2016

[www.alcon.com](http://www.alcon.com)  
W900087400-0316

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**APPENDIX I: C-QUANT STRAYLIGHT MEASUREMENT**

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

A large black rectangular redaction box covers the majority of the page content, starting below the header and ending above the footer. The redaction is not perfectly uniform, with some irregular edges and slight variations in black density, suggesting it was created by a digital tool rather than a physical redaction.

Page 1 of 6

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

Page 2 of 6

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

[REDACTED]

Page 3 of 6

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]


Page 4 of 6

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

[REDACTED]

Page 5 of 6

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**



Page 6 of 6

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**APPENDIX J: VISIONIX CORNEAL TOPOGRAPHY AND WAVEFRONT**

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

## ANSWER

100%  100%

113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or [research@uiowa.edu](mailto:research@uiowa.edu).

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or [research@iastate.edu](mailto:research@iastate.edu).

1. **What is the primary purpose of the study?** (Please check all that apply)

[REDACTED]


[REDACTED]

[REDACTED]

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1131 or [research@uiowa.edu](mailto:research@uiowa.edu).

1. **What is the primary purpose of the proposed legislation?**

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**



Page 2 of 8

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

[REDACTED]

[REDACTED]

[REDACTED]

||

[REDACTED]

[REDACTED]

Page 3 of 8

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or [www.iowa.edu/research/](http://www.iowa.edu/research/).

1. **What is the primary purpose of the study?**

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.


Page 5 of 8

## **Clinical Study Protocol**

### **Johnson & Johnson Vision Care, Inc.**

Page 6 of 8

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**



Page 7 of 8

# **Clinical Study Protocol**

## **Johnson & Johnson Vision Care, Inc.**

The figure consists of 10 distinct groups of horizontal bars, each group separated by a small gap. Within each group, the bars are also separated by small gaps. The bars are black and vary in length. The first nine groups each contain 1 to 4 bars, while the tenth group contains 5 bars. The bars are set against a white background with no grid lines.

Page 8 of 8

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**APPENDIX K: [REDACTED]**

- [REDACTED] LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS
- [REDACTED] EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING
- [REDACTED] DETERMINATION OF NEAR ADD
- [REDACTED] NEAR logMAR VISUAL ACUITY MEASUREMENT PROCEDURE
- [REDACTED] LENS FITTING CHARACTERISTICS
- [REDACTED] SUBJECT REPORTED OCULAR SYMPTOMS
- [REDACTED] DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
- [REDACTED] BIOMICROSCOPY SCALE
- [REDACTED] KERATOMETRY
- [REDACTED] DISTANCE AND NEAR VISUAL ACUITY EVALUATION
- [REDACTED] ETDRS DISTANCE VISUAL ACUITY MEASUREMENT PROCEDURE
- [REDACTED] PATIENT REPORTED OUTCOMES
- [REDACTED] VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION TESTING

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED], LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS**

# Clinical Study Protocol

**Johnson & Johnson Vision Care, Inc.**  
Limbal & Conjunctival (Bulbar) Redness

Title:

Work Instructions

Document Type:

Revision Number: 5

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

# Clinical Study Protocol

**Johnson & Johnson Vision Care, Inc.**  
Limbal & Conjunctival (Bulbar) Redness

Title:

Document Type: **Work Instructions**

Document Number: [REDACTED]

Revision Number: **5**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

# Clinical Study Protocol


**Johnson & Johnson Vision Care, Inc.**  
Limbal & Conjunctival (Bulbar) Redness

Title:

Document Type: **Work Instructions**

Document Number: [REDACTED]

Revision Number: **5**



# Clinical Study Protocol

**Johnson & Johnson Vision Care, Inc.**  
Limbal & Conjunctival (Bulbar) Redness

Title:

Document Type: **Work Instructions**

Document Number: [REDACTED]

Revision Number: **5**



# Clinical Study Protocol


**Johnson & Johnson Vision Care, Inc.**  
Limbal & Conjunctival (Bulbar) Redness

Title:

Document Type: **Work Instructions**

Document Number: [REDACTED]

Revision Number: **5**



# Clinical Study Protocol

**Johnson & Johnson Vision Care, Inc.**  
Limbal & Conjunctival (Bulbar) Redness

Title:

Work Instructions

Document Type:

Revision Number: 5

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED] EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING**

# Clinical Study Protocol

Title:

**Johnson & Johnson Vision Care, Inc.**

## **Document Type: Work Instructions**

**Document Number:**

## Revision Number: 5

1000 JOURNAL OF CLIMATE

For more information, visit [www.ams.org](http://www.ams.org).

10 of 10

11

10 of 10

© 2013 Pearson Education, Inc.

Term	Percentage
GMOs	~95%
Organic	~95%
Natural	~95%
Artificial	~95%
Organic	~95%
Natural	~95%
Artificial	~95%
Organic	~95%
Natural	~95%
Artificial	~95%

1. **What is the primary purpose of the study?** (Please select one)

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or [research@iastate.edu](mailto:research@iastate.edu).

# Clinical Study Protocol

Title:

Ex-**Johnson & Johnson Vision Care, Inc.**

Document Type: Work Instructions

Document Number: [REDACTED]

Revision Number: 5

[REDACTED]

[REDACTED]


[REDACTED]

[REDACTED]



[REDACTED]

[REDACTED]



# Clinical Study Protocol

Title:

Ex-**Johnson & Johnson Vision Care, Inc.**

Document Type:

Work Instructions

Document Number:

Revision Number: 5



# Clinical Study Protocol

Title:

Ex-**Johnson & Johnson Vision Care, Inc.**

Document Type:

Work Instructions

Document Number:

Revision Number: 5

# Clinical Study Protocol

## Title: **Ex-Johns-Seneca-Johnson Visions Game, Inc.**

**Document Type: Work Instructions**

**Document Number:**  **Revision Number:** 5

A solid black rectangular bar, likely a placeholder or a redacted section of the image.

© 2013 Pearson Education, Inc.

© 2013 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).

10 of 10

■ [REDACTED] ■ [REDACTED]

■ [REDACTED] ■ [REDACTED]

■ [REDACTED] ■ [REDACTED]

11. **What is the primary purpose of the *Journal of Clinical Endocrinology and Metabolism*?**

For more information, visit [www.ams.org](http://www.ams.org).

© 2013 Pearson Education, Inc.

100%  100%

# Clinical Study Protocol

Title:

Ex-**Johnson & Johnson Vision Care, Inc.**

Document Type:

Work Instructions

Document Number:

Revision Number: 5



**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**DETERMINATION OF NEAR ADDITION**

# Clinical Study Protocol

**Title:**

# DeJohnson & Johnson Vision Care, Inc.

## **Document Type: Work Instructions**

**Document Number:**

**Revision Number: 4**

1000

11. **What is the primary purpose of the *Journal of Clinical Endocrinology and Metabolism*?**

1000

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or [research@uiowa.edu](mailto:research@uiowa.edu).

100% of the time, the system is able to correctly identify the target class for the test samples.

A 2D grayscale heatmap showing a complex, high-contrast pattern of black and white regions. The pattern is highly irregular, with many sharp, jagged edges and a dense, noisy texture. It appears to be a binary mask or a highly processed image of a physical object. The background is white, and the main features are black.

For more information, visit [www.ams.org](http://www.ams.org).

# Clinical Study Protocol

Title:

DeJohnson & Johnson Vision Care, Inc.

Document Type:

Work Instructions

Document Number:

Revision Number: 4



# Clinical Study Protocol

Title:

DeJohnson & Johnson Vision Care, Inc.

Document Type: Work Instructions

Document Number: [REDACTED]

Revision Number: 4

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

# Clinical Study Protocol

Title:

DeJohnson & Johnson Vision Care, Inc.

Document Type: Work Instructions

Document Number: [REDACTED]

Revision Number: 4



# Clinical Study Protocol

**Title:**

# DeJohnson & Johnson Vision Care, Inc.

## **Document Type: Work Instructions**

**Document Number:**

## Revision Number: 4

[REDACTED]

10 of 10 pages

10.1002/anie.201907002

Digitized by srujanika@gmail.com

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6444 or [research@iastate.edu](mailto:research@iastate.edu).

Digitized by srujanika@gmail.com

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED], NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE**

# Clinical Study Protocol

Title:

Johnson & Johnson Vision Care, Inc.

Document Type:

Work Instructions

Document Number:

Revision Number: 8

[REDACTED]

# Clinical Study Protocol


Title:

N~~o~~Johnson & Johnson Vision Care, Inc.

Document Type: Work Instructions

Document Number: CTP-2006

Revision Number: 8



[REDACTED]

■ [REDACTED]

■ [REDACTED]

[REDACTED]

■ [REDACTED]

[REDACTED]

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**LENS FITTING CHARACTERISTICS**

# Clinical Study Protocol

Title: **Johnson & Johnson Vision Care, Inc.**

Document Type: **Work Instructions**

Document Number: [REDACTED]

Revision Number: **5**

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

# Clinical Study Protocol

Title:

Johnson & Johnson Vision Care, Inc.

Document Type:

Work Instructions

Document Number:

Revision Number: 5

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]

# Clinical Study Protocol

Title: **Johnson & Johnson Vision Care, Inc.**

Document Type: **Work Instructions**


Document Number: [REDACTED]

Revision Number: **5**

[REDACTED]

[REDACTED]

[REDACTED]



[REDACTED]

[REDACTED]

# Clinical Study Protocol

Title:


Johnson & Johnson Vision Care, Inc.

Document Type:

Work Instructions

Document Number:

Revision Number: 5



# Clinical Study Protocol

Title: **Johnson & Johnson Vision Care, Inc.**

Document Type: **Work Instructions**

Document Number: **CTP-2008**

Revision Number: **5**

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS**

# Clinical Study Protocol

Title:

Johnson & Johnson VisionCare, Inc.

Document Type: Work Instructions

Document Number: [REDACTED]

Revision Number: 3

[REDACTED]


**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED] DETERMINATION OF DISTANCE SPHEROCYLINDRICAL  
REFRACTIONS**

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**


[REDACTED]

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**



**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

[REDACTED]




**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

[REDACTED]

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**



**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**



**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED] BIOMICROSCOPY SCALE**

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:** Biomicroscopy Scale

**Document Type:** Work Instruction

**Document Number:** [REDACTED] **Revision Number:** 9

[REDACTED]

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:** Biomicroscopy Scale

**Document Type:** Work Instruction

**Document Number:** [REDACTED]

**Revision Number:** 9

---



## **Clinical Study Protocol**

### **Johnson & Johnson Vision Care, Inc.**


**Title:** Biomicroscopy Scale

**Document Type:** Work Instruction

**Document Number:** XXXXXXXXXX

Revision Number: 9

## **Sodium Fluorescein Corneal Staining Grading Scale**



**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:** Biomicroscopy Scale

**Document Type:** Work Instruction

**Document Number:** [REDACTED]

**Revision Number:** 9



**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:** Biomicroscopy Scale

**Document Type:** Work Instruction

**Document Number:** [REDACTED] **Revision Number:** 9



**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED] KERATOMETRY PROCEDURE**

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Keratometry Procedure**



**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED] DISTANCE AND NEAR VISUAL ACUITY EVALUATION**

# Clinical Study Protocol

Johnson & Johnson Vision Care, Inc.

Title:

Work Instructions

Document Type:

Revision Number: 4

[REDACTED]



# Clinical Study Protocol

Johnson & Johnson Vision Care, Inc.

Title:

Work Instructions

Document Type:

Document Number:

Revision Number: 4



# Clinical Study Protocol

Title:

Johnson & Johnson Vision Care, Inc.

Document Type: Work Instructions

Document Number: [REDACTED]

Revision Number: 4



[REDACTED]

# Clinical Study Protocol


Title:

Johnson & Johnson Vision Care, Inc.

Document Type: Work Instructions

Document Number: [REDACTED]

Revision Number: 4



**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED] DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT  
PROCEDURE**

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:**

**Distance LogMAR Visual Acuity Measurement Procedure**

**Document Type:**

**Clinical Test Procedure**

**Document Number:**

**Revision Number: 4**

[REDACTED]

[REDACTED]

[REDACTED]



## **Clinical Study Protocol**

### **Johnson & Johnson Vision Care, Inc.**

**Title:**

## Distance LogMAR Visual Acuity Measurement Procedure

---

**Document Type:**

## Clinical Test Procedure

Document Number:

---

Revision Number: 4

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:**

**Distance LogMAR Visual Acuity Measurement Procedure**

**Document Type:**

**Clinical Test Procedure**

**Document Number:**

**Revision Number: 4**



**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED] PATIENT REPORTED OUTCOMES**

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

Title:

Patient Reported Outcomes

Document Type:

Procedure

Document Number:

Revision Number: 2

[REDACTED]

**Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.**

**[REDACTED] VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION  
TESTING**

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:** Visual Acuity Chart Luminance and Room Illumination Testing  
**Document Type:** Work Instructions  
**Document Number:** [REDACTED] **Revision Number:** 3



**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**


**Title:** Visual Acuity Chart Luminance and Room Illumination Testing  
**Document Type:** Work Instructions  
**Document Number:** [REDACTED] **Revision Number:** 3



**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:** Visual Acuity Chart Luminance and Room Illumination Testing  
**Document Type:** Work Instructions  
**Document Number:** [REDACTED] **Revision Number:** 3

**PROCEDURE**



**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:** Visual Acuity Chart Luminance and Room Illumination Testing  
**Document Type:** Work Instructions  
**Document Number:** [REDACTED] **Revision Number:** 3









**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:** Visual Acuity Chart Luminance and Room Illumination Testing  
**Document Type:** Work Instructions  
**Document Number:** [REDACTED] **Revision Number:** 3



**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**APPENDIX L: GUIDELINES FOR COVID-19 RISK MITIGATION**

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

Title:

Guidelines for COVID-19 Risk Mitigation

Document Type:

Work Instruction

Document Number:

Revision Number: 3

### 1.0 PURPOSE

The purpose of this document is to provide guidelines for the re-opening or initiation of clinical study sites participating in Johnson & Johnson Vision Care, Inc. (JJVCI) clinical studies during the COVID-19 pandemic.

### 2.0 SCOPE

This document provides guidelines for Johnson & Johnson Vision Care (JJVCI) to address the potential risks from COVID-19 to study subjects, investigators, study site staff, and monitors at study sites. The guidance provided in this document is in effect from the date of approval through the date of retirement of this Work Instruction. At a minimum, this Work Instruction will be reviewed and updated on a quarterly basis, as appropriate.

**NOTE: Re-opening of sites outside of the US will be evaluated on a country by country basis subject to local health authority guidance.**

### 3.0 DEFINITIONS

**American Academy of Optometry (AAO):** The American Academy of Optometry is an organization of optometrists based in Orlando, Florida. Its goal is to maintain and enhance excellence in optometric practice, by both promoting research and the dissemination of knowledge. The AAO holds an annual meeting, publishes a monthly scientific journal, gives credentials to optometrists through the fellowship process and publishes position statements.

**American Optometric Association (AOA):** The American Optometric Association, founded in 1898, is the leading authority on quality care and an advocate for our nation's health, representing more than 44,000 Doctors of Optometry (O.D.), optometric professionals, and optometry students. Doctor of Optometry take a leading role in patient care with respect to eye and vision care, as well as general health and well-being. As primary health care providers, Doctor of Optometry have extensive, ongoing training to examine, diagnose, treat and manage ocular disorders, diseases and injuries and systemic diseases that manifest in the eye. The American Optometric Association is a federation of state, student, and armed forces optometric associations. Through these affiliations, the AOA serves members consisting of optometrists, students of optometry, paraoptometric assistants and technicians. The AOA and its affiliates work to provide the public with quality vision and eye care.

**Centers for Disease Control and Prevention (CDC):** The Centers for Disease Control and Prevention is a national public health institute in the United States. It is a United States federal agency, under the Department of Health and Human Services, and is headquartered in Atlanta, Georgia.

**COVID-19:** Current outbreak of respiratory disease caused by a novel coronavirus. The virus has been named "SARS-CoV-2" and the disease it causes has been named "Coronavirus Disease 2019" (COVID-19).

**Clinical Study:** Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments. May also be called clinical trials, studies, research, trials, or protocols.

**Clinical Study Site:** Location where a clinical study is conducted, such as a doctor's office, university, or laboratory. Clinical studies are conducted by Investigators who are individual(s) responsible for the conduct of the clinical study at a study site. If a study is conducted by a team of individuals, the Investigator is the responsible leader of the team and may be called the Principal Investigator.

**Clinical Operations Manager (COM):** The Johnson & Johnson Vision Care (JJVCI) individual responsible for the overall management of a clinical trial.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

Title:

Guidelines for COVID-19 Risk Mitigation

Document Type:

Work Instruction

Document Number:

Revision Number: 3

**Monitor:** An individual designated to oversee the progress of a clinical study and ensure that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and applicable regulatory requirements.

**Medical Safety Officer (MSO):** Physician who has primary accountability in their product portfolio for product health and safety, and who serves as an independent medical voice for patient safety.

**Safety Management Team (SMT):** A cross-functional, collaborative team responsible for review, assessment and evaluation of medical safety data arising from any source throughout the product life cycle.

### 4.0 GUIDANCE FOR STUDY DOCUMENTS

In alignment with recent health authority guidance, J JVCI is providing recommendations for study-related management in the event of disruption to the conduct of the clinical study. This guidance does not supersede any local or government requirements or the clinical judgement of the investigator to protect the health, safety and well-being of participants and site staff. If, at any time, a participant's safety is considered to be at risk, study intervention will be discontinued, and study follow-up will be conducted as outlined in the protocol.

During the COVID-19 pandemic, the additional risks listed below need to be considered for study participants and study personnel:

#### 4.1 Additional Risks Related to the COVID-19 Pandemic:

- The possible transmission of the Coronavirus infection and consequent complications, beyond the risk of adverse events due to the investigational device and/or procedures.
- The risk may be higher in an optometric clinical study because of the close contact the subject will have with health care professionals during the procedures and assessments (since the investigator must make the measurements close to the subject's face) and, in addition the need for multiple follow-up visits/exams which may expose the subject to other patients and/or healthcare professionals who might be transmitting the virus, even if they do not have symptoms.
- Potential disruptions to the study may be necessary due to current or future pandemic-related emergency restrictions, which may lead to delays in scheduled follow-up visits.
- Subjects experiencing an adverse event related to contact lens wear may receive delayed treatment due to COVID-19 restrictions. In this event, all assessments that can be conducted virtually will be completed by the investigator to determine the best course of treatment for the subject, including an unscheduled visit, up to discontinuation from the study, as appropriate.

If a study subject is found to have contracted COVID-19 during participation in a study, he/she will be discontinued from the study and followed until COVID-19 Adverse Event (AE) resolution.

To help minimize the above potential risks, J JVCI recommend reviewing/complying with local, state, and governmental guidance for COVID-19 risks.

J JVCI will provide the following study specific documents with language pertaining to COVID-19 risks:

##### 4.1.1 Informed Consent:

Will include information concerning the study-associated risks related to the COVID-19 pandemic in bold font and/or boxed on the first page of the Informed Consent document:

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

Title:

Guidelines for COVID-19 Risk Mitigation

Document Type:

Work Instruction

Document Number:

Revision Number: 3

### STUDY ASSOCIATED RISKS RELATED TO COVID-19 (CORONAVIRUS) PANDEMIC

It is important to note that this study will be conducted, at least in part, during the COVID-19 pandemic. As such, additional risks associated with the infection with COVID-19 exist for you. This is particularly important for this study due, in part, to the closeness of the doctor during the study examinations.

The potential effects of the disease are not fully known, at this time, and may include long-term serious health consequences. In severe cases, this may result in hospitalization and/or death. Based on current knowledge from the Centers for Disease Control and Prevention (CDC), those at high-risk for severe illness from COVID-19 include older adults and people with underlying medical conditions.

During this study, all appropriate measures will be taken to minimize risks including the use of personal protective equipment such as masks and gloves, as well as proper sanitization. This is in conformance to guidance from the CDC, local health departments, and the state and county in which the study doctor's office is located. However, these measures may not completely eliminate the risks associated with contracting COVID-19.

If you are found to have contracted COVID-19 or feel ill with flu-like symptoms during participation in the study, you will not be permitted to continue in-office study follow-up visits, but you will receive instructions and your condition will be monitored by the doctor and/or study staff.

#### 4.1.2 COVID-19 Risk Control Checklist:

Will include COVID-19 risk control methods that are required by a site to conduct JJVCI clinical studies. The risk controls are consistent with CDC, AOA, AAO Guidance. The Principle Investigator will review/sign the study specific checklist prior to the Site Initiation Meeting.

Study Number

Site Number

Principal Investigator (PI) Name

The following COVID-19 risk control methods are required to conduct Johnson & Johnson Vision Care clinical studies. Please review the following requirements and initial each requirement.

PI Initials	General Site Safety Planning Measures
	Signage within site describing Risk Control methods
	Social Distancing practices throughout site (waiting rooms, lobby, exam rooms, etc.)
	Non-contact thermometer available to assess temperatures of staff and patients
	Training on patient flow and physical distancing in waiting room
	Establish longer time frame between patient appointments to reduce persons in the site
	Staff should receive job-specific training on PPE and demonstrate competency with selection and proper use of PPE and wear at all times during interactions with subjects (e.g., putting on and removing without self-contamination)

PI Initials	Site Staff Daily Safety Measures
	As part of routine practice, site staff should regularly monitor themselves for fever and symptoms of COVID-19, including temperature checks
	Any staff member (including Investigators) showing signs of being sick or testing positive for COVID-19 should not be permitted to work and the Sponsor shall be informed <b>NOTE: Inform JJVC in 24 hours of any significant impact to the study.</b>
	Ensure that all staff wear a mask Gloves should be required when working directly with patients and changed between each patient

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**  
**Guidelines for COVID-19 Risk Mitigation**

**Title:**

**Document Type:**

**Document Number:** [REDACTED]

**Revision Number: 3**

	Have staff thoroughly wash hands for at least 20 seconds or use an alcohol-based hand sanitizer when they arrive, before and after each patient, before eating and after using the bathroom.
	Cleaning and disinfection procedures for exam rooms and instruments or equipment between patients with gloves.
	Cleaning and disinfection procedures for commonly touched surfaces (doors, chairs, computers, phones, etc.) with gloves.

PI Initials	Before a Patient or Study Visit:
	Patients should be asked prior to entering the site about fever and respiratory illness and whether they or a family member have had contact with another person with confirmed COVID-19 in the past 14 days. Patients exhibiting signs of being sick should be rescheduled when their symptoms resolve.
	Instruct patients that companions should remain outside of the facility and not accompany the patient into the facility unless they are a parent/guardian of the patient or if they are a true caregiver and need to assist the patient
	Request the patient to call or text the office upon arrival so entrance to and movement through facility can be coordinated by site staff

PI Initials	Patients Entering the site:
	Temperature checks utilizing a non-contact thermometer for all patients and companions entering the site.
	All patients and companions must wear cloth or disposable mask at all times in the site
	Maintain social distancing. Waiting rooms or lobbies should be as empty as possible. Advise seated patients to remain at least 6 feet from one another.
	Communal objects in (e.g. toys, reading materials, etc.) should be removed or cleaned regularly.

I certify that I have read and agree to implement all the listed COVID-19 Risk Control Measures required for the conduct of Johnson & Johnson Vision Care studies.

---

Principal Investigator Signature and Date

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

Title:

Guidelines for COVID-19 Risk Mitigation

Document Type:

Work Instruction

Document Number:

Revision Number: 3

### RESOURCE LINKS

#### US Resource Links

- OSHA Training  
<https://www.osha.gov/SLTC/covid-19/controlprevention.html>
- Personal Protective Equipment (PPE) Training  
CDC: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/using-ppe.html>
- I&R Training  
ACUVUE® LensAssist: <https://www.acuvue.com/lensassist>
- Clinic Preparedness Guides  
CDC: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinic-preparedness.html>  
AOA: <https://aoa.uberflip.com/i/1240437-aoa-guidance-for-re-opening-practices-covid-19/1?m4=1>  
American Optometric Association: <https://www.aoa.org/optometry-practice-reactivation-preparedness-guide>
- In-Office Disinfection of Multi-Patient Use Diagnostic Contact Lenses  
<https://www.gpli.info/wp-content/uploads/2020/03/2020-01-15-in-office-disinfecting-of-diagnostic-lenses.pdf>

#### OUS Resource Links

- Updates on local regulations in Hong Kong  
<https://www.coronavirus.gov.hk/eng/index.html>
- Resumption of optical services in England: Letter from Matt Neligan and Poonam Sharma  
<https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0601-reopening-of-optical-services-letter-17-june-2020.pdf>
- NHS Optical Letter  
<https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0127-optical-letter-1-april-2020.pdf>
- The College of Optometrists primary eye care COVID-19 guidance: Red phase  
<https://www.college-optometrists.org/the-college/media-hub/news-listing/coronavirus-covid-19-guidance-for-optometrists.html>
- The College of Optometrists COVID-19: College updates  
<https://www.college-optometrists.org/the-college/media-hub/news-listing/coronavirus-2019-advice-for-optometrists.html#CollegeGuidelines>

#### 4.1.3 Protocol Compliance Investigator(s) Signature Page:

Will include a statement indicating that the Principal Investigator (PI) agrees to conduct the study in compliance with all local, state, and governmental guidance's for COVID-19 risk mitigation.

I have read the suggested guidance provided by JJVCI pertaining to the COVID-19 risk mitigation, (COVID-19 Work Instruction in the Appendix of this protocol). I agree to conduct this study in compliance with local, state, governmental guidance for COVID-19 risks.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**Title:**

**Guidelines for COVID-19 Risk Mitigation**

**Document Type:**

**Work Instruction**

**Document Number:** [REDACTED]

**Revision Number: 3**

**4.1.4 Study Site Initiation Training Slides:**

Will include suggestions to help mitigate potential transmission of COVID-19. Suggestions may include maintaining social distancing in the clinical site by staggered scheduling of study patients, wearing proper PPEs, frequent disinfection, and installing shields on the slit lamp and other applicable equipment.

**5.0 GUIDANCE FOR REMOTE SUBJECT VISITS**

Potential disruptions to the study may be necessary due to current or future pandemic-related emergency restrictions. Possible disruption of the study as a result of COVID-19 control measures may lead to delays in scheduled follow-up visits.

Subjects may be delayed in being seen for study follow up visit(s), for example due to COVID-19 control measures or due to the subject's concerns or fears about COVID-19 risk. When appropriate, the remote assessment will be conducted to the extent possible. Discussions with the subject during remote assessments may include:

<b>Procedure</b>	<b>Details</b>
Subject Reported Ocular Symptoms	Subjects will respond to a verbal open-ended symptoms questionnaire regarding the test article when applicable and feasible.
Change of Medical History (Adverse Events) and Concomitant Medications / Therapies Review	Record any adverse events or medical history changes from the previous study visit with the subject/parents.  Review the subject's concomitant medications/therapies and record any changes from the previous study visit.
Wearing Time and Compliance	Record the average wearing time (including number of hours per day during weekdays and weekends, and number of days per week).  Confirm compliance with the prescribed wear schedule.  • Record and discuss the lens wear compliance based on the subject's self-report. For example, the subjects will be asked the time of the day the subject typically puts on the study lenses in the morning and takes off in the evening, the number of days per week lenses were worn, and the number of consecutive days the subject didn't wear the study lenses, etc.

The discussion with the subject will be documented in EDC under Tele-Visit and a minor protocol deviation will be noted. If during the telephone consultation, a subject states he/she wishes to discontinue participating in the study, instruct the subject to stop wearing the study lenses and schedule the subject to return to the clinic for a Final Evaluation at the earliest possible time. Subjects should return all unused lenses to the clinic at the last visit.

Changes in study visit schedules, missed visits, or participant discontinuations may lead to missing data, including data related to protocol-specified procedures. Case report forms should capture specific information regarding the basis of missing data, including the relationship to the COVID-19 pandemic.

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

Title:

Guidelines for COVID-19 Risk Mitigation

Document Type:

Work Instruction

Document Number:

Revision Number: 3

### 6.0 STUDY CONDUCT DURING PANDEMIC

It is recognized that the Coronavirus Disease 2019 (COVID-19) pandemic may have an impact on the conduct of this clinical study due to, for example, self-isolation/quarantine by participants and study-site personnel; travel restrictions/limited access to public places, including Optometry Clinics; and changes in clinic procedures required to address the COVID-19 challenge.

Every effort should be made to adhere to protocol-specified assessments for study participants, including follow-up. However, if scheduled visits cannot be conducted in person at the study site it is suggested that assessments be performed to the extent possible remotely/virtually or delayed until such time that on-site visits can be resumed in order to continue participant monitoring in accordance with the protocol where possible. At each contact, participants will be interviewed to collect safety data. Key efficacy endpoint assessments should be performed if required and as feasible.

Modifications to protocol-required assessments may be permitted via COVID-19 Appendix after consultation with the participant, investigator, and the sponsor. Missed assessments/visits will be captured in the clinical trial management system for protocol deviations. Interruptions of test article wear or discontinuations of study interventions and withdrawal from the study should be documented with the prefix “COVID-19-related” in the case report form (CRF).

The sponsor will continue to monitor the conduct and progress of the clinical study, and any changes will be communicated to the sites and to the health authorities according to local guidance.

If a participant has tested positive for COVID-19, the investigator should contact the sponsor’s responsible medical monitor to discuss initial plans for study intervention and follow-up. The medical monitor will notify the Safety Management Team of any subject(s) that have reported “COVID-19”, “Asymptomatic COVID-19”, or “Suspected COVID-19” adverse events within 24 hours of the notification.

Modifications made to the study conduct as a result of the COVID-19 pandemic will be summarized in the clinical study report.

COVID-19 screening procedures that may be mandated by local healthcare systems do not need to be reported as an amendment to the protocol even if done during clinical study visits.

#### 6.1 Monitoring Visits

When on-site monitoring by the sponsor is not feasible, the sponsor’s site monitor will contact the study site to schedule remote visits. In such cases, on-site monitoring visits will resume when feasible, with increased frequency to address the source data verification backlog.

Even with staffing limitations during this COVID-19 pandemic, all routine operations related to clinical trials should be well-documented and archived as part of standard process. When conditions permit, all parties involved in this clinical trial should communicate relevant information in a timely manner so that all relevant parties remain sufficiently informed.

##### 6.1.1 Study Site Initiation:

During the period that this Work Instruction is in effect, Site Initiation Meetings and training of study site staff will be conducted remotely. The JJVCI study team will conduct training via Skype, Zoom, Microsoft Teams or similar software as well as utilize online training materials, as applicable. Study site training will be documented utilizing Site Initiation Report [REDACTED]

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

**Title:**

**Guidelines for COVID-19 Risk Mitigation**

**Document Type:**

**Work Instruction**

**Document Number:**

**Revision Number: 3**

On-site visits may be considered when, for example, hands-on training or evaluation of site facilities is required. While on site, the Clinical Research Associate (CRA) will follow all local, state, and governmental policies for COVID-19 Risk Mitigation, including social distancing, wearing of PPE, etc. as applicable for the location of the study site.

### 6.1.2 Interim Monitoring Visits (if applicable):

During the period that this Work Instruction is in effect, Interim Monitoring On-site visits will be kept to a minimum and include only those tasks that the CRA cannot perform remotely (e.g., source document verification, test article reconciliation, etc.).

To ensure data integrity during the conduct of all JJVC studies, clinical study teams will follow the study specific Clinical Monitoring Plan [REDACTED]

While on site, the CRA will follow all local, state, and governmental policies for COVID-19 Risk Mitigation, including social distancing, wearing of PPE, etc. as applicable for the location of the study site.

### 6.1.3 Study Site Closure:

During the period that this Work Instruction is in effect, the duration of the Study Site Closure Visit will be limited to tasks that the CRA cannot perform remotely (e.g., source document verification, test article final reconciliation and return, etc.).

# Clinical Study Protocol

## Johnson & Johnson Vision Care, Inc.

**Title:**

Guidelines for COVID-19 Risk Mitigation

**Document Type:**

Work Instruction

**Document Number:**

**Revision Number: 3**

### Attachment A: Study Site Correspondence

XXXX XX, 2020

#### Re: COVID-19 Mitigation Plan, <<CR-xxxx/protocol title>>

Dear <<Principle Investigator>> and Study Team,

Coronavirus (COVID-19) has impacted several communities and business activities over the past several months. While we work toward the successful conduct of clinical studies, our commitment continues to be the safety of patients, healthcare professionals, and to our communities.

Therefore, we would like to share the following revisions/additions related to the above referenced Johnson & Johnson Vision Care company sponsored clinical trial(s) you are currently working on or considering participation within.

#### **Protocol:**

- Guidelines for COVID-19 Risk Mitigation provided in the Appendix section.

#### **Protocol Signature Page:**

- Will include a statement indicating the Principle Investigator agrees to conduct the study in compliance with all local, state, and governmental guidelines for COVID-19 risk mitigation.

#### **Informed Consent:**

- Will include information concerning the study-associated risks related to the COVID-19 pandemic in bold font and/or boxed on the first page of the Informed consent document.

#### **COVID-19 Risk Control Checklist for Clinical Studies:**

- Will include COVID-19 risk control measures that are required to ensure the safety and health of subjects, site staff and monitors during the pandemic.

We want to encourage the need for open lines of communication about potential challenges you may foresee as the result of the current COVID-19 situation. Therefore, we encourage you to regularly connect with your respective Johnson & Johnson clinical study team (Clinical Research Associate (CRA), Lead CRA or Study Managers).

Thank you for your continued engagement, collaboration, and dedication to your study subjects during this challenging time.

Please file this letter in your site file study correspondence.

**Clinical Study Protocol**  
**Johnson & Johnson Vision Care, Inc.**

**PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE**

Protocol Number and Title: CR-6392 Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Hyperopic Population

Version and Date: 3.0 02 October 2020

I have read and understand the protocol specified above and agree on its content.

I agree to conduct this study according to ISO 14155,<sup>1</sup> GCP and ICH guidelines,<sup>2</sup> the Declaration of Helsinki,<sup>3</sup> United States (US) Code of Federal Regulations (CFR),<sup>4</sup> and the pertinent individual country laws/regulations and to comply with its obligations, subject to ethical and safety considerations. The Principal Investigator is responsible for ensuring that all clinical site personnel, including Sub-Investigators adhere to all ICH<sup>2</sup> regulations and GCP guidelines regarding clinical trials during and after study completion.

I will assure that no deviation from or changes to the protocol will take place without prior agreement from the Sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants.

I am responsible for ensuring that all clinical site personnel including Sub-Investigators adhere to all ICH<sup>2</sup> regulations and GCP guidelines regarding clinical trials during and after study completion.

All clinical site personnel involved in the conduct of this study have completed Human Subjects Protection Training.

I agree to ensure that all clinical site personnel involved in the conduct of this study are informed about their obligations in meeting the above commitments.

I shall not disclose the information contained in this protocol or any results obtained from this study without written authorization.

I have read the suggested guidance provided by JJVCI pertaining to the COVID-19 risk mitigation, (COVID-19 Work Instruction in the Appendix of this protocol). I agree to conduct this study in compliance with local, state, governmental guidance for COVID-19 risks.

Principal  
Investigator:

Signature

Date

Name and Professional Position (Printed)

Institution/Site:

Institution/Site Name

Institution/Site Address